



(86) Date de dépôt PCT/PCT Filing Date: 2001/10/09

(87) Date publication PCT/PCT Publication Date: 2002/05/02

(85) Entrée phase nationale/National Entry: 2003/04/04

(86) N° demande PCT/PCT Application No.: US 2001/042562

(87) N° publication PCT/PCT Publication No.: 2002/034716

(30) Priorité/Priority: 2000/10/11 (60/239,481) US

(51) Cl.Int.⁷/Int.Cl.⁷ A61K 31/675, A61K 31/50, A61K 31/495,
A61K 31/445, A61K 31/44, A61K 31/40, C07D 209/44,
C07F 9/28, C07F 9/06, C07F 9/547, C07D 209/52,
C07D 401/00, C07F 9/02, C07D 403/00


(71) Demandeur/Applicant:
MERCK & CO., INC., US

(72) Inventeurs/Inventors:
HALE, JEFFREY J., US;
LYNCH, CHRISTOPHER L., US;
CALDWELL, CHARLES G., US;
WILLOUGHBY, CHRISTOPHER A., US;
...

(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : MODULATEURS A BASE DE PYRROLIDINE D'ACTIVITE DE RECEPTEUR DE CHIMIOKINES CCR5

(54) Title: PYRROLIDINE MODULATORS OF CCR5 CHEMOKINE RECEPTOR ACTIVITY



(57) Abrégé/Abstract:

Pyrrolidine compounds of Formula (I), (wherein R¹, R², R³, R⁴, R⁵, R^{6a}, R^{6b}, R⁷ and R⁸ are defined herein) are described. The compounds are modulators of CCR5 chemokine receptor activity. The compounds are useful, for example, in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.



(72) **Inventeurs(suite)/Inventors(continued)**: KIM, DOOSEOP, US; SHEN, DONG-MING, US; MILLS, SANDER G., US; CHAPMAN, KEVIN T., US; CHEN, LIYA, US; GENTRY, AMY, US; MACCOSS, MALCOLM, US

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
2 May 2002 (02.05.2002)

PCT

(10) International Publication Number
WO 02/034716 A3(51) International Patent Classification⁷: **A61K 31/675**,
31/495, 31/50, 31/445, 31/44, 31/40, C07F 9/02, 9/06,
9/28, 9/547, C07D 209/44, 209/52, 401/00, 403/00**CHEN, Liya** [CN/US]; 126 East Lincoln Avenue, Rahway,
NJ 07065-0907 (US). **GENTRY, Amy** [US/US]; 126 East
Lincoln Avenue, Rahway, NJ 07065-0907 (US). **MAC-**
COSS, Malcolm [GB/US]; 126 East Lincoln Avenue,
Rahway, NJ 07065-0907 (US).

(21) International Application Number: PCT/US01/42562

(22) International Filing Date: 9 October 2001 (09.10.2001)

(74) Common Representative: **MERCK & CO., INC.**; 126
East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/239,481 11 October 2000 (11.10.2000) US(71) Applicant (for all designated States except US): **MERCK
& CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway,
NJ 07065-0907 (US).


(72) Inventors; and

(75) Inventors/Applicants (for US only): **HALE, Jeffrey,
J.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ
07065-0907 (US). **LYNCH, Christopher, L.** [US/US];
126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
CALDWELL, Charles, G. [US/US]; 126 East Lincoln
Avenue, Rahway, NJ 07065-0907 (US). **WILLOUGHBY,
Christopher, A.** [US/US]; 126 East Lincoln Avenue,
Rahway, NJ 07065-0907 (US). **KIM, Doo-seop** [KR/US];
126 East Lincoln Avenue, Rahway, NJ 07065-0907
(US). **SHEN, Dong-Ming** [US/US]; 126 East Lincoln
Avenue, Rahway, NJ 07065-0907 (US). **MILLS, Sander,
G.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ
07065-0907 (US). **CHAPMAN, Kevin, T.** [US/US];
126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).**Published:**

— with international search report

(88) Date of publication of the international search report:
8 August 2002For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PYRROLIDINE MODULATORS OF CCR5 CHEMOKINE RECEPTOR ACTIVITY



(I)

(57) Abstract: Pyrrolidine compounds of Formula (I), (wherein R¹, R²,
R³, R⁴, R⁵, R^{6a}, R^{6b}, R⁷ and R⁸ are defined herein) are described. The
compounds are modulators of CCR5 chemokine receptor activity. The
compounds are useful, for example, in the prevention or treatment of
infection by HIV and the treatment of AIDS, as compounds or pharma-
ceutically acceptable salts, or as ingredients in pharmaceutical compo-
sitions, optionally in combination with other antivirals, immunomodu-
lators, antibiotics or vaccines. Methods of treating AIDS and methods
of preventing or treating infection by HIV are also described.

WO 02/034716 A3

TITLE OF THE INVENTION

PYRROLIDINE MODULATORS OF CCR5 CHEMOKINE RECEPTOR
ACTIVITY

5 BACKGROUND OF THE INVENTION

Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation (reviewed in Schall, Cytokine, 3, 165-183 (1991) and Murphy, Rev. Immun., 12, 593-633 (1994)). There are two classes of chemokines, C-
10 X-C (α) and C-C (β), depending on whether the first two cysteines are separated by a single amino acid (C-X-C) or are adjacent (C-C). The α -chemokines, such as interleukin-8 (IL-8), neutrophil-activating protein-2 (NAP-2) and melanoma growth stimulatory activity protein (MGSA) are chemotactic primarily for neutrophils, whereas β -chemokines, such as RANTES, MIP-1 α , MIP-1 β , monocyte chemotactic
15 protein-1 (MCP-1), MCP-2, MCP-3 and eotaxin are chemotactic for macrophages, T-cells, eosinophils and basophils (Deng, et al., Nature, 381, 661-666 (1996)).

The chemokines bind specific cell-surface receptors belonging to the family of G-protein-coupled seven-transmembrane-domain proteins (reviewed in Horuk, Trends Pharm. Sci., 15, 159-165 (1994)) which are termed "chemokine
20 receptors." On binding their cognate ligands, chemokine receptors transduce an intracellular signal through the associated trimeric G protein, resulting in a rapid increase in intracellular calcium concentration. There are at least sixteen human chemokine receptors that bind or respond to β -chemokines with the following characteristic pattern: CCR1 (or "CKR-1" or "CC-CKR-1") [MIP-1 α , MIP-1 β , MCP-
25 3, RANTES] (Ben-Barruch, et al., J. Biol. Chem., 270, 22123-22128 (1995); Beote, et al, Cell, 72, 415-425 (1993)); CCR2A and CCR2B (or "CKR-2A"/"CKR-2A" or "CC-CKR-2A"/"CC-CKR-2A") [MCP-1, MCP-3, MCP-4]; CCR3 (or "CKR-3" or "CC-CKR-3") [eotaxin, RANTES, MCP-3] (Combadiere, et al., J. Biol. Chem., 270, 16491-16494 (1995); CCR4 (or "CKR-4" or "CC-CKR-4") [MIP-1 α , RANTES,
30 MCP-1] (Power, et al., J. Biol. Chem., 270, 19495-19500 (1995)); CCR5 (or "CKR-5" or "CC-CKR-5") [MIP-1 α , RANTES, MIP-1 β] (Sanson, et al., Biochemistry, 35, 3362-3367 (1996)); and the Duffy blood-group antigen [RANTES, MCP-1] (Chaudhun, et al., J. Biol. Chem., 269, 7835-7838 (1994)). The β -chemokines include eotaxin, MIP ("macrophage inflammatory protein"), MCP ("monocyte

chemoattractant protein") and RANTES ("regulation-upon-activation, normal T expressed and secreted").

Chemokine receptors, such as CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CXCR-3, CXCR-4, have been implicated as being important mediators of inflammatory and immunoregulatory disorders and diseases, including asthma, rhinitis and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. A review of the role of chemokines in allergic inflammation is provided by Kita, H., et al., J. Exp. Med. 183, 2421-2426 (1996). Accordingly, agents which modulate chemokine receptors would be useful in such disorders and diseases. Compounds which modulate chemokine receptors would be especially useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.

A retrovirus designated human immunodeficiency virus (HIV-1) is the etiological agent of the complex disease that includes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system. This virus was previously known as LAV, HTLV-III, or ARV.

Certain compounds have been demonstrated to inhibit the replication of HIV, including soluble CD4 protein and synthetic derivatives (Smith, et al., Science, 238, 1704-1707 (1987)), dextran sulfate, the dyes Direct Yellow 50, Evans Blue, and certain azo dyes (U.S. Patent No. 5,468,469). Some of these antiviral agents have been shown to act by blocking the binding of gp120, the coat protein of HIV, to its target, the CD4 glycoprotein of the cell.

Entry of HIV-1 into a target cell requires cell-surface CD4 and additional host cell cofactors. Fusin has been identified as a cofactor required for infection with virus adapted for growth in transformed T-cells, however, fusin does not promote entry of macrophagetropic viruses which are believed to be the key pathogenic strains of HIV in vivo. It has recently been recognized that for efficient entry into target cells, human immunodeficiency viruses require a chemokine receptors, most probably CCR5 or CXCR-4, as well as the primary receptor CD4 (Levy, N. Engl. J. Med., 335(20), 1528-1530 (Nov. 14 1996). The principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-trophic strains of HIV-1 is CCR5, a receptor for the β -chemokines RANTES, MIP-1 α and MIP-1 β (Deng, et al., Nature, 381, 661-666 (1996)). HIV attaches to the CD4

molecule on cells through a region of its envelope protein, gp120. It is believed that the CD-4 binding site on the gp120 of HIV interacts with the CD4 molecule on the cell surface, and undergoes conformational changes which allow it to bind to another cell-surface receptor, such as CCR5 and/or CXCR-4. This brings the viral envelope
5 closer to the cell surface and allows interaction between gp41 on the viral envelope and a fusion domain on the cell surface, fusion with the cell membrane, and entry of the viral core into the cell. It has been shown that β -chemokine ligands prevent HIV-1 from fusing with the cell (Dragic, et al., Nature, 381, 667-673 (1996)). It has further been demonstrated that a complex of gp120 and soluble CD4 interacts specifically
10 with CCR5 and inhibits the binding of the natural CCR5 ligands MIP-1 α and MIP-1 β (Wu, et al., Nature, 384, 179-183 (1996); Trkola, et al., Nature, 384, 184-187 (1996)).

Humans who are homozygous for mutant CCR5 receptors which are not expressed on the cell surface appear to be unusually resistant to HIV-1 infection and are not immuno-compromised by the presence of this genetic variant (Nature,
15 382, 722-725 (1996)). Absence of CCR5 appears to confer substantial protection from HIV-1 infection (Nature, 382, 668-669 (1996)). Other chemokine receptors may be used by some strains of HIV-1 or may be favored by non-sexual routes of transmission. Although most HIV-1 isolates studied to date utilize CCR5 or fusin, some can use both as well as the related CCR2B and CCR3 as co-receptors (Nature
20 Medicine, 2(11), 1240-1243 (1996)). Nevertheless, drugs targeting chemokine receptors may not be unduly compromised by the genetic diversity of HIV-1 (Zhang, et al., Nature, 383, 768 (1996)). Accordingly, an agent which could block chemokine receptors in humans who possess normal chemokine receptors should prevent infection in healthy individuals and slow or halt viral progression in infected patients.
25 By focusing on the host's cellular immune response to HIV infection, better therapies towards all subtypes of HIV may be provided. These results indicate that inhibition of chemokine receptors presents a viable method for the prevention or treatment of infection by HIV and the prevention or treatment of AIDS.

The peptides eotaxin, RANTES, MIP-1 α , MIP-1 β , MCP-1, and MCP-
30 3 are known to bind to chemokine receptors. As noted above, the inhibitors of HIV-1 replication present in supernatants of CD8+ T cells have been characterized as the β -chemokines RANTES, MIP-1 α and MIP-1 β .


SUMMARY OF THE INVENTION

The present invention is directed to compounds which inhibit the entry of human immunodeficiency virus (HIV) into target cells and are of value in the prevention of infection by HIV, the treatment of infection by HIV, the prevention and/or treatment of the resulting acquired immune deficiency syndrome (AIDS), and the delay in the onset of AIDS. The present invention also relates to pharmaceutical compositions containing the compounds and to a method of use of the present compounds and other agents for the prevention and treatment of AIDS and viral infection by HIV.

The present invention is further directed to compounds which are modulators of CCR5 chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

DETAILED DESCRIPTION OF THE INVENTION

The present invention includes compounds of Formula I:




wherein:

R¹ is:

- (1) -CO₂H,
- (2) -NO₂,
- (3) -tetrazolyl,
- (4) -hydroxyisoxazole,
- (5) -SO₂NHCO-(C₀₋₃ alkyl)-R^a, or
- (6) -P(O)(OH)(OR^a);

wherein R^a is independently selected from hydrogen, C₁₋₆ alkyl, C₅₋₆ cycloalkyl, benzyl and phenyl, where any one of which except hydrogen is optionally substituted with 1-3 substituents where the substituents are independently selected from halo, C₁₋₃ alkyl, -O-C₁₋₃ alkyl, and -CF₃,

R² is:



wherein “~” denotes the point of attachment;

R⁹ is selected from:

- (1) hydrogen,
- (2) C₁₋₆ alkyl, which is unsubstituted or substituted with 1-4 substituents where the substituents are independently selected from hydroxy, cyano, and halo,
- (3) cyano,
- (4) hydroxy, and
- (5) halo; and

Y is:

- (1) a direct single bond;

- (2) -C₁₋₁₀ alkyl- or -(C₀₋₆ alkyl)C₃₋₆cycloalkyl(C₀₋₆ alkyl)-, either of which is optionally substituted with 1-7 substituents independently selected from:

- 5 (a) halo,
 (b) hydroxy,
 (c) -O-C₁₋₃ alkyl,
 (d) -CF₃,
 (e) -(C₁₋₃ alkyl)hydroxy, and
 (f) ethylenedioxy;

- 10 (3) -(C₀₋₆ alkyl)-Z¹-(C₀₋₆ alkyl)-, wherein each alkyl is optionally substituted with 1-7 substituents independently selected from:

- 15 (a) halo,
 (b) hydroxy,
 (c) -O-C₁₋₃ alkyl, and
 (d) -CF₃;

and where Z¹ is selected from -SO₂-, -N(R^u)-,

-N(R^u)C(=CHR^s)N(R^u)-, -N(R^u)C(=NR^s)N(R^u)-, -S-, -O-, -SO-,
 -SO₂N(R^u)-, -N(R^u)SO₂-, and -PO₂-;

20 R^u is hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, benzyl, phenyl,
 (CO)C₁₋₆ alkyl, -SO₂-C₁₋₆ alkyl, -SO₂-phenyl, -SO₂-heterocycle, or
 C₁₋₆ alkyl-C₃₋₆ cycloalkyl; wherein any of which except hydrogen is
 optionally substituted with 1-3 substituents independently selected
 from halo, C₁₋₃ alkyl, -O-C₁₋₃ alkyl, and -CF₃;

R^s is hydrogen, C₁₋₄ alkyl, -NO₂ or -CN;

- 25 (4) -(C₀₋₆ alkyl)-Z²-(C₀₋₆ alkyl)-, wherein each alkyl is optionally substituted with 1-7 substituents independently selected from:

- 30 (a) halo,
 (b) hydroxy,
 (c) -O-C₁₋₃ alkyl, and
 (d) -CF₃;

and where:

Z² is selected from -C(=O)-, -C(=O)O-, -OC(=O)-,
 -C(=O)NR^v-, -NR^vC(=O)-, -OC(=O)NR^v-, -NR^vC(=O)O-, and -
 NR^wC(=O)NR^v-;

R^V is hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, benzyl, phenyl, or C₁₋₆ alkyl-C₃₋₆ cycloalkyl; wherein any of which except hydrogen is optionally substituted with 1-3 substituents independently selected from halo, C₁₋₃ alkyl, -O-C₁₋₃ alkyl, and -CF₃; and


R^W is hydrogen or C₁₋₆ alkyl;


R^{10} is:

- (1) a heterocycle selected from pyrazolyl and imidazolyl, wherein the pyrazolyl or imidazolyl is substituted with three of R^d , wherein each R^d is independently selected from the group consisting of:
 - (a) halo,
 - (b) cyano,
 - (c) hydroxy,
 - (d) C₁₋₆ alkyl, which is unsubstituted or substituted with 1-5 of R^e where R^e is independently selected from halo, cyano, hydroxy, -O-C₁₋₆ alkyl, -C₃₋₆ cycloalkyl, -CO₂H, -CO₂-(C₁₋₆ alkyl), -CF₃, -SO₂R^a, -NR^aR^b (where R^a is independently as defined above and R^b is independently selected from the definitions of R^a), phenyl, naphthyl, biphenyl, and heterocycle; wherein phenyl, naphthyl, biphenyl, or heterocycle is unsubstituted or substituted with 1-7 of R^f where R^f is independently selected from halo, cyano, hydroxy, C₁₋₆ alkyl, C₁₋₆ haloalkyl, -O-C₁₋₆ alkyl, -O-C₁₋₆ haloalkyl, -CO₂H, -CO₂(C₁₋₆ alkyl), -NR^aR^b, -(C₁₋₆ alkyl)-NR^aR^b, -SO₂R^a, -N(R^a)SO₂R^b, -N(R^a)COR^b, -(C₁₋₆ alkyl)hydroxy, -O-C₃₋₆ cycloalkyl, benzyloxy, phenoxy, and -NO₂,
 - (e) -O-C₁₋₆ alkyl, which is unsubstituted or substituted with 1-5 of R^e ,
 - (f) -O-phenyl, which is unsubstituted or substituted with 1-5 of R^f ,

- (g) -O-heterocycle, which is unsubstituted or substituted with 1-5 of R^f ,
 (h) -NO₂,
 (i) phenyl,
 (j) -CO₂R^a,
 (k) tetrazolyl,
 (l) -NR^aR^b,
 (m) -NR^a-COR^b,
 (n) -NR^a-CO₂R^b,
 (o) -CO-NR^aR^b,
 (p) -OCO-NR^aR^b,
 (q) -NR^aCO-NR^aR^b,
 (r) -S(O)_m-R^a, wherein m is an integer selected from 0, 1, and 2,
 (s) -S(O)₂-NR^aR^b,
 (t) -NR^aS(O)₂-R^b,
 (u) -NR^aS(O)₂-NR^aR^b,
 (v) C₂₋₆ alkenyl,
 (w) furanyl, which is unsubstituted or substituted with benzyl which is unsubstituted or substituted with 1-7 of R^f wherein R^f is independently as defined above,
 (x) -C₃₋₆ cycloalkyl, and
 (y) -O-C₃₋₆ cycloalkyl; or

(2) a heterocycle selected from:





wherein n is an integer equal to zero or 1, and

5

the heterocycle is mono-substituted in the pyrazolyl or imidazolyl ring with any one of R^d as defined above, and is either unsubstituted in the other ring or is substituted with 1 or more substituents where each substituent is independently selected from (a) to (y) of R^d as defined above;

10

R^3 is phenyl, naphthyl, or heterocycle, any one of which is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

15

- (a) halo,
- (b) C_{1-4} alkyl,
- (c) C_{1-4} haloalkyl,
- (d) hydroxy,
- (e) $-O-C_{1-4}$ alkyl,
- (f) $-O-C_{1-4}$ haloalkyl,
- (g) $-CO_2R^a$,
- (h) $-NR^aR^b$, and
- (i) $-CONR^aR^b$;

20

25

R^4 is hydrogen, C_{1-10} alkyl, C_{3-8} cycloalkyl, $-(C_{1-3}$ alkyl)- C_{3-8} cycloalkyl, $-(C_{0-2}$ alkyl)- $(C_{3-8}$ cycloalkylidenyl)- $(C_{1-2}$ alkyl), C_{2-10} alkenyl, C_{2-10} alkynyl, cyclohexenyl, phenyl, $-(C_{1-6}$ alkyl)-phenyl, naphthyl, dihydronaphthyl,

tetrahydronaphthyl, octahydronaphthyl, biphenyl, or heterocycle; wherein any one of which except for hydrogen is unsubstituted or substituted with 1-7 of R^d where R^d is independently as defined above;

- 5 R^5 is hydrogen or C_{1-6} alkyl, wherein the alkyl is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:
- (a) halo,
 - (b) $-CF_3$,
 - (c) hydroxy,
 - 10 (d) C_{1-3} alkyl,
 - (e) $-O-C_{1-3}$ alkyl,
 - (f) $-CO_2R^a$,
 - (g) $-NR^aR^b$, and
 - (h) $-CONR^aR^b$;

15

or alternatively R^4 and R^5 together with the carbon atom to which they are attached form a C_{3-8} cycloalkyl ring which may be unsubstituted or substituted with 1-7 of R^d ;

- 20 R^{6a} and R^{6b} are each independently C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, phenyl, naphthyl, or heterocycle; wherein any one of which is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:
- (a) halo,
 - 25 (b) C_{1-4} haloalkyl,
 - (c) hydroxy,
 - (d) C_{1-4} alkyl,
 - (e) $-O-C_{1-4}$ alkyl,
 - (f) $-O-C_{1-4}$ haloalkyl,
 - 30 (g) C_{3-8} cycloalkyl,
 - (h) $-CO_2R^a$,
 - (i) $-NR^aR^b$, and
 - (j) $-CONR^aR^b$;

or alternatively R^{6a} and R^{6b} together with the carbon atom to which they are attached form:

- (a) a 3- to 8-membered saturated carbocyclic ring, in which one of the ring carbons is optionally a member of a 3- to 8-membered spiro ring containing carbon atoms and optionally 1 or 2 heteroatoms independently selected from nitrogen, oxygen and sulfur;
- (b) a 4- to 8-membered monocyclic heterocycle containing from 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, in which one of the ring carbons is optionally a member of a 3- to 8-membered spiro ring containing carbon atoms and optionally 1 or 2 heteroatoms independently selected from nitrogen, oxygen and sulfur;
- (c) a 5- to 8-membered saturated carbocyclic ring to which is fused a C₃₋₈ cycloalkyl, or
- (d) a 5- to 8-membered heterocyclic ring containing from 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, to which is fused a C₃₋₈ cycloalkyl,


wherein the ring system of (a), (b), (c) or (d) is optionally substituted with from 1 to 3 substituents selected from halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, -O-C₁₋₄ alkyl, -O-C₁₋₄ haloalkyl, and hydroxy;

R^7 is hydrogen or C₁₋₆ alkyl; and

R^8 is hydrogen or C₁₋₆ alkyl;

or a pharmaceutically acceptable salt thereof.

An aspect of the present invention is a compound of Formula I as just defined, except that the choice of heterocycles in part (2) of the definition of R^{10} does



A first embodiment of the present invention is a compound of Formula I, wherein R^1 is:

- (1) $-\text{CO}_2\text{H}$,
- (2) $-\text{P}(\text{O})(\text{OH})_2$, or
- (3) $-\text{tetrazolyl}$;

5 and all other variables are as originally defined;


or a pharmaceutically acceptable salt thereof.

In one aspect of the first embodiment, R^1 is:

- 10 (1) $-\text{CO}_2\text{H}$, or
- (2) $-\text{tetrazolyl}$.

In another aspect of the first embodiment, R^1 is $-\text{CO}_2\text{H}$.

15 A second embodiment of the present invention is a compound of Formula I, R^2 is:




20 and all other variables are as originally defined;

or a pharmaceutically acceptable salt thereof.

In an aspect of the second embodiment, R^2 is:

25



A third embodiment of the present invention is a compound of Formula I, wherein R^3 is phenyl, thienyl, pyrazolyl, thiazolyl, thiadiazolyl, furanyl, oxadiazolyl, pyrazinyl, pyrimidinyl, or pyridyl, any one of which is unsubstituted or

30

substituted with 1-5 substituents where the substituents are independently selected from:

- (a) halo,
- (b) -CF₃,
- 5 (c) hydroxy,
- (d) C₁₋₃ alkyl, and
- (e) -O-C₁₋₃ alkyl;

10 and all other variables are as originally defined;
or a pharmaceutically acceptable salt thereof.

In an aspect of the third embodiment, R³ is phenyl or thienyl, either of which is unsubstituted or substituted with 1-5 substituents where the substituents are
15 independently selected from:

- (a) halo,
- (b) -CF₃,
- (c) hydroxy, and
- (d) C₁₋₃ alkyl.

20 In another aspect of the third embodiment, R³ is phenyl or thienyl, wherein the phenyl is optionally substituted with 1-5 substituents independently selected from fluoro and chloro.

25 In still another aspect of the third embodiment, R³ is unsubstituted phenyl, 3-fluorophenyl, or 3-thienyl.

A fourth embodiment of the present invention is a compound of Formula I, wherein R⁴ and R⁵ are both hydrogen;

30 and all other variables are as originally defined;
or a pharmaceutically acceptable salt thereof.

A fifth embodiment of the present invention is a compound of Formula I, wherein R^{6a} and R^{6b} are each independently C_{1-6} alkyl or C_{3-6} cycloalkyl, either of which is unsubstituted or substituted with 1-7 substituents independently selected from:

- 5 (a) halo,
 (b) $-CF_3$,
 (c) hydroxy, and
 (d) $-O-C_{1-3}$ alkyl;
- 10 or R^{6a} and R^{6b} together with the carbon atom to which they are attached form:
 (a) a 3- to 6-membered saturated carbocyclic ring,
 (b) a 4- to 6-membered saturated heterocyclic ring containing one
 oxygen atom, or
 (c) a 5- or 6-membered saturated carbocyclic ring to which is fused
15 a C_{3-6} cycloalkyl;
 wherein the ring system of (a), (b), or (c) is optionally substituted with
 from 1 to 3 substituents selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, $-O-C_{1-4}$
 alkyl, $-O-C_{1-4}$ haloalkyl, or hydroxy;
- 20 and all other variables are as originally defined;

or a pharmaceutically acceptable salt thereof.

25 In one aspect of the fifth embodiment, R^{6a} and R^{6b} are each C_{1-3}
alkyl;

or one of R^{6a} and R^{6b} is C_{1-3} alkyl, and the other of R^{6a} and R^{6b} is C_{3-6}
cycloalkyl;

30 or R^{6a} and R^{6b} together with the carbon atom to which they are attached form
cyclopropylidenyl, cyclobutylidenyl, cyclopentylidenyl, cyclohexylidenyl,
bicyclo[3.1.0]cyclohexylidenyl, tetrahydropyranylidenyl, or tetrahydrofuranylidenyl.

In another aspect of the fifth embodiment, R^{6a} and R^{6b} are just as defined in the preceding aspect, except that cyclopropylidenyl is not included among the choice of rings formed by R^{6a} and R^{6b} together with the carbon atom to which they are attached.

5

A sixth embodiment of the present invention is a compound of Formula I, wherein R⁷ is hydrogen;

and all other variables are as originally defined;

10

or a pharmaceutically acceptable salt thereof.

A seventh embodiment of the present invention is a compound of Formula I, wherein R⁸ is hydrogen;

15

and all other variables are as originally defined;

or a pharmaceutically acceptable salt thereof.

20

An eighth embodiment of the present invention is a compound of Formula I, wherein R⁸ is methyl;

and all other variables are as originally defined;

25

or a pharmaceutically acceptable salt thereof.

A ninth embodiment of the present invention is a compound of Formula I, wherein R⁹ is hydrogen, fluoro, hydroxy or C₁₋₆ alkyl;

30

and all other variables are as originally defined;

or a pharmaceutically acceptable salt thereof.

In an aspect of the ninth embodiment, R⁹ is hydrogen or fluoro. In another aspect of the ninth embodiment, R⁹ is hydrogen.

A tenth embodiment of the present invention is a compound of
5 Formula I, wherein Y is a direct single bond;

and all other variables are as originally defined;

or a pharmaceutically acceptable salt thereof.
10


An eleventh embodiment of the present invention is a compound of Formula I, wherein R¹⁰ is:

- (1) a heterocycle selected from pyrazolyl and imidazolyl, wherein the pyrazolyl or imidazolyl is substituted with three substituents independently
15 selected from the group consisting of:
- (a) halo,
 - (b) cyano,
 - (c) hydroxy,
 - (d) C₁₋₆ alkyl, which is unsubstituted or substituted with 1-
20 5 of R^e where R^e is independently selected from halo, cyano, hydroxy, -O-C₁₋₆ alkyl, -C₃₋₅ cycloalkyl, -CO₂H, -CO₂(C₁₋₆ alkyl), -CF₃, -SO₂R^a, -NR^aR^b,
where R^a and R^b are independently selected from hydrogen, C₁₋₆ alkyl, C₅₋₆ cycloalkyl,
25 benzyl or phenyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from halo, C₁₋₃ alkyl, -O-C₁₋₃ alkyl, C₁₋₃ fluoroalkyl, and -O-C₁₋₃ fluoroalkyl,
30 phenyl, naphthyl, biphenyl, and heterocycle,
wherein the phenyl, naphthyl, biphenyl or heterocycle is unsubstituted or substituted with 1-7 of R^f where R^f is independently selected from halo, cyano, hydroxy, C₁₋₄ alkyl, -O-C₁₋₄

alkyl, -O-C₃₋₅ cycloalkyl, -CO₂H, -CO₂(C₁₋₆ alkyl), -CF₃, -OCF₃, -SO₂R^a, -N(R^a)SO₂R^b and -NR^aR^b,

- (e) -O-C₁₋₆ alkyl, which is unsubstituted or substituted with 1-5 of R^e,
 (f) -NO₂,
 (g) phenyl,
 (h) -CO₂R^a,
 (i) tetrazolyl,
 (j) -NR^aR^b,
 (k) -NR^a-CO-R^b,
 (l) -NR^a-CO₂R^b,
 (m) -CO-NR^aR^b,
 (n) -OCO-NR^aR^b,
 (o) -NR^aCO-NR^aR^b,
 (p) -S(O)_m-R^a, wherein m is an integer selected from 0, 1, and 2,
 (q) -S(O)₂-NR^aR^b,
 (r) -NR^aS(O)₂-R^b,
 (s) -NR^aS(O)₂-NR^aR^b,
 (t) -C₂₋₃ alkenyl,
 (u) -C₃₋₆ cycloalkyl, and
 (v) -O-C₃₋₆ cycloalkyl; or

(2) a heterocycle selected from:



wherein the heterocycle is mono-substituted in the pyrazolyl or imidazolyl ring with any one of R^d as defined above, and is either unsubstituted in the other ring or substituted with 1 to 3 substituents independently selected from:

- 5
- (a) halo,
 - (b) C₁₋₄ alkyl,
 - (c) C₁₋₄ haloalkyl,
 - (d) -OH,
 - (e) -O-C₁₋₄ alkyl,
 - (f) -O-C₁₋₄ haloalkyl, and
 - (g) -CN;

10 and all other variables are as originally defined;
or a pharmaceutically acceptable salt thereof.

In an aspect of the eleventh embodiment, R¹⁰ is:

- 15 (1) a heterocycle selected from pyrazolyl and imidazolyl, wherein
the pyrazolyl or imidazolyl is substituted with three substituents independently
selected from the group consisting of:


- 20
- (a) halo,
 - (b) cyano,
 - (c) -NO₂,
 - (d) -CF₃,
 - (e) -CHF₂,
 - (f) -CH₂F,
 - (g) -CH₂OH,
 - (h) -CH₂OCH₃,
 - 25 (i) -(CH₂)₁₋₂SO₂-(C₁₋₂ alkyl)
 - (j) phenyl,
 - (k) C₁₋₆ alkyl, which is unsubstituted or substituted with
phenyl,

30 which is unsubstituted or substituted with 1-4 of
R^f where R^f is independently selected from
halo, cyano, hydroxy, -C₁₋₄ alkyl, -O-C₁₋₄
alkyl, -O-C₃₋₅ cycloalkyl, -CO₂H, -CO₂(C₁₋₆
alkyl), -CF₃, -OCF₃, -SO₂-(C₁₋₃ alkyl), and
-N(R^a)SO₂-(C₁₋₃ alkyl),

- (l) -O-C₁₋₆ alkyl,
- (m) -C₃₋₅ cycloalkyl,
- (n) -CH₂-(C₃₋₅ cycloalkyl), and
- (o) -O-C₃₋₅ cycloalkyl; or

5

(2) a heterocycle selected from:



10 wherein the heterocycle is mono-substituted in the pyrazolyl or imidazolyl ring with any one of R^d as defined above, and is either unsubstituted in the other ring or substituted with 1 to 3 substituents independently selected from:

- (a) halo,
- (b) C₁₋₄ alkyl,
- 15 (c) -CF₃,
- (d) -OH,
- (e) -O-C₁₋₄ alkyl,
- (f) -OCF₃, and
- (g) -CN.

20

In another aspect of the eleventh embodiment, R¹⁰ is:


(1) pyrazolyl substituted with three substituents independently selected from the group consisting of:

- (a) fluoro,
- 25 (b) chloro,
- (c) C₁₋₆ alkyl,
- (d) -CH₂-phenyl, wherein the phenyl is unsubstituted or substituted with 1 or 2 substituents independently selected from chloro, fluoro, -CN, -C₁₋₃ alkyl, -O-C₁₋₃ alkyl, -O-cyclopropyl, -O-cyclobutyl, -CF₃, -OCF₃, -SO₂-(C₁₋₃ alkyl), and -N(H)SO₂-(C₁₋₃ alkyl),
- 30

- (e) -CH₂CH₂-phenyl, and
- (f) phenyl; or

(2) a heterocycle selected from:

5



10 wherein the heterocycle is mono-substituted in the pyrazolyl ring with any one of R^d as defined above, and is either unsubstituted in the other ring or substituted with 1 to 3 substituents independently selected from:

- (a) fluoro,
- (b) chloro,
- (b) C₁₋₄ alkyl,
- (c) -CF₃,
- 15 (d) -OH,
- (e) -O-C₁₋₄ alkyl,
- (f) -OCF₃, and
- (g) -CN.


20 In still another aspect of the eleventh embodiment, R¹⁰ is as defined in the eleventh embodiment, except that (t) -C₂₋₃ alkenyl is not included as a possible substituent(s) on the heterocycle (1) selected from pyrazolyl and imidazolyl.

25 It is to be understood that additional embodiments of the present invention include, but are not limited to, compounds of Formula I wherein each of two or three or more of R¹, R², R³, R⁴, R⁵, R^{6a}, R^{6b}, R⁷, R⁸, R⁹, R¹⁰ and Y is independently defined in accordance with one of the foregoing embodiments or aspects thereof as set forth above. Any and all possible combinations of these variables in Formula I are within the scope of the present invention.

30 The compounds of the instant invention have at least two asymmetric centers at the ring junction of the substituents bearing R² and R³. Additional


asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are
 5 included within the ambit of this invention.

A first class of compounds of the present invention are compounds having the trans orientation, depicted as:



10 and pharmaceutically acceptable salts thereof.

A second class of the present invention is compounds of Formula (II):




15 wherein


R^{6a} and R^{6b} are each C_{1-3} alkyl;

or one of R^{6a} and R^{6b} is C_{1-3} alkyl, and the other of R^{6a} and R^{6b} is C_{3-6} cycloalkyl;

or R^{6a} and R^{6b} together with the carbon atom to which they are attached form:



R^{10} is:



R^{12} is C_{1-3} alkyl, C_{1-3} fluoroalkyl, or $-CH_2$ -phenyl wherein the phenyl is optionally substituted with 1 or 2 substituents independently selected from chloro, fluoro, $-CN$, $-C_{1-3}$ alkyl, $-O-C_{1-3}$ alkyl, $-O$ -cyclopropyl, $-O$ -cyclobutyl, $-CF_3$, $-OCF_3$, $-SO_2$ -(C_{1-3} alkyl), and $-NHSO_2$ -(C_{1-3} alkyl);

15

each of R^{14} and R^{16} is independently $-C_{1-3}$ alkyl, C_{1-3} fluoroalkyl, $-O-C_{1-3}$ alkyl, $-O-C_{1-3}$ fluoroalkyl, cyclopropyl, cyclobutyl, or $-CH_2$ -phenyl wherein the phenyl is optionally substituted with 1 or 2 substituents independently selected from chloro,

fluoro, -CN, -C₁₋₃ alkyl, -O-C₁₋₃ alkyl, -O-cyclopropyl, -O-cyclobutyl, -CF₃, -OCF₃, and -SO₂-(C₁₋₃ alkyl);

R¹⁸ is C₁₋₃ alkyl;


5

R²⁰ is -C₁₋₃ alkyl; and

X is hydrogen or fluoro;

10 or a pharmaceutically acceptable salt thereof.

A first sub-class of the present invention is a compound of Formula II, wherein R¹⁰ is:



R¹² is methyl or ethyl;

R¹⁴ is methyl or ethyl;

20

R¹⁶ is halo, methyl, or ethyl;

each R²² is independently chloro, fluoro, -CN, -C₁₋₃ alkyl, -O-C₁₋₃ alkyl, -O-cyclopropyl, -O-cyclobutyl, -CF₃, -OCF₃, or -SO₂-(C₁₋₃ alkyl); and


25

p is an integer from zero to 3;


and all other variables are as defined for the second class;

30 or a pharmaceutically acceptable salt thereof.

A second sub-class of the present invention is a compound of Formula II, wherein R¹⁰ is:




A third sub-class of the present invention is a compound of Formula II, wherein R¹⁰ is:



5 and all other variables are as defined in the second class;

or a pharmaceutically acceptable salt thereof.

A fourth sub-class of the present invention is a compound of
10 Formula II, wherein R¹⁰ is:



and all other variables are as defined in the second class;

15 or a pharmaceutically acceptable salt thereof.

The independent syntheses of the diastereomers described above or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry
20 may be determined by the x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration.

Other embodiments of the present invention include the following:

(a) A pharmaceutical composition comprising a compound of
25 Formula (I) and a pharmaceutically acceptable carrier.

(b) The pharmaceutical composition of (a), further comprising at least one antiviral selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, and nucleoside HIV reverse transcriptase inhibitors.

5 (c) A method for modulating (e.g., inhibiting) CCR5 chemokine receptor activity in a subject which comprises administering to the subject an effective amount of the compound of Formula (I).

(d) A method of preventing or treating infection by HIV in a subject in need thereof which comprises administering to the subject a therapeutically
10 effective amount of a compound of Formula (I).

(e) The method of (d), wherein the compound of Formula (I) is administered in combination with a therapeutically effective amount of at least one antiviral selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, and nucleoside HIV reverse
15 transcriptase inhibitors.

(f) A method of delaying the onset or AIDS or treating AIDS in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of Formula (I).

(g) The method of (f), wherein the compound is administered in
20 combination with a therapeutically effective amount of at least one antiviral selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, and nucleoside HIV reverse transcriptase inhibitors

(h) A method of modulating (e.g., inhibiting) CCR5 chemokine receptor activity in a subject in need thereof which comprises administering to the
25 subject a therapeutically effective amount of the composition of (a) or (b).

(i) A method of preventing or treating infection by HIV in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of the composition of (a) or (b).

(j) A method of treating AIDS or delaying the onset of AIDS in a
30 subject in need thereof which comprises administering to the subject a therapeutically effective amount of the composition of (a) or (b).

Still other embodiments of the present invention include the following:

(k) A pharmaceutical composition which comprises the product prepared by combining (e.g., mixing) an effective amount of a compound of Formula (I) and a pharmaceutically acceptable carrier.

5 (l) A combination useful for inhibiting HIV integrase, for treating or preventing infection by HIV, or for preventing, treating or delaying the onset of AIDS, which is a therapeutically effective amount of a compound of Formula (I) and a therapeutically effective amount of an HIV infection/AIDS treatment agent selected from the group consisting of HIV/AIDS antiviral agents, immunomodulators, and anti-infective agents.

10 (m) The combination of (l), wherein the HIV infection/AIDS treatment agent is an antiviral selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors and nucleoside HIV reverse transcriptase inhibitors.

15 Additional embodiments of the invention include the pharmaceutical compositions and methods set forth in (a)-(j) above and the compositions and combinations set forth in (k)-(m), wherein the compound employed therein is a compound of one of the embodiments, classes, sub-classes, or aspects of compounds described above. In all of these embodiments, the compound may optionally be used in the form of a pharmaceutically acceptable salt.

20 As used herein, the term "C₁₋₆ alkyl" (or "C₁-C₆ alkyl") means linear or branched chain alkyl groups having from 1 to 6 carbon atoms and includes all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. "C₁₋₄ alkyl" means n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. Similar terms such as "C₁₋₁₀ alkyl" have analogous meanings.

25 The term "C₀" as employed in expressions such as "C₀₋₆ alkyl" means a direct covalent bond.

30 The term "C₂₋₆ alkenyl" (or "C₂-C₆ alkenyl") means linear or branched chain alkenyl groups having from 2 to 6 carbon atoms and includes all of the hexenyl and pentenyl isomers as well as 1-butenyl, 2-butenyl, 3-butenyl, isobutenyl, 1-propenyl, 2-propenyl, and ethenyl (or vinyl). Similar terms such as "C₂₋₁₀ alkenyl" have analogous meanings.

The term "C₂₋₆ alkynyl" (or "C₂-C₆ alkynyl") means linear or branched chain alkynyl groups having from 2 to 6 carbon atoms and includes all of

the hexynyl and pentynyl isomers as well as 1-butyne, 2-butyne, 3-butyne, 1-propyne, 2-propyne, and ethyne (or acetylene). Similar terms such as "C₂-10 alkynyl" have analogous meanings.


The term "C₃-8 cycloalkyl" (or "C₃-C₈ cycloalkyl") means a cyclic ring of an alkane having three to eight total carbon atoms (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl). The term "C₃-6 cycloalkyl" refers to a cyclic ring selected from cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Similar terms such as "C₅-6 cycloalkyl" have analogous meanings.

The term "halogen" (or "halo") refers to fluorine, chlorine, bromine and iodine (alternatively, fluoro, chloro, bromo, and iodo).

The term "C₁-6 haloalkyl" (which may alternatively be referred to as "C₁-C₆ haloalkyl" or "halogenated C₁-C₆ alkyl") means a C₁ to C₆ linear or branched alkyl group as defined above with one or more halogen substituents. The term "C₁-4 haloalkyl" has an analogous meaning. Similarly, "C₁-6 fluoroalkyl" means a C₁ to C₆ linear or branched alkyl group as defined above with one or more fluorine substituents. Representative examples of suitable fluoroalkyls include the series (CH₂)₀₋₄CF₃ (i.e., trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoro-n-propyl, etc.), 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 3,3,3-trifluoroisopropyl, 1,1,1,3,3,3-hexafluoroisopropyl, and perfluorohexyl.

The term "-(C₁-6 alkyl)hydroxy" refers to a C₁-6 alkyl group as defined above which is substituted on one of its carbons by a hydroxy group. Exemplary groups include hydroxymethyl, hydroxyethyl, 3-hydroxy-n-propyl, 2-hydroxy-n-propyl, and so forth.

The term "C₃-8 cycloalkylidenyl" refers to a C₃-8 cycloalkyl group as defined above in which one of the ring carbons is attached to each of two carbon atoms not in the ring such that the three carbon atoms form a carbon chain or part of a carbon chain. Thus, "-(C₀-2 alkyl)-(C₃-8 cycloalkylidenyl)-(C₁-2 alkyl)" refers to and encompasses such groups as:



The term "carbocycle" (and variations thereof such as "carbocyclic" or "carbocyclyl") as used herein broadly refers to a C₃ to C₈ monocyclic, saturated or unsaturated ring or a C₇ to C₁₄ bicyclic ring system in which the rings are
5 independent or fused and in which each ring is saturated or unsaturated.

The term "aryl" refers to aromatic mono- and poly-carbocyclic ring systems, wherein the individual carbocyclic rings in the polyring systems may be fused or attached to each other via a single bond. Suitable aryl groups include, but are not limited to, phenyl, naphthyl, and biphenylenyl.

10 The term "heterocycle" (and variations thereof such as "heterocyclic" or "heterocyclyl") broadly refers to a 4- to 8-membered monocyclic ring, 7- to 14-membered bicyclic ring system, or an 11 to 16-membered tricyclic ring system, any ring of which is saturated or unsaturated, and which consists of carbon atoms and one or more heteroatoms (e.g., from 1 to 4 heteroatoms) selected from N, O and S, and
15 wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The heterocyclic ring may be attached at any heteroatom or carbon atom, provided that attachment results in the creation of a stable structure.

The term "heterocycle" as used herein is intended to include the
20 following groups: benzoimidazolyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolaziny, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl,
25 pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl,
30 dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl,

dihydrotriazolyl, methylenedioxybenzyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof.

The term "heterocycle" as used herein is also intended to include, but is not limited to, the following groups: methylenedioxyphenyl, imidazopyridyl, 5 imidazopyrimidinyl, imidazopyridazinyl, imidazopyrazinyl, imidazotriazinyl, imidazothiophenyl, pyrazolopyridyl, pyrazolopyrimidinyl, pyrazolopyridazinyl, pyrazolopyrazinyl, pyrazolotriazinyl, pyrazolothiophenyl, triazolopyridyl, triazolopyrimidinyl, triazolopyridazinyl, triazolopyrazinyl, triazolothiophenyl, tetrahydroimidazopyridinyl, tetrahydropyrazolopyridinyl, tetrahydrotriazopyridinyl, 10 tetrahydrotriazolopyridazinyl, and tetrahydroindazolyl.

The term "heterocycle" as used herein is also intended to include, but is not limited to, the following groups: tetrahydroimidazopyrimidinyl, tetrahydroimidazopyrazinyl, tetrahydroimidazopyridazinyl, tetrahydrotriazolopyrimidinyl, tetrahydrotriazolopyrazinyl, 15 tetrahydropyrazolopyrimidinyl, tetrahydropyrazolopyrazinyl, imidazothiazolyl, and imidazothiadiazolyl.

The term "heterocycle" as used herein is also intended to include, but is not limited to, oxopyridinyl (e.g., 2-oxopyridinyl), oxopiperidinyl, and oxopyrazolyl.

The terms "thiophenyl" and "thienyl" have the same meaning herein and are used interchangeably. Similarly, the following pairs of terms have the same meaning: "indazolyl" and "benzopyrazolyl"; "pyridinyl" and "pyridyl". 20

Unless expressly set forth to the contrary, an "unsaturated" ring is a partially or fully unsaturated ring.


The term "substituted" in reference to substitution on alkyl, cycloalkyl, 25 phenyl, heterocycle, or some other chemical group is intended to include mono- and poly-substitution by a named substituent to the extent such single and multiple substitution is chemically allowed in any of the named chemical groups.

It is understood that the definition of a substituent at a particular location in a molecule is independent of its definition at other locations in the molecule. Thus, for example, when $Z^1 = -N(R^u)C(=CHR^s)N(R^u)-$, the value of R^u 30 (defined elsewhere) on one of the nitrogens is independent of the value of R^u at the other nitrogen; i.e., they can be the same or different.

Exemplifying the invention are the compounds disclosed in the Examples and the use of these compounds as disclosed herein (e.g., for treating HIV infection or AIDS).


5 An aspect of the present invention is a compound selected from the group consisting of:

1-{[(3*S*,4*S*)-3-{[4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclopentanecarboxylic acid;




10

1-{[(3*S*,4*S*)-3-{[4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid;




15


1-{[(3*R*,4*S*)-3-{(1*R*)-1-[4-(1,3-diethyl-5-methyl-1*H*-pyrazol-4-yl)piperidin-1-yl]ethyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclobutanecarboxylic acid;




5 (1*R*,5*R*)-3-[[[(3*S*,4*S*)-3-(3,5-difluorophenyl)-4-{[4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]methyl}pyrrolidin-1-yl)methyl]bicyclo[3.1.0]hexane-3-carboxylic acid;




10 3-[(3*R*,4*S*)-3-{(1*R*)-1-[4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]ethyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]-2,2-dimethylpropanoic acid;




1-[[[(3*R*,4*S*)-3-{(1*R*)-1-[4-(1,3-diethyl-4-methyl-1*H*-pyrazol-5-yl)piperidin-1-yl]ethyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl]cyclopentanecarboxylic acid;



1-[[[(3*R*,4*S*)-3-{(1*R*)-1-[4-(1,3-diethyl-4-methyl-1*H*-pyrazol-5-yl)piperidin-1-yl]ethyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl]cyclohexanecarboxylic acid;




1-[(3*S*,4*S*)-3-{[4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methylcyclobutanecarboxylic acid;




5


1-[(3*S*,4*S*)-3-{[4-(1,3-diethyl-4-methyl-1*H*-pyrazol-5-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methylcyclohexanecarboxylic acid;




1-[[[(3*S*,4*S*)-3-{[4-(1,3-diethyl-4-methyl-1*H*-pyrazol-5-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl]cyclopentanecarboxylic acid;



1-[[[(3*S*,4*S*)-3-{[4-(2-ethyl-4,5,6,7-tetrahydro-2*H*-indazol-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl]cyclopentanecarboxylic acid;




1-{[(3*S*,4*S*)-3-{[4-(2-ethyl-4,5,6,7-tetrahydro-2*H*-indazol-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid;




5

2-ethyl-2-{[(3*S*,4*S*)-3-{[4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}butanoic acid;




10

2-{[(3*S*,4*S*)-3-{[4-(1,3-diethyl-5-methyl-1*H*-pyrazol-4-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}-2-ethylbutanoic acid;




5 (1*R*,5*S*)-3-{[(3*S*,4*S*)-3-{[4-(1,3-diethyl-4-methyl-1*H*-pyrazol-5-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}bicyclo[3.1.0]hexane-3-carboxylic acid;




10


(1*R*,5*S*)-3-{[(3*S*,4*S*)-3-{[4-(1,3-diethyl-5-methyl-1*H*-pyrazol-4-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}bicyclo[3.1.0]hexane-3-carboxylic acid;




3-[(3*S*,4*S*)-3-{[4-(1,3-diethyl-5-methyl-1*H*-pyrazol-4-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]-2,2-dimethylpropanoic acid;




(1*R*,5*S*)-3-{[(3*R*,4*S*)-3-{(1*R*)-1-[4-(1,3-diethyl-5-methyl-1*H*-pyrazol-4-yl)piperidin-1-yl]ethyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}bicyclo[3.1.0]hexane-3-carboxylic acid;



3-[(3*R*,4*S*)-3-{(1*R*)-1-[4-(1,3-diethyl-5-methyl-1*H*-pyrazol-4-yl)piperidin-1-yl]ethyl}-
 5 4-(3-fluorophenyl)pyrrolidin-1-yl]-2,2-dimethylpropanoic acid;



(1*R*,5*R*)-3-{[(3*S*,4*S*)-3-{[4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}bicyclo[3.1.0]hexane-3-carboxylic acid;



5

and pharmaceutically acceptable salts thereof.

The subject compounds are useful in a method of modulating (e.g., inhibiting) CCR5 chemokine receptor activity in a patient in need of such modulation (inhibition) comprising the administration of an effective amount of the compound.

The present invention is directed to the use of the foregoing compounds as modulators (inhibitors) of CCR5 chemokine receptor activity.

The utility of the compounds in accordance with the present invention as modulators of CCR5 chemokine receptor activity may be demonstrated by methodology known in the art, such as the assay for chemokine binding as disclosed by Van Riper, et al., *J. Exp. Med.*, 177, 851-856 (1993) which may be readily adapted for measurement of CCR5 binding. Cell lines for expressing the receptor of interest include those naturally expressing the receptor, such as EOL-3 or THP-1, or a cell engineered to express a recombinant receptor, such as CHO, RBL-2H3, HEK-293.

The utility of the compounds in accordance with the present invention as inhibitors of the spread of HIV infection in cells may be demonstrated by methodology known in the art, such as the HIV quantitation assay disclosed by Nunberg, et al., *J. Virology*, 65 (9), 4887-4892 (1991).

In particular, the compounds of the following examples had activity in binding to the CCR5 receptor in the aforementioned assays, generally with an IC₅₀ of

less than about 5 μ M. Such a result is indicative of the intrinsic activity of the compounds in use as modulators of CCR5 chemokine receptor activity.

Mammalian chemokine receptors provide a target for interfering with or promoting eosinophil and/or lymphocyte function in a mammal, such as a human.

5 Compounds which inhibit or promote chemokine receptor function, are particularly useful for modulating eosinophil and/or lymphocyte function for therapeutic purposes. Accordingly, the present invention is directed to compounds which are useful in the prevention and/or treatment of a wide variety of inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis,
10 dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis.

For example, an instant compound which inhibits one or more functions of a mammalian chemokine receptor (e.g., a human chemokine receptor) may be administered to inhibit (i.e., reduce or prevent) inflammation. As a result, one
15 or more inflammatory processes, such as leukocyte emigration, chemotaxis, exocytosis (e.g., of enzymes, histamine) or inflammatory mediator release, is inhibited. For example, eosinophilic infiltration to inflammatory sites (e.g., in asthma) can be inhibited according to the present method.

Similarly, an instant compound which promotes one or more functions
20 of a mammalian chemokine receptor (e.g., a human chemokine) is administered to stimulate (induce or enhance) an inflammatory response, such as leukocyte emigration, chemotaxis, exocytosis (e.g., of enzymes, histamine) or inflammatory mediator release, resulting in the beneficial stimulation of inflammatory processes. For example, eosinophils can be recruited to combat parasitic infections.

25 In addition to primates, such as humans, a variety of other mammals can be treated according to the method of the present invention. For instance, mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species can be treated. However, the method can also be practiced in other species, such as avian
30 species (e.g., chickens).

Diseases and conditions associated with inflammation and infection can be treated using the method of the present invention. In a preferred embodiment, the disease or condition is one in which the actions of eosinophils and/or lymphocytes are to be inhibited or promoted, in order to modulate the inflammatory response.

Diseases or conditions of humans or other species which can be treated with inhibitors of chemokine receptor function, include, but are not limited to: inflammatory or allergic diseases and conditions, including respiratory allergic diseases such as asthma, particularly bronchial asthma, allergic rhinitis, hypersensitivity lung diseases, hypersensitivity pneumonitis, eosinophilic pneumonias (e.g., Loeffler's syndrome, chronic eosinophilic pneumonia), delayed-type hypersensitivity, interstitial lung diseases (ILD) (e.g., idiopathic pulmonary fibrosis, or ILD associated with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, Sjogren's syndrome, polymyositis or dermatomyositis); systemic anaphylaxis or hypersensitivity responses, drug allergies (e.g., to penicillin, cephalosporins), insect sting allergies; autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, juvenile onset diabetes; glomerulonephritis, autoimmune thyroiditis, Behcet's disease; graft rejection (e.g., in transplantation), including allograft rejection or graft-versus-host disease; inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis; spondyloarthropathies; scleroderma; psoriasis (including T-cell mediated psoriasis) and inflammatory dermatoses such as dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria; vasculitis (e.g., necrotizing, cutaneous, and hypersensitivity vasculitis); eosinophilic myositis, eosinophilic fasciitis; cancers with leukocyte infiltration of the skin or organs. Other diseases or conditions in which undesirable inflammatory responses are to be inhibited can be treated, including, but not limited to, reperfusion injury, atherosclerosis, certain hematologic malignancies, cytokine-induced toxicity (e.g., septic shock, endotoxic shock), polymyositis, dermatomyositis.

Diseases or conditions of humans or other species which can be treated with promoters of chemokine receptor function, include, but are not limited to: immunosuppression, such as that in individuals with immunodeficiency syndromes such as AIDS, individuals undergoing radiation therapy, chemotherapy, therapy for autoimmune disease or other drug therapy (e.g., corticosteroid therapy), which causes immunosuppression; immunosuppression due congenital deficiency in receptor function or other causes; and infectious diseases, such as parasitic diseases, including, but not limited to helminth infections, such as nematodes (round worms); (Trichuriasis, Enterobiasis, Ascariasis, Hookworm, Strongyloidiasis, Trichinosis, filariasis); trematodes (flukes) (Schistosomiasis, Clonorchiasis), cestodes (tape

worms) (Echinococcosis, Taeniasis saginata, Cysticercosis); visceral worms, visceral larva migrans (e.g., Toxocara), eosinophilic gastroenteritis (e.g., Anisaki spp., *Phocanema ssp.*), cutaneous larva migrans (*Ancylostoma braziliense*, *Ancylostoma caninum*).

5 The compounds of the present invention are accordingly useful in the prevention and treatment of a wide variety of inflammatory and immunoregulatory disorders and diseases, allergic conditions, atopic conditions, as well as autoimmune pathologies.

 In another aspect, the instant invention may be used to evaluate
10 putative specific agonists or antagonists of CCR5 chemokine receptors. Accordingly, the present invention is directed to the use of these compounds in the preparation and execution of screening assays for compounds which modulate the activity of CCR5 chemokine receptors. For example, the compounds of this invention are useful for isolating receptor mutants, which are excellent screening tools for more potent
15 compounds. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other compounds to chemokine receptors, e.g., by competitive inhibition. The compounds of the instant invention are also useful for the evaluation of putative specific modulators of the CCR5 chemokine receptors. As appreciated in the art, thorough evaluation of specific agonists and antagonists of the
20 above chemokine receptors has been hampered by the lack of availability of non-peptidyl (metabolically resistant) compounds with high binding affinity for these receptors. Thus the compounds of this invention are commercial products to be sold for these purposes.

 The present invention is further directed to a method for the
25 manufacture of a medicament for modulating CCR5 chemokine receptor activity in humans and animals comprising combining a compound of the present invention with a pharmaceutical carrier or diluent.

 The present invention is further directed to the use of these compounds in the prevention or treatment of infection by a retrovirus, in particular, the human
30 immunodeficiency virus (HIV) and the treatment of, and delaying of the onset of consequent pathological conditions such as AIDS. Treating AIDS or preventing or treating infection by HIV is defined as including, but not limited to, treating a wide range of states of HIV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HIV. For

example, the compounds of this invention are useful in treating infection by HIV after suspected past exposure to HIV by, e.g., blood transfusion, organ transplant, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.

5 In an aspect of the present invention, a subject compound may be used in a method of inhibiting the binding of a chemokine to a CCR5 chemokine receptor of a target cell, which comprises contacting the target cell with an amount of the compound which is effective at inhibiting the binding of the chemokine to the CCR5 chemokine receptor.

10 The subject treated in the methods above is a mammal, preferably a human being, male or female, in whom modulation of CCR5 chemokine receptor activity is desired. "Modulation" as used herein is intended to encompass antagonism, agonism, partial antagonism, inverse agonism and/or partial agonism. In an aspect of the present invention, modulation refers to antagonism of CCR5 chemokine receptor activity. The term "therapeutically effective amount" means the amount of the subject
15 compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.

The term "composition" as used herein is intended to encompass a
20 product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

25 The terms "administration of" and or "administering a" compound should be understood to mean providing a compound of the invention to the individual in need of treatment.

The term "subject," (alternatively referred to herein as "patient") as
used herein refers to an animal, preferably a mammal, most preferably a human, who
30 has been the object of treatment, observation or experiment.

Combined therapy to modulate CCR5 chemokine receptor activity and thereby prevent and treat inflammatory and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, and those pathologies noted above is

illustrated by the combination of the compounds of this invention and other compounds which are known for such utilities.

For example, in the treatment or prevention of inflammation, the present compounds may be used in conjunction with an antiinflammatory or analgesic agent such as an opiate agonist, a lipxygenase inhibitor, such as an inhibitor of 5-lipxygenase, a cyclooxygenase inhibitor, such as a cyclooxygenase-2 inhibitor, an interleukin inhibitor, such as an interleukin-1 inhibitor, an NMDA antagonist, an inhibitor of nitric oxide or an inhibitor of the synthesis of nitric oxide, a non-steroidal antiinflammatory agent, or a cytokine-suppressing antiinflammatory agent, for example with a compound such as acetaminophen, aspirin, codiene, fentanyl, ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam, a steroidal analgesic, sufentanyl, sunlindac, tenidap, and the like. Similarly, the instant compounds may be administered with a pain reliever; a potentiator such as caffeine, an H₂-antagonist, simethicone, aluminum or magnesium hydroxide; a decongestant such as phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxy-ephedrine; an antiitussive such as codeine, hydrocodone, caramiphen, carbetapentane, or dextramethorphan; a diuretic; and a sedating or non-sedating antihistamine. Likewise, compounds of the present invention may be used in combination with other drugs that are used in the treatment/prevention/suppression or amelioration of the diseases or conditions for which compounds of the present invention are useful. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present invention. When a compound of the present invention is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of the present invention is preferred. Accordingly, the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of the present invention. Examples of other active ingredients that may be combined with a compound of the present invention, either administered separately or in the same pharmaceutical compositions, include, but are not limited to: (a) VLA-4 antagonists such as those described in US 5,510,332, WO95/15973, WO96/01644, WO96/06108, WO96/20216, WO96/22966, WO96/31206, WO96/40781, WO97/03094, WO97/02289, WO 98/42656, WO98/53814, WO98/53817, WO98/53818,

WO98/54207, and WO98/58902; (b) steroids such as beclomethasone, methylprednisolone, betamethasone, prednisone, dexamethasone, and hydrocortisone; (c) immunosuppressants such as cyclosporin, tacrolimus, rapamycin and other FK-506 type immunosuppressants; (d) antihistamines (H₁-histamine antagonists) such as

5 bromopheniramine, chlorpheniramine, dexchlorpheniramine, triprolidine, clemastine, diphenhydramine, diphenylpyraline, tripeleminamine, hydroxyzine, methdilazine, promethazine, trimeprazine, azatadine, cyproheptadine, antazoline, pheniramine pyrilamine, astemizole, terfenadine, loratadine, cetirizine, fexofenadine, descarboethoxyloratadine, and the like; (e) non-steroidal anti-asthmatics such as β 2-

10 agonists (terbutaline, metaproterenol, fenoterol, isoetharine, albuterol, bitolterol, and pirbuterol), theophylline, cromolyn sodium, atropine, ipratropium bromide, leukotriene antagonists (zafirlukast, montelukast, pranlukast, iralukast, pobilukast, SKB-106,203), leukotriene biosynthesis inhibitors (zileuton, BAY-1005); (f) non-steroidal antiinflammatory agents (NSAIDs) such as propionic acid derivatives

15 (alminoprofen, benoxaprofen, bucloxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen, indoprofen, ketoprofen, miroprofen, naproxen, oxaprozin, piroprofen, pranoprofen, suprofen, tiaprofenic acid, and tioxaprofen), acetic acid derivatives (indomethacin, acemetacin, alclofenac, clidanac, diclofenac, fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac,

20 sulindac, tiopinac, tolmetin, zidometacin, and zomepirac), fenamic acid derivatives (flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid and tolfenamic acid), biphenylcarboxylic acid derivatives (diflunisal and flufenisal), oxicams (isoxicam, piroxicam, sudoxicam and tenoxicam), salicylates (acetyl salicylic acid, sulfasalazine) and the pyrazolones (apazone, bezpiperylon, feprazone, mofebutazone,

25 oxyphenbutazone, phenylbutazone); (g) cyclooxygenase-2 (COX-2) inhibitors; (h) inhibitors of phosphodiesterase type IV (PDE-IV); (i) other antagonists of the chemokine receptors, especially CXCR-4, CCR1, CCR2, CCR3 and CCR5; (j) cholesterol lowering agents such as HMG-CoA reductase inhibitors (lovastatin, simvastatin and pravastatin, fluvastatin, atorvastatin, and other statins), sequestrants

30 (cholestyramine and colestipol), nicotinic acid, fenofibric acid derivatives (gemfibrozil, clofibrat, fenofibrate and benzaifibrate), and probucol; (k) anti-diabetic agents such as insulin, sulfonylureas, biguanides (metformin), α -glucosidase inhibitors (acarbose) and glitazones (troglitazone and pioglitazone); (l) preparations of interferon beta (interferon beta-1 α , interferon beta-1 β); (m) other compounds such as

5-aminosalicylic acid and prodrugs thereof, antimetabolites such as azathioprine and 6-mercaptopurine, and cytotoxic cancer chemotherapeutic agents. The weight ratio of the compound of the compound of the present invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient.

5 Generally, an effective dose of each will be used. Thus, for example, when a compound of the present invention is combined with an NSAID the weight ratio of the compound of the present invention to the NSAID will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200. Combinations of a compound of the present invention and other active ingredients will generally also be
10 within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.

The present invention is further directed to combinations of the present compounds with one or more agents useful in the prevention or treatment of AIDS. For example, the compounds of this invention may be effectively administered,
15 whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of the antiviral agents, immunomodulators, anti-infectives, or vaccines suitable for treating HIV infection and AIDS, and known to those of ordinary skill in the art, including those listed in the following Table:

20

ANTIVIRALS

<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
Amprenavir 141 W94 GW 141	Glaxo Wellcome	HIV infection, AIDS, ARC (protease inhibitor)
Abacavir GW 1592 1592U89	Glaxo Wellcome	HIV infection, AIDS, ARC (reverse transcriptase inhibitor)
Acemannan	Carrington Labs (Irving, TX)	ARC
Acyclovir	Burroughs Wellcome	HIV infection, AIDS, ARC, in combination with AZT

AD-439	Tanox Biosystems	HIV infection, AIDS, ARC
AD-519	Tanox Biosystems	HIV infection, AIDS, ARC
Adefovir dipivoxil	Gilead Sciences	HIV infection
AL-721	Ethigen (Los Angeles, CA)	ARC, PGL, HIV positive, AIDS
Alpha Interferon	Glaxo Wellcome	Kaposi's sarcoma, HIV, in combination w/Retrovir
Ansamycin	Adria Laboratories	ARC
LM 427	(Dublin, OH) Erbamont (Stamford, CT)	
Antibody which neutralizes pH labile alpha aberrant Interferon	Advanced Biotherapy Concepts (Rockville, MD)	AIDS, ARC
AR177	Aronex Pharm	HIV infection, AIDS, ARC
beta-fluoro-ddA	Nat'l Cancer Institute	AIDS-associated diseases
BMS-232623 (CGP-73547)	Bristol-Myers Squibb/ Novartis	HIV infection, AIDS, ARC (protease inhibitor)
BMS-234475 (CGP-61755)	Bristol-Myers Squibb/ Novartis	HIV infection, AIDS, ARC (protease inhibitor)
CI-1012	Warner-Lambert	HIV-1 infection
Cidofovir	Gilead Science	CMV retinitis, herpes, papillomavirus
Curdlan sulfate	AJI Pharma USA	HIV infection
Cytomegalovirus immune globin	MedImmune	CMV retinitis
Cytovene	Syntex	sight threatening CMV
Ganciclovir		peripheral CMV retinitis

Delaviridine	Pharmacia-Upjohn	HIV infection, AIDS, ARC (protease inhibitor)
Dextran Sulfate	Ueno Fine Chem. Ind. Ltd. (Osaka, Japan)	AIDS, ARC, HIV positive asymptomatic
ddC	Hoffman-La Roche	HIV infection, AIDS, ARC
Dideoxycytidine		
ddI	Bristol-Myers Squibb	HIV infection, AIDS, ARC; combination with AZT/d4T
Dideoxyinosine		
mozenavir (DMP-450)	AVID (Camden, NJ)	HIV infection, AIDS, ARC (protease inhibitor)
EL10	Elan Corp, PLC (Gainesville, GA)	HIV infection
Efavirenz (DMP 266) (-) 6-Chloro-4(S)- cyclopropylethynyl- 4(S)-trifluoro-methyl- 1,4-dihydro-2H-3,1- benzoxazin-2-one,	DuPont (SUSTIVA®), Merck (STOCRIN®)	HIV infection, AIDS, ARC (non-nucleoside RT inhibitor)
Famciclovir	Smith Kline	herpes zoster, herpes simplex
FTC	Emory University	HIV infection, AIDS, ARC (reverse transcriptase inhibitor)
GS 840	Gilead	HIV infection, AIDS, ARC (reverse transcriptase inhibitor)
HBV097	Hoechst Marion Roussel	HIV infection, AIDS, ARC (non-nucleoside reverse transcriptase inhibitor)

Hypericin	VIMRx Pharm.	HIV infection, AIDS, ARC
Recombinant Human Interferon Beta	Triton Biosciences (Alameda, CA)	AIDS, Kaposi's sarcoma, ARC
Interferon alfa-n3	Interferon Sciences	ARC, AIDS
Indinavir	Merck	HIV infection, AIDS, ARC, asymptomatic HIV positive, also in combination with AZT/ddI/ddC
Compound A	Merck	HIV infection, AIDS, ARC, asymptomatic HIV positive
ISIS 2922	ISIS Pharmaceuticals	CMV retinitis
KN1-272	Nat'l Cancer Institute	HIV-assoc. diseases
Lamivudine, 3TC	Glaxo Wellcome	HIV infection, AIDS, ARC (reverse transcriptase inhibitor); also with AZT
Lobucavir	Bristol-Myers Squibb	CMV infection
Nelfinavir	Agouron Pharmaceuticals	HIV infection, AIDS, ARC (protease inhibitor)
Nevirapine	Boehrering Ingelheim	HIV infection, AIDS, ARC (protease inhibitor)
Novapren	Novaferon Labs, Inc. (Akron, OH)	HIV inhibitor
Peptide T Octapeptide Sequence	Peninsula Labs (Belmont, CA)	AIDS
Trisodium Phosphonoformate	Astra Pharm. Products, Inc	CMV retinitis, HIV infection, other CMV infections
PNU-140690	Pharmacia Upjohn	HIV infection, AIDS, ARC (protease inhibitor)
Probucol	Vyrex	HIV infection, AIDS

RBC-CD4	Sheffield Med. Tech (Houston TX)	HIV infection, AIDS, ARC
Ritonavir (ABT-538)	Abbott	HIV infection, AIDS, ARC (protease inhibitor)
Saquinavir	Hoffmann-LaRoche	HIV infection, AIDS, ARC (protease inhibitor)
Stavudine; d4T Didhydrodeoxy- thymidine	Bristol-Myers Squibb	HIV infection, AIDS, ARC
Valaciclovir	Glaxo Wellcome	genital HSV & CMV infections
Virazole	Viratek/ICN	asymptomatic HIV
Ribavirin	(Costa Mesa, CA)	positive, LAS, ARC
VX-478	Vertex	HIV infection, AIDS, ARC
Zalcitabine	Hoffmann-La Roche	HIV infection, AIDS, ARC, with AZT
Zidovudine; AZT	Glaxo Wellcome	HIV infection, AIDS, ARC, Kaposi's sarcoma in combination with other therapies (reverse transcriptase inhibitor)
ABT-378; Lopinavir	Abbott	HIV infection, AIDS, ARC (protease inhibitor)
ABT-378/r; contains lopinavir and ritonavir; Kaletra	Abbott	HIV infection, AIDS, ARC (protease inhibitor)
JE2147/AG1776	Agouron	HIV infection, AIDS, ARC (protease inhibitor)
T-20	Trimeris	HIV infection, AIDS, ARC (fusion inhibitor)
T-1249	Trimeris	HIV infection, AIDS, ARC (fusion inhibitor)
atazanavir (BMS 232632)	Bristol-Myers-Squibb	HIV infection, AIDS, ARC (protease inhibitor)

PRO 542	Progenics	HIV infection, AIDS, ARC (attachment inhibitor)
PRO 140	Progenics	HIV infection, AIDS, ARC (CCR5 co-receptor inhibitor)
TAK-779	Takeda	HIV infection, AIDS, ARC (injectable CCR5 receptor antagonist)
DPC 681 & DPC 684	DuPont	HIV infection, AIDS, ARC (protease inhibitors)
DPC 961 & DPC 083	DuPont	HIV infection AIDS, ARC (nucleoside reverse transcriptase inhibitors)
Trizivir (contains abacavir, lamivudine, and zidovudine)	GlaxoSmithKline	HIV infection, AIDS, ARC (reverse transcriptase inhibitors)
tipranavir (PNU-140690)	Boehringer Ingelheim (purchased from Pharmacia & Upjohn)	HIV infection, AIDS, ARC (protease inhibitor)
tenofovir disoproxil fumarate	Gilead	HIV infection, AIDS, ARC (reverse transcriptase inhibitor)
TMC-120 & TMC-125	Tibotec	HIV infections, AIDS, ARC (non-nucleoside reverse transcriptase inhibitors)
TMC-126	Tibotec	HIV infection, AIDS, ARC (protease inhibitor)

IMMUNO-MODULATORS

<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
AS-101	Wyeth-Ayerst	AIDS
Bropirimine	Pharmacia Upjohn	advanced AIDS
Acemannan	Carrington Labs, Inc. (Irving, TX)	AIDS, ARC

CL246,738	American Cyanamid Lederle Labs	AIDS, Kaposi's sarcoma
EL10	Elan Corp, PLC (Gainesville, GA)	HIV infection
FP-21399	Fuki ImmunoPharm	blocks HIV fusion with CD4+ cells
Gamma Interferon	Genentech	ARC, in combination w/TNF (tumor necrosis factor)
Granulocyte Macrophage Colony Stimulating Factor	Genetics Institute Sandoz	AIDS
Granulocyte Macrophage Colony Stimulating Factor	Hoeschst-Roussel Immunex	AIDS
Granulocyte Macrophage Colony Stimulating Factor	Schering-Plough	AIDS, combination w/AZT
HIV Core Particle Immunostimulant	Rorer	seropositive HIV
IL-2	Cetus	AIDS, in combination w/AZT
Interleukin-2		
IL-2	Hoffman-La Roche	AIDS, ARC, HIV, in combination w/AZT
Interleukin-2	Immunex	
IL-2	Chiron	AIDS, increase in CD4 cell counts
Interleukin-2 (aldeslukin)		
Immune Globulin Intravenous (human)	Cutter Biological (Berkeley, CA)	pediatric AIDS, in combination w/AZT
IMREG-1	Imreg (New Orleans, LA)	AIDS, Kaposi's sarcoma, ARC, PGL

IMREG-2	Imreg (New Orleans, LA)	AIDS, Kaposi's sarcoma, ARC, PGL
Imuthiol Diethyl Dithio Carbamate	Merieux Institute	AIDS, ARC
Alpha-2 Interferon	Schering Plough	Kaposi's sarcoma w/AZT, AIDS
Methionine- Enkephalin	TNI Pharmaceutical (Chicago, IL)	AIDS, ARC
MTP-PE	Ciba-Geigy Corp.	Kaposi's sarcoma
Muramyl-Tripeptide Granulocyte Colony Stimulating Factor	Amgen	AIDS, in combination w/AZT
Remune rCD4 Recombinant Soluble Human CD4 rCD4-IgG hybrids	Immune Response Corp. Genentech	immunotherapeutic AIDS, ARC
Recombinant Soluble Human CD4	Biogen	AIDS, ARC
Interferon Alfa 2a	Hoffman-La Roche	Kaposi's sarcoma, AIDS, ARC, in combination w/AZT
SK&F106528	Smith Kline	HIV infection
Soluble T4		
Thymopentin	Immunobiology Research Institute	HIV infection
Tumor Necrosis Factor; TNF etanercept	Genentech Immunex Corp (Enbrel®)	ARC, in combination w/gamma Interferon rheumatoid arthritis
infliximab	Centocor (Remicade®)	rheumatoid arthritis and Crohn's disease

ANTI-INFECTIVES

<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
Clindamycin with Primaquine	Pharmacia Upjohn	PCP
Fluconazole	Pfizer	cryptococcal meningitis, candidiasis
Pastille Nystatin Pastille	Squibb Corp.	prevention of oral candidiasis
Ornidyl Eflornithine	Merrell Dow	PCP
Pentamidine Isethionate (IM & IV)	LyphoMed (Rosemont, IL)	PCP treatment
Trimethoprim		antibacterial
Trimethoprim/sulfa		antibacterial
Piritrexim	Burroughs Wellcome	PCP treatment
Pentamidine isethionate for inhalation	Fisons Corporation	PCP prophylaxis
Spiramycin	Rhone-Poulenc	cryptosporidia diarrhea
Intraconazole- R51211	Janssen Pharm.	histoplasmosis; cryptococcal meningitis
Trimetrexate	Warner-Lambert	PCP

OTHER

5

<u>Drug Name</u>	<u>Manufacturer</u>	<u>Indication</u>
Daunorubicin	NeXstar, Sequus	Karposi's sarcoma
Recombinant Human Erythropoietin	Ortho Pharm. Corp.	severe anemia assoc. with AZT therapy
Recombinant Human Growth Hormone	Serono	AIDS-related wasting, cachexia

Leukotriene B4 Receptor Antagonist	-	HIV infection
Megestrol Acetate	Bristol-Myers Squibb	treatment of anorexia assoc. w/AIDS
Soluble CD4 Protein and Derivatives	-	HIV infection
Testosterone	Alza, Smith Kline	AIDS-related wasting
Total Enteral Nutrition	Norwich Eaton Pharmaceuticals	diarrhea and malabsorption, related to AIDS

It will be understood that the scope of combinations of the compounds of this invention with HIV/AIDS antivirals, immunomodulators, anti-infectives or vaccines is not limited to the list in the above Table, but includes in principle any combination with any pharmaceutical composition useful for the treatment of HIV infection or AIDS. When employed in combination with the compounds of the invention, the HIV/AIDS antivirals and other agents are typically employed in their conventional dosage ranges and regimens as reported in the art, including the dosages described in the Physicians' Desk Reference, 54th edition, Medical Economics Company, 2000. The dosage ranges for a compound of the invention in these combinations are the same as those set forth above just before the above Table.

Preferred combinations are simultaneous or alternating treatments with a compound of the present invention and an inhibitor of HIV protease and/or a non-nucleoside inhibitor of HIV reverse transcriptase. An optional fourth component in the combination is a nucleoside inhibitor of HIV reverse transcriptase, such as AZT, 3TC, ddC or ddI. Preferred agents for combination therapy include: Zidovudine, Lamivudine, Stavudine, Efavirenz, Ritonavir, Nelfinavir, Abacavir, Indinavir, 141-W94 (4-amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-ylloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide), N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(4-(2-benzo[b]furanylmethyl)-2(S)-N'(t-butylcarbox-amido)-piperazinyl))-pentaneamide, and Delavirdine. A preferred inhibitor of HIV protease is indinavir, which is the sulfate salt of N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4-(S)-hydroxy-5-(1-(4-(3-pyridyl-methyl)-2(S)-N'(t-butylcarbo-xamido)-piperazinyl))-pentane-amide ethanolate, and is synthesized

according to U.S. 5,413,999. Indinavir is generally administered at a dosage of 800 mg three times a day. Other preferred inhibitors of HIV protease include nelfinavir and ritonavir. Preferred non-nucleoside inhibitors of HIV reverse transcriptase include (-) 6-chloro-4(S)-cyclopropylethynyl-4(S)-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one, which may be prepared by methods disclosed in EP 0,582,455. The preparation of ddC, ddI and AZT are also described in EPO 0,484,071. These combinations may have unexpected effects on limiting the spread and degree of infection of HIV. Preferred combinations with the compounds of the present invention include the following: (1) Zidovudine and Lamivudine; (2) Stavudine and Lamivudine; (3) Efavirenz; (4) Ritoavir; (5) Nelfinavir; (6) Abacavir; (7) Indinavir; (8) 141-W94; and (9) Delavirdine. Preferred combinations with the compounds of the present invention further include the following (1) indinavir, with efavirenz or (-) 6-chloro-4(S)-cyclopropylethynyl-4(S)-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one, and, optionally, AZT and/or 3TC and/or ddI and/or ddC; (2) indinavir, and any of AZT and/or ddI and/or ddC.

Compound A in the foregoing Table is N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(2-benzo[b]furanylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))pentaneamide, preferably administered as the sulfate salt. Compound A can be prepared as described in US 5646148.

In such combinations the compound of the present invention and other active agents may be administered separately or in conjunction. In addition, the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).

The compounds of the present invention may be administered in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" is intended to include all acceptable salts such as acetate, lactobionate, benzenesulfonate, laurate, benzoate, malate, bicarbonate, maleate, bisulfate, mandelate, bitartrate, mesylate, borate, methylbromide, bromide, methylnitrate, calcium edetate, methylsulfate, camsylate, mucate, carbonate, napsylate, chloride, nitrate, clavulanate, N-methylglucamine, citrate, ammonium salt, dihydrochloride, oleate, edetate, oxalate, edisylate, pamoate (embonate), estolate, palmitate, esylate, pantothenate, fumarate, phosphate/diphosphate, gluceptate, polygalacturonate, gluconate, salicylate, glutamate, stearate, glycollylarsanilate, sulfate, hexylresorcinate, subacetate, hydrabamine, succinate, hydrobromide, tannate, hydrochloride, tartrate,

hydroxynaphthoate, teoate, iodide, tosylate, isothionate, triethiodide, lactate, pantoate, valerate, and the like which can be used as a dosage form for modifying the solubility or hydrolysis characteristics or can be used in sustained release or pro-drug formulations. Depending on the particular functionality of the compound of the present invention, pharmaceutically acceptable salts of the compounds of this invention include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethyl-amine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and tetramethylammonium hydroxide. These salts may be prepared by standard procedures, e.g. by reacting a free acid with a suitable organic or inorganic base. Where a basic group is present, such as amino, an acidic salt, i.e. hydrochloride, hydrobromide, acetate, pantoate, and the like, can be used as the dosage form.

Also, in the case of an acid (-COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed, e.g. acetate, maleate, pivaloyloxymethyl, and the like, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.

The compounds of the present invention may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant), by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, monkeys, etc., the compounds of the invention are effective for use in humans.

The pharmaceutical compositions for the administration of the compounds of this invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing the

active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases. As
5 used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

The pharmaceutical compositions containing the active ingredient may
10 be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting
15 of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose,
20 calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a
25 sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Patents 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin
30 capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally- occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy

bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.

5 Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.

 The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated
10 according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water,
15 Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

 The compounds of the present invention may also be administered in
20 the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

25 For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention are employed. (For purposes of this application, topical application shall include mouthwashes and gargles.)

 The pharmaceutical composition and method of the present invention may further comprise other therapeutically active compounds as noted herein which
30 are usually applied in the treatment of the above mentioned pathological conditions.

 In the treatment or prevention of conditions which require chemokine receptor modulation an appropriate dosage level will generally be about 0.01 to 500 mg per kg patient body weight per day which can be administered in single or multiple doses. Preferably, the dosage level will be about 0.1 to about 250 mg/kg per

day; more preferably about 0.5 to about 100 mg/kg per day. A suitable dosage level may be about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day. Within this range the dosage may be 0.05 to 0.5, 0.5 to 5 or 5 to 50 mg/kg per day. For oral administration, the compositions are preferably
 5 provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day,
 10 preferably once or twice per day.

It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight,
 15 general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

Abbreviations used in the instant specification, particularly the Schemes and Examples, include the following:

Ac = acetyl
 20 Bn = benzyl
 BOC or Boc = t-butyloxycarbonyl
 Bu = butyl
i-Bu = isobutyl
t-Bu = tert-butyl
 25 n-BuLi = n-butyl lithium
 DDQ = 2,3-dichloro-5,6-dicyano-1,4-benzoquinone
 DIBAL = diisobutylaluminum hydride
 DIEA or DIPEA = diisopropylethylamine
 DMAP = dimethylaminopyridine
 30 DMF = N,N-dimethylformamide
 DMSO = dimethylsulfoxide
 EDC or EDAC = 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
 Et = ethyl
 ether = diethyl ether

h = hour(s)

HMDS = hexamethyldisilazyl

LDA = lithium diisopropylamide

LHMDS or LiHMDS = lithium hexamethyldisilazide

5 Me = methyl

min = minute(s)

Ph = phenyl

Pr = propyl

i-Pr = isopropyl

10 PMB = *p*-methoxybenzyl

rt = room temperature

sat'd = saturated aqueous


TBSO = *t*-butyldimethylsiloxy

TEA = triethylamine

15 TFA = trifluoroacetic acid

The compounds of the present invention can be readily prepared according to the following reaction schemes and examples, or modifications thereof. Starting materials can be made from procedures known in the art or as illustrated. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art, but are not mentioned in greater detail. Furthermore, other methods for preparing compounds of the invention will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. Unless otherwise indicated, the variables are as defined above.


SCHEME 1



30 The preparation of cinnamate esters such as 1-3 (wherein R^3 = an aromatic group) as intermediates that can be used for the synthesis of compounds


within the scope of the instant invention is detailed in Scheme 1. Cinnamate esters of structure 1-3 can be obtained commercially or can be synthesized by reacting a suitable aromatic aldehyde 1-1 with a phosphonoacetate such as 1-2 or a stabilized Wittig reagent in the presence of sodium hydride or other bases such as sodium, lithium or potassium hexamethyldisilazide, potassium t-butoxide, and the like. The aldehyde 1-1 can be obtained commercially or can be prepared in a variety of ways from commercial materials (see March J. "Advanced Organic Chemistry", 4th ed., John Wiley & Sons, New York, pp. 1270-1271 (1992)).

10


SCHEME 2

The preparation of compounds within the scope of the instant invention which bear a 1,3,4-trisubstituted pyrrolidine framework is detailed in Scheme 2.


Treatment of a trans-cinnamic ester such as 2-1 with commercially available N-benzyl-N-methoxymethyl-N-(trimethylsilyl)-methylamine (2-2) in the presence of a substoichiometric amount of an acid such as TFA, titanium tetrafluoride, lithium fluoride or cesium fluoride, according to the procedure of Padwa et al (*J. Org. Chem.* **1987**, 52, 235) preferentially affords the 3,4-trans pyrrolidine 2-3. Executing this sequence starting from the cis-cinnamic ester results in preferential formation of the 3,4-cis pyrrolidine. Reduction of ester 2-3, for example, with diisobutylaluminum hydride, lithium aluminium hydride, or sodium bis(2-methoxyethoxy)aluminum hydride, provides the primary alcohol 2-4. Oxidation to the aldehyde 2-5 can be carried out under numerous conditions, such as with the Dess-Martin periodinane, with DMSO and oxalyl chloride at low temperature, followed by triethylamine (Swern oxidation), or with various chromium trioxide-based reagents (see March J. "Advanced Organic Chemistry", 4th ed., John Wiley & Sons, New York, pp. 1167-1171 (1992)). Reductive amination with cyclic amine 2-6 then provides diamine 2-7, which can itself be a chemokine receptor modulator. Alternatively, the N-benzyl group is cleaved in a hydrogen atmosphere or with ammonium formate in the presence of 20% palladium hydroxide to provide the secondary amine 2-8.



20




Scheme 3 shows the preparation of optically pure pyrrolidine intermediates. Hydrolysis of unsaturated ester 3-1 provided acid 3-2, which is converted to diacyl derivative 3-4 by activation of the acid group, for example by formation of a mixed anhydride with pivaloyl chloride, followed by reaction with the lithium salt of 4-(S)-benzyloxazolidin-2-one (3-3). Treatment of 3-4 with commercially available N-benzyl-N-methoxymethyl-N-(trimethylsilyl)-methylamine (2-2) in the presence of a substoichiometric amount of an acid such as TFA, titanium tetrafluoride, lithium fluoride or cesium fluoride according to the procedure of Padwa et al (*J. Org. Chem.* **1987**, 52, 235) affords the diastereomeric pyrrolidines 3-6 and 3-7, which can be separated by flash chromatography, preparative thin layer chromatography, medium pressure liquid chromatography, high pressure liquid chromatography, fractional crystallization, or similar methods known in the art. The separated products are then individually reduced, for example with lithium aluminum hydride (LAH) or other strong hydride reducing agents, to provide pyrrolidines 3-8 and 3-9 in optically enriched form.




- Preparation of a protected pyrrolidine for use as an intermediate in the synthesis of compounds in the instant invention is shown in Scheme 4. The pyrrolidine 4-1 (prepared as shown in Schemes 2 and 3) is protected with a suitable protecting group such as t-butyl-dimethylsilyl to provide silyl ether 4-2. Other silyl groups can also be used in this role, as can other protecting groups for a hydroxy residue (see Greene, T. W.; Wuts, P. G. M. "Protective Groups in Organic Synthesis", 2nd edition, Wiley-Interscience, New York, pp. 10-143 (1991)), subject to the group being stable to conditions used to remove the benzyl group and being removable under conditions that would not adversely affect the remainder of the molecule. Removal of the benzyl group on nitrogen is then carried out by hydrogenolysis, for example by transfer hydrogenation with ammonium formate in the presence of 20% palladium hydroxide or with catalytic hydrogenation with 10% palladium on carbon under one or more atmospheres of hydrogen. Alternatively, compound 4-1 can be debenzylated first under the conditions noted above and then silylated on the hydroxy group, to provide 4-3.

SCHEME 5



One method of preparing compounds within the scope of the instant invention is given in Scheme 5. Doubly protected pyrrolidine 5-1 (obtained either as shown in Scheme 4 for 4-2 when P = benzyl or by protection of 4-3 with Boc anhydride in THF/water in the presence of triethylamine when P = Boc) is desilylated with tetrabutylammonium fluoride in THF to provide alcohol 5-2. Oxidation of 5-2 to 5-3 is carried out using Swern's oxidation conditions. Other methods for oxidizing a primary hydroxy group to an aldehyde can also be used, for example the Dess-Martin periodinane, or with various chromium trioxide-based reagents (see March J. "Advanced Organic Chemistry", 4th ed., John Wiley & Sons, New York, pp. 1167-1171 (1992)). Reductive amination with cyclic amine 5-4 then provides diamine 5-5. Deprotection of the pyrrolidine nitrogen, when P = Boc, can be carried out with HCl in methanol or with trifluoroacetic acid and anisole in dichloromethane, to give secondary amine 5-6. When P = benzyl, debenzylation is carried out in the presence of palladium on carbon as a catalyst, using either hydrogen gas or ammonium formate to effect transfer hydrogenation. Reductive amination with formyl ester 5-7 then provides pyrrolidine 5-8. Removal of the benzyl group can be carried out under standard reductive conditions, for example, hydrogen gas in the presence of a supported or unsupported palladium catalyst, to afford acid 5-9. Alternatively, if a 4-methoxybenzyl ester is utilized in place of the benzyl ester of compound 5-7, then the final deprotection can be carried out under acid conditions, for example, formic acid at 55°C. This latter approach is useful if the parent molecule contains functionality sensitive to catalytic hydrogenation.



5


Another method for preparing compounds in the instant invention is shown in Scheme 6. Reductive amination of pyrrolidine 4-3 with aldehyde ester 6-1 affords pyrrolidine 6-2. Removal of the silyl protecting group with


10 tetrabutylammonium fluoride provides alcohol 6-3, which can be oxidized under standard conditions, for example the Swern oxidation, to give aldehyde 6-4.

Reductive amination of 6-4 with a suitable secondary amine 6-5 yields ester 6-6 which can be deprotected under acidic conditions, for example, with formic acid, to afford compound 6-7.


5

SCHEME 7






A method for preparing compounds in the instant invention wherein an additional substituent R^8 is present is given in Scheme 7. Protection of pyrrolidine 4-3 with Boc anhydride under standard conditions provides doubly protected pyrrolidine 7-1, which can be desilylated by exposure to tetrabutylammonium fluoride in THF, affording 7-2. Oxidation of 7-2 to aldehyde 7-3 is carried out using Swern's oxidation conditions. Other methods for oxidizing a primary hydroxy group to an aldehyde can also be used, for example the Dess-Martin periodinane, or with various chromium trioxide-based reagents (see March J. "Advanced Organic Chemistry", 4th ed., John Wiley & Sons, New York, pp. 1167-1171 (1992)). Treatment of 7-3 with a secondary amine 7-4, and trimethylsilyl cyanide in the presence of lithium perchlorate affords cyanoamine 7-5. Treatment of 7-5 with a suitable organomagnesium reagent $R^8\text{MgBr}$ yields the branched compound 7-6. The diastereomers formed in this process can be separated at this stage, or at any point later in the synthesis by standard methods, including fractional crystallization, column chromatography, flash chromatography, high pressure liquid chromatography (HPLC) or medium pressure liquid chromatography (MPLC), optionally by use of a stationary phase derivatized with chiral, non-racemic groups to enable separation of enantiomers and to enhance separation of isomeric mixtures. The Boc group of 7-6 can be removed under acidic conditions, for example hydrochloric acid in methanol, to afford secondary pyrrolidine 7-7. Reductive amination with aldehyde 7-8 under mild conditions, for example with sodium cyanoborohydride in methylene chloride, provides ester 7-9. Removal of the benzyl protecting group by catalytic reduction then affords compound 7-10.




5 Synthesis of aldehyde esters such as 6-1 and 7-8 can be carried out by a number of routes, one of which is shown in Scheme 8. The available hydroxy acid 8-1 is esterified with a suitable protecting group (such as a para-methoxybenzyl group) in the presence of a suitable base (such as triethylamine or DIEA), to give ester 8-2. Oxidation of 8-2, for example by Swern oxidation, then affords aldehyde 8-3.




15 Synthesis of aldehyde ester 6-1 where the R⁶ substituents are distinct or identical can be accomplished as shown in Scheme 9. Alkylation of dibenzyl malonate with a suitable alkylating agent, such as an alkyl iodide, bromide, toluenesulfonate and the like, in the presence of a base such as cesium carbonate, potassium carbonate, or other agents of moderate basicity, followed by repetition of

the procedure with a second alkyl halide or alkyl toluenesulfonate, provides dialkylated product 9-2. Treatment of diester 9-2 with di-isobutylaluminum hydride at low temperature affords ester aldehyde 9-3.

5




Synthesis of aldehyde ester 6-1 where the R^{6a} and R^{6b} form a ring substituents can be accomplished as shown in Scheme 10. Dialkylation of dibenzyl malonate with a suitable dialkylating agent, such as an alkyl diiodide, dibromide, ditoluenesulfonate and the like, in the presence of a base such as cesium carbonate, potassium carbonate, or other agents of moderate basicity, provides cyclic derivative 10-1. Treatment of diester 10-1 with di-isobutylaluminum hydride at low temperature affords ester aldehyde 10-2. An analogous scheme can be used for cyclic derivatives containing a heteroatom in the ring by selection of the appropriate precursor.



5


An alternative synthesis of aldehyde ester intermediates is given in Scheme 11. Treatment of a commercially available alkyl methyl bromide with potassium cyanide in the presence of 18-crown-6 provides nitrile 11-2. Hydrolysis under acidic conditions affords acid 11-3. Esterification with benzyl bromide in the presence of cesium carbonate in DMF yields ester 11-4. Deprotonation of ester 11-4 with a strong, non-nucleophilic base, such as lithium hexamethyldisilazide, followed by treatment with benzyl cyanoformate, provides diester 11-5, which can be alkylated with a suitably activated haloalkyl group to provide dialkylated product 11-6. Reduction with DIBAL at low temperature then provides the desired intermediate 11-7.

15




- One synthesis of a bicyclic aldehyde ester intermediate is given in
- 5 Scheme 12. Treatment of dibenzyl malonate with lithium hydride in DMF followed by addition of 1,4-dichloro-cis-butene affords cyclopentene 12-2. Treatment of this olefin with diethylzinc and diiodomethane in methylene chloride and dimethoxyethane provides bicycle 12-3. Exposure to diisobutylaluminum hydride at or below -65°C then yields a mixture of the aldehydes 12-4 and 12-5, which can be
- 10 separated at this stage and employed individually as described above.

SCHEME 13



- One synthesis of a secondary amine intermediate is given in Scheme 13. Bromination of 2-butanone, followed by condensation with 2-aminopyridine, affords imidazopyridine 13-3. Bromination and then palladium-catalysed coupling with the pyridyl stannane 13-5 provides pyridine derivative 13-6, which upon hydrogenation under acidic conditions yield intermediate 13-7.


SCHEME 14




A synthesis of a secondary amine intermediate bearing an indazole substituent is given in Scheme 14. Alkylation of indazole with sodium hydride and then ethyl iodide affords the 2-alkylindazole derivative 14-2. Bromination under standard conditions provides bromide 14-3. Halogen-metal exchange, followed by trapping with the indicated piperidone derivative affords adduct 14-4, which can be dehydrated to yield 14-5. Hydrogenation produces 14-6, which can itself be employed as a secondary amine intermediate. Alternatively, it can be oxidized with DDQ and then treated with TFA to provide intermediate 14-7 as its TFA salt.

10


SCHEME 15





- One synthesis of a secondary amine bearing a monocyclic pyrazole substituent is given in Scheme 15. Conversion of the Weinreb amide of Boc-protected isonipecotic acid to the aldehyde can be accomplished by treatment with DIBAL at low temperature in methylene chloride, to give aldehyde 15-3. Separately, formation of the lithium enolate of 3-pentanone, followed by addition of 15-3, affords aldol 15-5. Oxidation to the diketone followed by treatment with ethylhydrazine in acetonitrile/water affords the pyrazole 15-7. Deprotection under acidic conditions then provides intermediate 15-8. Other substituents on the pyrazole nitrogen can be synthesized by utilizing other mono-substituted hydrazines in the condensation step with 15-6.


SCHEME 16




5


One synthesis of a secondary amine bearing a bicyclic pyrazole-based substituent is given in Scheme 16. Condensation of 2-butanone and methyl 5-chlorovalerate in the presence of sodium hydride in THF affords diketone 16-3. Treatment of this compound with hydrazine in acetonitrile/water provides

pyrazolopiperidine 16-4, which upon exposure to bromine in ethanol yields bromide 16-5. Halogen-metal exchange of 16-5, followed by addition of ketone 16-6, affords 16-7. Dehydration in toluene and then hydrogenation under standard conditions provides piperidine 16-9, which can then be deprotected under acidic conditions, for example HCl in methanol, to afford desired secondary amine 16-10.







Another synthesis of a secondary amine bearing a monocyclic pyrazole substituent is given in Scheme 17. Addition of anion 17-2 to propionaldehyde affords alcohol 17-3, which can be oxidized to ketone 17-4. Treatment with ethylhydrazine yields pyrazole 17-5, which can be iodinated under phase-transfer conditions to provide iodide 17-6. Coupling of this aldehyde with 4-pyridineboronic acid in the presence of a suitable palladium catalyst affords 17-8. Alkylation of 17-8 with benzyl bromide, followed by reduction with sodium borohydride, yields tetrahydropyridine 17-9. Catalytic hydrogenation then provides secondary intermediate 17-10. The pyrazole nitrogen substituent can be varied by utilizing alternative mono-substituted hydrazine derivatives in the condensation with 17-4.



Another synthesis of a secondary amine bearing a bicyclic pyrazole-based substituent is given in Scheme 18. Condensation of N-Boc piperidone (18-1) with the anion of triethyl phosphonoacetate, followed by catalytic hydrogenation, provides piperidine 18-2. Formation of the enolate of 18-2 with a strong, non-nucleophilic base, such as LDA, followed by addition of 5-chlorovaleraldehyde, yields alcohol 18-3. Following Swern oxidation to diketone 18-4, refluxing with hydrazine in xylenes affords bicycle 18-5. Exposure of 18-5 to diazomethane in ether provides methoxy derivative 18-6, which upon deprotection under acidic conditions then affords the desired secondary amine 18-7.

10






Another synthesis of a secondary amine bearing a monocyclic pyrazole substituent is given in Scheme 19. Condensation of N-Boc piperidone (19-1) with the anion of triethyl phosphonoacetate, followed by catalytic hydrogenation, provides piperidine 19-2. Formation of the enolate of 18-2 with a strong, non-nucleophilic base, such as LDA, followed by addition of acetaldehyde, yields alcohol 19-3. Following Swern oxidation to diketone 19-4, refluxing with hydrazine in xylenes affords pyrazolone 19-5. Exposure of 19-5 to diazomethane in ether provides methoxy derivative 19-6. Alkylation of pyrazole 19-6 by treating with sodium hydride and then ethyl iodide affords fully-substituted pyrazole 19-7. Alternatively, other alkylating agents can be employed in place of ethyl iodide to provide differently substituted pyrazoles. Deprotection with trifluoroacetic acid in methylene chloride then provides secondary amine 19-8.

15

SCHEME 20



5

Synthesis of secondary amines with an azabicyclo[3.1.0]hexane ring system is shown in Scheme 20. Treatment of bicycle 20-1 (prepared as described in Brighty, K. E.; Castaldi, M. J. *Synlett* **1996**, 1097) with Boc anhydride in methylene chloride affords protected derivative 20-2. Swern oxidation provides aldehyde 20-3, which upon treatment with 1-nitropropane and potassium fluoride in isopropanol, followed by elimination by addition of dicyclohexylcarbodiimide and copper (I) chloride, yields olefin 20-4 as a mixture of geometric isomers. Treatment of this nitro-olefin with diazopropane, followed by treatment with potassium hydroxide in

10

aqueous ethanol, affords the pyrazole 20-5. Alkylation of 20-5 with methyl iodide in the presence of potassium carbonate yields the N-methyl derivative 20-6, which can be deprotected to the desired secondary amine intermediate 20-7 with trifluoroacetic acid in methylene chloride. Other alkylating agents can be used in place of methyl iodide to afford the corresponding N-substituted derivatives. Likewise, other nitromethylalkanes can be employed in place of 1-nitropropane, and alternative diazoalkanes in place of diazopropane can be utilized, to afford the corresponding final products analogous to 20-7.

The following examples serve only to illustrate the invention and its practice. The examples are not to be construed as limitations on the scope or spirit of the invention.

GENERAL

Concentration of solutions was carried out on a rotary evaporator under reduced pressure. Conventional flash chromatography was carried out on silica gel (230-400 mesh). Flash chromatography was also carried out using a Biotage Flash Chromatography apparatus (Dyax Corp.) on silica gel (32-63 microns, 60 Å pore size) in pre-packed cartridges of the size noted. NMR spectra were obtained in CDCl₃ solution unless otherwise noted. Coupling constants (J) are in hertz (Hz).

HPLC CONDITIONS

LC 1. Retention time using the following conditions: Column: YMC ODS A, 5 µ, 4.6 x 50 mm; Gradient Eluent: 10:90 to 95:5 v/v acetonitrile/water + 0.05% TFA over 4.5 min; Detection: PDA, 200-600 nm; Flow Rate: 2.5 mL/min.

LC 2. Retention time using the following conditions: Column: YMC Pro-C18, 5 µ, 4.6 x 50 mm; Gradient Eluent: 10:90 to 95:5 v/v acetonitrile/water + 0.05% TFA over 3.0 min; Detection: PDA, 200-600 nm; Flow Rate: 2.5 mL/min.

HPLC A. Retention time using the following conditions: Column: YMC ODS A, 5 µ, 4.6 x 50 mm; Gradient Eluent: 10:90 to 90:10 v/v acetonitrile/water + 0.05% TFA over 4.5 min, hold 30 sec; Detection: PDA, 210-400 nm; Flow Rate: 2.5 mL/min.

HPLC B. Retention time using the following conditions: Column: Analytical Sales & Services Advantage HL C18 5 μ 4.6 x 100 mm column; Gradient Eluent: 10:90 to 90:10 v/v acetonitrile/water + 0.05% TFA over 10 min, hold 2 min; Detection: PDA, 200-400 nm; Flow Rate: 2.25 mL/min.

5

ALDEHYDE 1

2-Formyl-2-methyl-propionic acid, *para*-methoxybenzyl esterStep A: 2,2-Dimethyl-3-hydroxypropionic acid, *para*-methoxybenzyl ester

10

A solution of 1.03 g (8.7 mmol) of 2, 2-dimethyl-3-hydroxypropionic acid, 1.8 mL (12.9 mmol), of TEA and 1.3 mL (9.5 mmol) of *para*-methoxybenzyl chloride in 8 mL of DMF was stirred at rt for 24 h. The mixture was partitioned between 200 mL Et₂O and 100 mL of H₂O. After separating layers, the organic phase was washed with 100 mL of 1 N NaHCO₃, 100 mL of 2 N HCl, 2 X 100 mL of H₂O, 100 mL of brine, dried over MgSO₄ and concentrated. The residue was purified by flash chromatography using a gradient of 3:1 v/v to 3:2 v/v of hexanes/EtOAc as the eluant to afford the title compound: R_F: 0.17 (4:1 v/v hexanes/EtOAc); ¹H-NMR (500 MHz) δ 1.21 (s, 6H), 3.57 (s, 2H), 3.82 (s, 3H), 5.09 (s, 2H), 6.90 (d, J = 8.8, 2H), 7.28 (d, J = 8.8, 2H).

20

Step B: 2-Formyl-2-methyl-propionic acid, *para*-methoxybenzyl ester

25

A solution of 0.2 mL (2.2 mmol) of oxalyl chloride in 4 mL of CH₂Cl₂ at -78 °C was treated with 0.32 mL (4.5 mmol) of DMSO in 0.5 mL of CH₂Cl₂ maintaining the temperature at less than -60 °C. The resulting mixture was stirred cold for 5 min. A solution of 211 mg (0.94 mmol) of 2, 2-dimethyl-3-hydroxypropionic acid, *para*-methoxybenzyl ester (from Step A) in 1 mL of CH₂Cl₂ was added maintaining the temperature at less than -60 °C. The resulting mixture was stirred cold for 15 min. The mixture was treated with 1.6 mL (9.1 mmol) of DIEA maintaining the temperature at less than -60 °C. The reaction was warmed to 0 °C, stirred for 30 min and quenched with H₂O. The mixture was partitioned between 50 mL of CH₂Cl₂ and 50 mL of H₂O and the layers were separated. The aqueous layer was extracted with 50 mL of CH₂Cl₂. The combined organic phases were washed with 100 mL of brine, dried over Na₂SO₄ and concentrated to afford the title compound which was used without further purification: R_F: 0.43 (4:1 v/v

30

hexanes/EtOAc); ¹H-NMR (500 MHz) δ 1.35 (s, 6H), 3.81 (s, 3H), 5.12 (s, 2H), 6.89 (d, J = 8.7, 2H), 7.27 (d, J = 8.7, 2H), 9.66 (s, 1H).

ALDEHYDE 2

5 2-Formyl-2-methyl-propionic acid, benzyl ester

The title compound was prepared using procedures analogous to those described to prepare Aldehyde 1, except that benzyl bromide was substituted for *para*-methoxybenzyl chloride in Step A. ¹H-NMR (500 MHz) δ 1.38 (s, 6H), 5.20 (s, 2H), 7.27-7.40 (m, 5H), 9.69 (s, 1H).

ALDEHYDE 3

2-Ethyl-2-formyl-butyric acid, benzyl ester

15 Step A: Diethylmalonic acid, dibenzyl ester

A solution of 2 mL (7.9 mmol) of dibenzyl malonate, 2 mL (25.0 mmol) of iodoethane and 7.84 g (24.0 mmol) of cesium carbonate in 50 mL of DMF was stirred overnight at rt. The reaction was partitioned between 250 mL of Et₂O and 250 mL of brine. After separating phases, the organic layer was washed with 250 mL of brine, dried over MgSO₄ and concentrated to afford the title compound, which was used without further purification. R_F: 0.47 (9:1 v/v hexanes/EtOAc); ¹H-NMR (500 MHz) δ 0.80 (t, J = 7.5, 6H), 1.99 (q, J = 7.5, 4H), 5.13 (s, 4H), 7.27-7.33 (m, 10H).

Step B: 2-Ethyl, 2-formyl-butyric acid, benzyl ester

A solution of dibenzyl diethylmalonate (7.9 mmol, from Step A) in CH₂Cl₂ at -78 °C was treated with 16 mL (16.0 mmol) of 1 M DIBAL in CH₂Cl₂ maintaining the temperature at less than -65 °C (J. Organic Chemistry, 1993, 58, 6843-6850). After stirring for 2.75 h, the reaction was quenched cold with 8 mL of saturated NH₄Cl and 10 mL of 2 N HCl. The reaction was warmed to rt and partitioned between 200 mL of CH₂Cl₂ and 300 mL of saturated Rochelle salts. After separating phases, the aqueous layer was extracted with 200 mL CH₂Cl₂. The combined organics were dried over MgSO₄ and concentrated. The residue was purified by flash chromatography using 9:1 v/v of hexanes/EtOAc as the eluant to afford the title compound as a colorless oil, which contained 15% starting material:

R_F: 0.44 (9:1 v/v hexanes/EtOAc); ¹H-NMR (500 MHz) δ 0.83 (t, J = 7.5, 6H), 1.82-1.95 (m, 4H), 5.23 (s, 2H), 7.27-7.39 (m, 5H), 9.85 (s, 1H).

ALDEHYDE 4

5 1-Formyl-cyclohexane carboxylic acid, benzyl ester

The title compound was prepared using procedures analogous to those described to prepare Aldehyde 3, except that 1,5-dibromopentane was substituted for iodoethane in Step A. ¹H-NMR (500 MHz) δ 1.43-1.55 (m, 6H), 1.88-1.93 (m, 2H),
10 2.02-2.07 (m, 2H), 5.19 (s, 4H), 7.27-7.39 (m, 5H), 9.55 (s, 1H).

ALDEHYDE 5

1-Formyl-cyclobutane carboxylic acid, benzyl ester

15 Step A: 1,1-Cyclobutanedicarboxylic acid, dibenzyl ester

A solution of 2.0 g (13.8 mmol) of cyclobutanedicarboxylic acid in 20 mL of DMF at 0 °C was treated with 7.7 mL (55.5 mmol) of triethylamine and 5.0 mL (41.6 mmol) of benzyl bromide. The reaction was warmed to rt and stirred overnight. The reaction was partitioned between H₂O and CH₂Cl₂. The residue was purified with
20 a 40M Biotage column using 1:1 v/v of hexanes/EtOAc as the eluant to afford the title compound: ¹H-NMR (500 MHz) δ 1.95-2.03 (m, 2H), 2.55-2.58 (m, 4H), 5.14 (s, 4H), 7.24-7.37 (m, 10H).

Step B: 1-Formyl-cyclobutane carboxylic acid, benzyl ester

25 The title compound was prepared from 1,1-cyclobutanedicarboxylic acid, dibenzyl ester (from Step A) using a procedure analogous to that described for Aldehyde 3, Step B. ¹H-NMR (500 MHz) δ 1.90-2.05 (m, 2H), 2.47-2.50 (m, 4H), 5.21 (s, 2H), 7.25-7.39 (m, 5H), 9.79 (s, 1H).

30 ALDEHYDE 6

1-Formyl-cyclopentane carboxylic acid, benzyl ester

The title compound was prepared using procedures analogous to those described to prepare Aldehyde 3, except that 1,4-dibromobutane and potassium carbonate were substituted for iodoethane and cesium carbonate in Step A. ¹H-NMR

(500 MHz) δ 1.55-1.76 (m, 4H), 1.98-2.23 (m, 4H), 5.19 (s, 2H), 7.23-7.38 (m, 5H), 9.67 (s, 1H).

ALDEHYDE 7

5 4-(4-Formyl –tetrahydropyranyl)-carboxylic acid, benzyl ester

The title compound was prepared using procedures analogous to those described to prepare Aldehyde 8, except that 2-chloroethyl ether was substituted for 1,4-dibromobutane. $^1\text{H-NMR}$ (500 MHz) δ 1.99-2.04 (m, 2H), 2.12-2.17 (m, 2H), 3.61-3.68 (m, 4H), 5.21 (s, 2H), 7.25-7.39 (m, 5H), 9.56 (s, 1H).

10

ALDEHYDE 8

3-(3-Formyl-bicyclo[3.1.0]hexane)-*exo*-carboxylic acid, benzyl ester
and

ALDEHYDE 9

15 3-(3-Formyl-bicyclo[3.1.0]hexane)-*endo*-carboxylic acid, benzyl ester

Step A: 1,1-(Cyclopent-3-ene)-dicarboxylic acid, dibenzyl ester

A solution of 4.3 mL (17.1 mmol) of dibenzyl malonate in 20 mL of DMF at 0 °C was treated with 0.36 g (43 mmol) of LiH. After two hours at 0 °C, 2
20 mL (19 mmol) of *cis*-1,4-dichloro-2-butene was added (J. Org. Chem. 1984, 49, 928-931). The reaction was warmed to rt and stirred for 3.5 days. The reaction was partitioned between 200 mL of 1:1 v/v hexane/Et₂O and 200 mL of H₂O. After separating phases, the organic layer was washed with 200 mL H₂O, dried over MgSO₄ and concentrated. The residue was purified with a 40M Biotage column using 13:7
25 v/v of hexanes/CH₂Cl₂ and 11:9 v/v of hexanes/ CH₂Cl₂ as the eluant to afford the title compound as a white solid: R_F: 0.25 (3:2 v/v hexanes/CH₂Cl₂); $^1\text{H-NMR}$ (500 MHz) δ 3.07 (s, 4H), 5.15 (s, 4H), 5.63 (s, 2H), 7.25-7.34 (m, 10H).

Step B: 3,3-Bicyclo[3.1.0]hexane dicarboxylic acid, dibenzyl ester

30 A solution of 8.8 mL (8.8 mmol) of 1.0 M diethyl zinc in hexane at -10 °C in 8mL of CH₂Cl₂ and 0.92 mL (8.8 mmol) of ethylene glycol dimethyl ether was treated with 1.4 mL (17.6 mmol) of diiodomethane dropwise maintaining an internal temperature $\leq$ -9 °C (J. Organic Chemistry 1995, 60, 1081-1083). After stirring for 15 minutes, 1.0 g (2.9 mmol) of 1,1-(cyclopent-3-ene)-dicarboxylic acid, dibenzyl ester

(from Step A) was added. The reaction was warmed to reflux for 24 hours. After cooling to rt, the reaction was partitioned between 200 mL of Et₂O and 200 mL of NH₄Cl. After separating phases, the organic layer was washed with 200 mL 10 % Na₂S₂O₃, dried over MgSO₄ and concentrated. The residue was purified with a 40M Biotage column using 24:1 v/v of hexanes/MTBE as the eluant to afford the title compound as a colorless oil and a mixture of product and starting material: R_F: 0.26 (19:1 v/v of hexanes/MTBE); ¹H-NMR (500 MHz) δ -0.01 (m, 1H), 0.41 (m, 1H), 1.34-1.37 (m, 2H), 2.45-2.48 (m, 2H), 2.58-2.61 (m, 2H), 5.08 (s, 2H), 5.10 (s, 2H), 7.23-7.33 (m, 10H).

Step C: 3-(3-Formyl-bicyclo[3.1.0]hexane)-*exo*-carboxylic acid, benzyl ester and 3-(3-Formyl-bicyclo[3.1.0]hexane)-*endo*-carboxylic acid, benzyl ester

The title compounds were prepared as a separable mixture (1:5 *exo:endo*) from 3,3-bicyclo[3.1.0]hexane dicarboxylic acid, dibenzyl ester (from Step B) using a procedure analogous to that described for Aldehyde 3, Step B. Aldehyde 10: 3-(3-formyl-bicyclo[3.1.0]hexane)-*exo*-carboxylic acid, benzyl ester R_F: 0.37 (9:1 v/v hexanes/Et₂O); ¹H-NMR (500 MHz) δ -0.18 (m, 1H), 0.38 (m, 1H), 1.35-1.39 (m, 2H), 2.41-2.45 (m, 2H), 2.54-2.57 (m, 2H), 5.15 (s, 2H), 7.27-7.39 (m, 5H), 9.55 (s, 1H). Aldehyde 11: 3-(3-formyl-bicyclo[3.1.0]hexane)-*endo*-carboxylic acid, benzyl ester R_F: 0.29 (9:1 v/v hexanes/Et₂O); ¹H-NMR (500 MHz) δ 0.01 (m, 1H), 0.48 (m, 1H), 1.39-1.44 (m, 2H), 2.26-2.32 (m, 2H), 2.47-2.52 (m, 2H), 5.19 (s, 2H), 7.27-7.40 (m, 5H), 9.44 (s, 1H).

Aldehyde 10
(2R or 2S)-2-Formyl-2-methyl-butyric acid, benzyl ester
and
Aldehyde 11
(2S or 2R)- 2-Formyl-2-methyl-butyric acid, benzyl ester

Step A: Ethylmalonic acid, dibenzyl ester

A solution of 2.0 g (15 mmol) of ethyl-malonic acid, 4.7 mL (31 mmol) of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and 3.9 mL (32 mmol) of benzyl bromide in 100 mL of benzene was refluxed for 22 hours. After cooling, the reaction

was washed with 150 mL of H₂O. After separating layers, the organic phase was dried over MgSO₄ and concentrated. The residue was purified on a 40M Biotage column using 24:1 v/v hexane/EtOAc as the eluant to afford the title compound as a colorless oil: R_F: 0.40 (9:1 v/v hexane/EtOAc); ¹H-NMR (500 MHz) δ 0.97 (t, J = 7.4, 3H), 1.99 (quint, J = 7.4, 2H), 3.39 (t, J = 7.4, 1H), 5.17 (s, 2H), 7.29-7.36 (m, 10H).

Step B: 2-Formyl-butyric acid, benzyl ester

The title compound was prepared from ethylmalonic acid, dibenzyl ester (from Step A) using a procedure analogous to that described for Aldehyde 3, Step B. R_F: 0.35 (9:1 v/v hexane/EtOAc); ¹H-NMR (500 MHz: Equilibrium mixture of aldehyde and enol) δ 0.92-1.00 (m), 1.04-1.08 (m), 1.93-2.01 (m), 2.14-2.18 (m), 5.17, 5.23, 5.26 (3s), 7.05 (d, J = 12.6), 7.30-7.41 (m), 9.74 (d, J = 2.3), 11.33 (d, J = 12.6).

Step C: 2-((E)-{[(2S)-2-(Methoxymethyl)-1-pyrrolidinyl]imino}methyl)butyric acid, benzyl ester

A suspension of 395 mg (1.9 mmol) of 2-formyl-butyric acid, benzyl ester (from Step B), 0.26 mL (1.9 mmol) of (S)-(-)-1-amino-2-methoxymethylpyrrolidine (S-AMP) and 0.24 g of 4A molecular sieves in 4 mL of CH₂Cl₂ was stirred at room temperature for 16 hours. The reaction was filtered and concentrated. The residue was purified on a 40M Biotage column using 9:1 v/v hexane/EtOAc as the eluant to afford the title compound as a colorless oil: R_F: 0.23 (9:1 v/v hexane/EtOAc); ¹H-NMR (500 MHz: Mixture of diastereomers) δ 0.90-0.95 (m, 3H), 1.64-1.99 (m, 6H), 2.79 (m, 1H), 3.19-3.57 (m, 8H), 5.13-5.19 (m, 2H), 6.53 (m, 1H), 7.30-7.38 (m, 5H).

Step D: (2R or 2S)-((E)-{[(2S)-2-(Methoxymethyl)-1-pyrrolidinyl]imino}methyl)-2-methyl-butyric acid, benzyl ester and (2S or 2R)-((E)-{[(2S)-2-(Methoxymethyl)-1-pyrrolidinyl]imino}methyl)-2-methyl-butyric acid, benzyl ester

A solution of 98 mg (0.3 mmol) of 2-((E)-{[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]imino}methyl)butyric acid, benzyl ester (from Step C) in 1 mL of THF was added to a solution of 1.4 mL (0.35 mmol) of 0.25 M LDA at -78 °C. After 20 min 0.023 mL (0.36 mmol) of methyl iodide was added. The reaction was allowed to

warm to room temperature overnight. The reaction was poured into 25 mL of H₂O and extracted with 3 X 50 mL of Et₂O. The combined organics were dried over Na₂SO₄ and concentrated. Diastereomers were separated using preparative HPLC Chiralcel OD (Analytical Column: Chiralcel OD; Mobile Phase: 96:4 v/v

5 hexane/isopropanol; 2 mg/mL; 0.02 mL/injection; Flow: 0.5 mL/min; 220 nm; Retention Times: 10.7 and 12.4 min). Diastereomer 1: ¹H-NMR (500 MHz) δ 0.86 (t, J = 7.4, 3H), 1.35 (s, 3H), 1.69-1.99 (m, 6H), 2.75 (m, 1H), 3.29-3.59 (m, 7H), 5.16 (ABq, J = 12.5, 2H), 6.67 (s, 1H), 7.30-7.38 (m, 5H); Diastereomer 2: ¹H-NMR (500 MHz) δ 0.85 (t, J = 7.4, 3H), 1.35 (s, 3H), 1.70-1.99 (m, 6H), 2.75 (m, 1H), 3.30-3.59
10 (m, 7H), 5.14 (ABq, J = 12.6, 2H), 6.67 (s, 1H), 7.30-7.39 (m, 5H).

Step E: (2R or 2S)-2-Formyl-2-methyl-butyric acid, benzyl ester and (2S or 2R)-2-Formyl-2-methyl-butyric acid, benzyl ester

The diastereomers from Step D were separately treated in CH₂Cl₂ with
15 ozone at -78 °C, followed by treatment with dimethylsulfide. The residue was purified by flash chromatography using 92:8 v/v hexane/EtOAc as the eluant to afford the title compounds as a colorless oil: ¹H-NMR (500 MHz) δ 0.88 (t, J = 12.4, 3H), 1.32 (s, 3H), 1.80 (m, 1H), 1.97 (m, 1H), 5.21 (s, 2H), 7.33-7.40 (m, 5H), 9.74 (s, 1H).

20

Aldehyde 12

(2R or 2S)-2-Formyl-2-methyl-4,4,4-trifluorobutyric acid, benzyl ester
and

Aldehyde 13

25 (2S or 2R)- 2-Formyl-2-methyl-4,4,4-trifluorobutyric acid, benzyl ester

The title compounds were prepared from (R/S)-2-formyl-2-methyl-4,4,4-trifluorobutyric acid, benzyl ester using procedures analogous to that described for Aldehydes 10 and 11, except (R)-(+)-1-amino-2-methoxymethylpyrrolidine (R-AMP) was substituted for (S)-(-)-1-amino-2-methoxymethylpyrrolidine (S-AMP) in
30 Step C. ¹H-NMR (500 MHz) δ 1.51 (s, 3H), 2.68-2.88 (m, 2H), 5.22 (s, 2H), 7.33-7.41 (m, 5H), 9.64 (s, 1H).

Aldehyde 14

1-Formyl-cyclopropane carboxylic acid, benzyl ester

The title compound was prepared from 1,1-cyclopropanedicarboxylic acid using procedures analogous to that described for Aldehydes 10 and 11 (Steps A and B). ¹H-NMR (500 MHz) δ 1.63-1.73 (m, 4H), 5.27 (s, 2H), 7.35-7.42 (m, 5H), 10.43 (s, 1H).

5

The following are representative Procedures for the preparation of the piperidines used in the following Examples or which can be substituted for the piperidines used in the following Examples and which are not commercially available.

10

PIPERIDINE 1

4-(Imidazo[1,2-a]pyridin-3-yl)piperidine di-TFA salt

Step A: 1-tert-Butoxycarbonyl-4-(2-hydroxyethyl)piperidine

15 A mixture of 4-(2-hydroxyethyl) piperidine (5.0 g, 40 mmol), di-*t*-butyl dicarbonate (10.9 g, 50 mmol), and triethylamine (7 mL, 50 mmol) in 100 mL of anhydrous methylene chloride was stirred overnight at room temperature. Volatiles were removed *in vacuo* and the resulting oil was purified on a silica gel column using 20% ethyl acetate in hexane as eluent to give the desired product as a colorless oil.

20

Step B: 1-tert-Butoxycarbonyl-4-(formylmethyl)piperidine

Oxalyl chloride (2.2 mL, 25 mmol) was added to 75 mL of anhydrous methylene chloride at -78⁰C. DMSO (3.5 mL, 50 mmol) was then added dropwise over 5 min, and the resulting mixture was stirred for 15 min. 1-tert-butoxycarbonyl-4-(2-hydroxyethyl)piperidine (2.29 g, 10 mmol, from Step A) was dissolved in 5 mL
25 of anhydrous methylene chloride and added over 10 min to the above mixture. After stirring 30 min, DIEA (17.4 mL, 100 mmol) was added over 10 min. The mixture was then warmed to 0⁰C and maintained at that temperature for 1 h. After quenching with water, the reaction mixture was diluted with 75 mL of methylene chloride and the layers were separated. The organic phase was washed with 3 x 50 mL of water
30 and dried over anhydrous magnesium sulfate. Solvent removal gave an oil, which was purified on silica gel using 20% ethyl acetate in hexane to give the desired aldehyde which hardened overnight into an oily solid.

NMR: (CDCl₃) δ 2.15 (2H, d, J=3); 9.8 (1H,s); 1.2, 1.5, 1.7, 2.75, 4.1(all multiplets)

Step C: 1-*tert*-Butoxycarbonyl-4-(1-bromo-formylmethyl)piperidine

A mixture of 1-*tert*-butoxycarbonyl-4-(formylmethyl)piperidine (0.57 g, 2.25 mmol, step B), 3,3-dibromo-Meldrum's acid (0.75 g, 2.5 mmol) in 10 mL of anhydrous ether was stirred for 2 days at room temperature under nitrogen. The

5 reaction mixture was diluted with ethyl acetate and washed with sat'd. sodium bicarbonate solution. The organic phase was dried over anhydrous magnesium sulfate. Solvent removal and purification on silica gel using 20% ethyl acetate in hexane as solvent gave the pure bromo aldehyde as a colorless oil.

10 ¹H NMR: (CDCl₃) δ: 4.04 (1H,dd; J=1.5;2); 9.46 (1H,d; J=1.5) 1.35, 1.7, 1.95, 2.1, 2.75, 4.2 (all multiplets)

Step D: 1-(*tert*-Butoxycarbonyl)-4-(imidazo[1,2-a]pyridin-3-yl)piperidine

To a solution of 1.15 g of 1-*tert*-butoxycarbonyl-4-(1-bromo-formylmethyl)piperidine (from Step C) in 15 mL ethanol was added 388 mg of 2-aminopyridine. After refluxing for 18 h, the solvent was evaporated. The mixture

15 was partitioned between ethyl acetate and saturated sodium bicarbonate solution. Aqueous layer was extracted with ethyl acetate (3x). The combined organic phase was washed with brine, dried over magnesium sulfate and concentrated. The residue was purified by flash chromatography with 50% ethyl acetate in hexanes,

20 followed by 100% ethyl acetate to give the title compound as a solid. ¹H NMR (500 MHz, CDCl₃) δ 1.48 (s, 9H), 1.70 (m, 2H), 2.06 (d, J = 13Hz, 2H), 2.93-3.02 (m, 3H), 4.26 (br, 2H), 6.87 (t, J = 6.8 Hz, 1H). 7.21(m, 1H), 7.44(s, 1H), 7.69(d, J= 9.2 Hz,1H), 7.99 (d, J = 6.9 Hz, 1H).

25 Step E: 4-Imidazo[1,2-a]pyridin-3-yl)piperidine di-TFA salt

To 100 mg of 1-(*tert*-butoxycarbonyl)-4-(imidazo[1,2-a]pyridin-3-yl)piperidine from Step D was added 2 mL TFA. The reaction was stirred at rt for 1 h. The mixture was concentrated to afford a viscous oil.

30 PIPERIDINE 2

4-(7-*tert*-butylimidazo[1,2-a]pyridin-3-yl)piperidine, TFA salt

Step A: 2-Amino-4-*tert*-butylpyridine

To 790 mg of sodium amide were added 20 mL of *N,N*-dimethylaniline and 2.74 g of 4-*tert*-butyl pyridine at rt. The mixture was stirred at 150 °C for 6 h. During this period, 3 more portions of sodium amide (790 mg each) were added. The reaction was cooled down to rt. The mixture was partitioned between ethyl acetate and water. Aqueous layer was extracted with ethyl acetate (3x). The combined organic phase was washed with brine, dried over magnesium sulfate and concentrated. The residue was purified by flash chromatography with 50% ethyl acetate in hexanes followed by 100% ethyl acetate to give the title compound as a solid:

¹H NMR (500 MHz, CDCl₃) δ 1.21 (s, 9H), 6.44 (t, 1H), 6.6.62 (dd, J= 5.5 Hz and, 1H), 7.94 (d, J = 5.5Hz, 1H).

Step B: 1-(*tert*-Butoxycarbonyl)-4-(7-*tert*-butylimidazo[1,2-*a*]pyridin-3-yl)piperidine

The title compound was prepared from 470 mg of 1-*t*-butyloxycarbonyl-4-(1-bromo-formylmethyl)piperidine (from Piperidine 1, Step C) and 277 mg of 2-amino-4-*tert*-butyl pyridine (from Step A) in 12 mL ethanol using a procedure analogous to that described in Piperidine 1, Step D to provide the title compound as a solid.

Step C: 4-(7-*tert*-butylimidazo[1,2-*a*]pyridin-3-yl)piperidine, TFA salt

The title compound was prepared from 35 mg of 1-(*tert*-butoxycarbonyl)-4-((7-*tert*-butyl)imidazo[1,2-*a*]pyridin-3-yl)piperidine (from Step B) in 2 mL of TFA, using a procedure analogous to that described in Piperidine 1, Step E to provide the title compound as a viscous oil.

PIPERIDINE 3

4-(2-Ethyl-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyridin-3-yl)piperidine, acetic acid salt

Step A: 2-Ethyl-imidazo[1,2-*a*]pyridine

The title compound was prepared from 2-aminopyridine and 1-bromo-2-butanone, employing procedures analogous to those described for Piperidine 1. ¹H NMR (500 MHz, CDCl₃) δ 1.34 (t, J = 7.3 Hz, 3H), 2.82 (q, J = 7.6 Hz, 2H), 6.70 (t, J = 6.6 Hz, 1H), 7.10 (m, 1H), 7.32 (s, 3H), 7.51 (d, J = 8.9 Hz, 1H), 8.03 (dd, J = 6.6, 0.9 Hz, 1H).

Step B: 3-Bromo-2-ethyl-imidazo[1,2-a]pyridine

To a solution of 2-ethyl-imidazo[1,2-a]pyridine (2.17 g, 14.9 mmol) in ethanol (25 mL) was added bromine (2.0 g, 12.5 mmol) in water (5 mL) dropwise at
5 rt. After stirring at rt for 4h, ethanol was evaporated under reduced pressure. The residue was basified with aqueous sodium bicarbonate and extracted with methylene chloride (3X). The organic phase was washed with brine and dried over anhydrous magnesium sulfate. Concentration followed by flash chromatography eluting with 20 % ethyl acetate in hexanes, followed by 50 % ethyl acetate in hexanes afforded the
10 title compound as a viscous oil. ¹H NMR (500 MHz, CDCl₃) δ 1.36 (t, J = 7.5 Hz, 3H), 2.83 (q, J = 7.6 Hz, 2H), 6.88 (t, J = 6.8 Hz, 1H), 7.20 (m, 1H), 7.55 (dd, J = 8.9, 0.9 Hz, 1H), 8.05 (dd, J = 6.9, 1.2 Hz, 1H).

Step C: 2-Ethyl-3-(4-pyridyl)-imidazo[1,2-a]pyridine

To a solution of 3-bromo-2-ethyl-imidazo[1,2-a]pyridine (1.4 g, 6.28 mmol), 4-tributylstannylpyridine (2.31 g, 6.28 mmol) and Pd (II) (Ph₃P)₂Cl₂ (442 mg, 0.63 mmol) in toluene (5 mL) was added lithium chloride (26.7 mg, 0.63). After refluxing for 18 h, the mixture was partitioned between ethyl acetate and aqueous sodium bicarbonate. The aqueous layer was extracted with ethyl acetate (3X).
20 Combined organic phase was washed with brine and dried over anhydrous magnesium sulfate. Concentration followed by flash chromatography eluting with 100 % ethyl acetate, then 10 % methanol in methylene chloride afforded the title compound as a viscous oil. ¹H NMR (500 MHz, CDCl₃) δ 1.36 (t, J = 7.5 Hz, 3H), 2.84 (q, J = 7.5 Hz, 2H), 6.68 (dt, J = 6.8, 1.1 Hz, 1H), 7.21 (m, 1H), 7.39 (dd, J = 5.9, 1.6 Hz, 2H), 7.61 (dd, J = 8.9, 1.0 Hz, 1H), 8.75 (d, J = 5.9 Hz, 2H).
25

Step D: 4-(2-Ethyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)piperidine, acetic acid salt

A solution of 2-ethyl-3-(4-pyridyl)-imidazo[1,2-a]pyridine (700 mg, 3.13 mmol) in ethanol (12 mL) and acetic acid (4 mL) was hydrogenated using Platinum (IV) oxide (40 mg) under 40 psi of H₂ gas in a Parr shaker at rt for 18 h.
30 The mixture was filtered through celite and concentrated to give the title compound as a viscous oil.

PIPERIDINE 4

4-(2-Ethyl-4,5,6,7-tetrahydro-(2H)-indazol-3-yl)piperidine

Step A: (1-Benzylpiperidin-4-yl)-(cyclohexanon-2-yl)ketone

5 To a suspension of 1.60 g 60% sodium hydride in 10 mL dry THF was added a solution of 1.963 g (20 mmole) cyclohexanone and 9.893 g (40 mmole) of 1-benzylpiperidine-4-carboxylic acid ethyl ester in 30 mL THF. This mixture was heated to reflux over night. Work-up followed by silica gel FC (15~50% ethyl acetate in hexanes with 1% triethylamine) provided a product containing about 5.7:1 molar
10 ratio of starting 1-benzylpiperidine-4-carboxylic acid ethyl ester and title compound. ESI-MS 300.3 (M+H), HPLC A: 2.90 and 3.57 min. (for tautomeric forms).

Step B: 4-(2-Ethyl-4,5,6,7-tetrahydro-(2H)-indazol-3-yl)-1-benzylpiperidine

The title compound was prepared from the semi-crude (1-benzylpiperidin-4-yl)-(cyclohexanon-2-yl)ketone from step A and 34% aqueous
15 ethylhydrazine in 4:1 acetonitrile and water at rt. This provided 8:1 ratio of isomeric ethyl pyrazoles in favor of the title compound. (Note: Use of ethyl hydrazine oxalate in the presence of DIEA gave about 2:1 ratio of the same isomers.) The 1-benzylpiperidine-4-carboxylic acid ethyl ester present in the starting β -diketone was
20 removed after saponification of the crude product with sodium hydroxide in water ethanol mixture followed by extractive work-up. The desired ethyl isomer is the higher R_f isomer. It was isolated on silica gel chromatography (60~100% ethyl acetate in hexanes and 5~20% methanol in ethyl acetate, both with 1% triethylamine).
 ^1H NMR (500 MHz) δ 7.33~7.36 (m, 4H), 7.26~7.30 (m, 1H), 4.07 (q, 7.2 Hz, 2H),
25 3.57 (s, 2H), 3.00~3.03 (m, 2H), 2.64~2.66 (m, 2H), 2.60~2.63 (m, 2H), 2.57~2.63 (m, 1H), 1.96~2.08 (m, 4H), 1.69~1.81 (m, 6H), 1.39 (t, 7.2 Hz, 3H). The identity of the title compound was confirmed by NOE difference spectroscopy.

Step C: 4-(2-Ethyl-4,5,6,7-tetrahydro-(2H)-indazol-3-yl)piperidine

30 A mixture of 0.273 g 4-(2-ethyl-4,5,6,7-tetrahydro-(2H)-indazol-3-yl)-1-benzylpiperidine from Step B above, 0.789 g ammonium formate, and 35 mg 20% Pd(OH)₂ in 6 mL methanol was heated at 65 °C for 1 h. Basic aqueous work-up with ether extraction provided the title compound as a colorless solid.

¹H NMR (500 MHz) δ 4.08 (q, 7.2 Hz, 2H), 3.19 (br d, 11.9 Hz, 2H), 2.71~2.77 (m, 1H), 2.68~2.74 (m, 2H), 2.64~2.66 (m, 2H), 2.60~2.62 (m, 2H), 1.82~1.91 (m, 2H), 1.71~1.80 (m, 6H), 1.40 (t, 7.2 Hz, 3H). The identity of the title compound was confirmed again by NOE difference spectroscopy.

5

PIPERIDINE 5

4-(7-Chloroimidazo[1,2-a]pyridin-3-yl)piperidine, TFA salt

The title compound was prepared from 350 mg of 1-(*tert*-butoxycarbonyl)-4-(1-bromo-2-oxoethyl)piperidine (from Piperidine 1, Step C) and 162 mg of 2-amino-4-chloropyridine (prepared using procedures analogous to those described by R.J. Sundberg *et al*, *Org. Preparations & Procedures Int.* **1997**, 29, (1), 117-122) in 10 mL ethanol using a procedure analogous to that described in Piperidine 1, Step D to provide the BOC intermediate as a solid prior to the cleavage of the Boc-group to give the title TFA salt.

15

PIPERIDINE 6

4-(7-*n*-Propylimidazo[1,2-a]pyridin-3-yl)piperidine, TFA salt

The title compound was prepared according to the general procedures of Piperidines 1 and 2, employing 2-amino-4-*n*-propylpyridine (prepared using a procedure analogous to that described in Piperidine 2, Step A) in place of 2-aminopyridine in Piperidine 1, Step D.

20

PIPERIDINE 7

4-(2-Ethylindazol-3-yl)piperidine, TFA salt

25

Step A: 2-Ethylindazole

To a solution of indazole (6.2 g, 52.5 mmol) in DMF (30 mL) was added sodium hydride (60 % dispersion in mineral oil, 3.0 g, 75.0 mmol) at 0 °C. After stirring at 0 °C for 20 min., ethyl iodide (5 mL, 62.5 mmol) was added dropwise at 0 °C. The mixture was stirred at rt for 1 h, and then partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate (3X). The combined organic phases were washed with brine, and dried over anhydrous magnesium sulfate. TLC indicated that a 2 : 1 mixture of two isomers was formed.

30

The mixture was purified by flash chromatography (hexanes : ethyl acetate = 4 : 1, then 1 : 1) to give the title compound as a viscous oil (slow moving isomer).

Step B: 2-Ethyl-3-bromoindazole

5 To a solution of 2-ethylindazole (2.32 g, 15.87 mmol) in ethanol (20 mL) was added bromine (2.54 g, 15.87 mmol) in ethanol (1 mL)/water (1 mL) at 0 °C. After stirring at 0 °C for 10 min. and at rt for 1h, the reaction was quenched with aq. sodium bicarbonate. The mixture was partitioned between ethyl acetate and aq. sodium bicarbonate. The aqueous layer was extracted with ethyl acetate (3X). The
10 combined organic phase was washed with brine, and dried over anhydrous magnesium sulfate. Purification by flash chromatography (hexanes : ethyl acetate = 1 : 1, then 100 % ethyl acetate) gave the title compound as a viscous oil.

Step C: 1-(tert-Butoxycarbonyl)-4-hydroxy-4-(2-ethyl-indazol-3-yl)piperidine

15 To a solution of 2-ethyl-3-bromoindazole (3.4 g, 15.18 mmol) in THF (30 mL) was added t-BuLi (1.7 M in pentane, 10.72 mL, 18.22 mmol) dropwise at –78 °C. After stirring at –78 °C for 20 min., was added *tert*-butyl 4-oxo-1-piperidinecarboxylate (3.03 g, 15.18 mmol) in THF (10 mL) dropwise at –78 °C. The mixture was stirred at –78 °C for 10 min. and at rt for 18 h. After the reaction was
20 quenched with aq. NH₄Cl, the mixture was partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate (3X). The combined organic phases were washed with brine, and dried over anhydrous magnesium sulfate. Concentration followed by purification by flash chromatography (hexanes : ethyl acetate = 4 : 1, then 1 : 1) to give the title compound as a foamy solid.

25

Step D: 1-(tert-Butoxycarbonyl)-4-(2-ethyl-indazol-3-yl)-[1,2,3,6]tetrahydropyridine

To a solution of 1-(*tert*-butoxycarbonyl)-4-hydroxy-4-(2-ethyl-indazol-3-yl)piperidine (651 mg, 1.89 mmol) in toluene (5 mL) was added
30 (methoxycarbonylsulfamoyl)-triethylammonium hydroxide inner salt (540 mg, 2.27 mmol). After heating up to ~70 °C for 10 min., was added additional 5 mL of toluene. The mixture was stirred at 70 °C for additional 2h. The mixture was partitioned between ethyl acetate and aq. sodium bicarbonate. Aqueous layer was extracted with ethyl acetate (3X). The combined organic phases were washed with

brine, and dried over anhydrous magnesium sulfate. Concentration followed by purification by flash chromatography (hexanes : ethyl acetate = 4 : 1, then 1 : 1) gave the title compound as a viscous oil.

5 Step E: 1-(*tert*-Butoxycarbonyl)-4-(2-ethyl-[5,6,7,8]tetrahydroindazol-3-yl)piperidine

A solution of 1-(*tert*-butoxycarbonyl)-4-(2-ethyl-indazol-3-yl)-[1,2,3,6]tetrahydropyridine (500 mg, 1.53 mmol) in methanol (5 mL) was hydrogenated using Pd(OH)₂ (100 mg) under atmospheric H₂ for 4.5 h. After the
10 addition of Platinum (IV) oxide (100 mg) hydrogenation was continued for additional 4h. The mixture was filtered through celite and concentrated to give the title compound as a viscous oil. ESI-MS 333 (M+1); HPLC A: 2.45 min.

Step F: 1-(*tert*-Butoxycarbonyl)-4-(2-ethylindazol-3-yl)piperidine

15 To a solution of 1-(*tert*-butoxycarbonyl)-4-(2-ethyl-[5,6,7,8]tetrahydroindazol-3-yl)piperidine (80 mg, 0.24 mmol) in toluene (3 mL) was added DDQ (115 mg, 0.51 mmol) at rt. After refluxing for 4 h, the mixture was partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate (3X). The combined organic phases were washed with brine, and dried
20 over anhydrous magnesium sulfate. Concentration gave the title compound as a viscous oil. ESI-MS 274 (M+1-t-Bu); HPLC A: 3.09 min.

Step G: 4-(2-Ethylindazol-3-yl)piperidine, TFA salt

25 Using essentially the same method as for Piperidine 1, Step B, the title compound was obtained as the TFA salt.

PIPERIDINE 8

4-(1,3-Diethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine di-HCl salt

30 Step A: 1-(*tert*-Butoxycarbonyl)-4-(*N*-methyl-*N*-methoxycarboxamido)piperidine

A solution of 1-(*tert*-butoxycarbonyl)isonipecotic acid (13.74 g, 0.06 mol), TEA (14.7 mL, 0.105 mol), 4-DMAP (1.83 g, 0.015 mol), *N*-ethyl-*N'*-(3-dimethylaminopropyl)carbodiimide x HCl (11.50 g, 0.06 mol) and *O,N*-

dimethylhydroxylamine x HCl (6.27 g, 0.09 mol) in methylene chloride (250 mL) was stirred at rt for 60 h. The mixture was partitioned between 1 L of ether and 500 mL of water and the layers were separated. The organic layer was washed with 500 mL of 1.0 N HCl, 500 mL of 1.0 N NaOH, 500 mL of sat'd sodium chloride, dried over magnesium sulfate and concentrated to afford the title compound:

¹H NMR (500 MHz) δ 1.46 (s, 9H), 1.65-1.80 (4H), 2.76-2.86 (3H), 3.19 (s, 3H), 3.71 (s, 3H), 4.15 (2H).

Step B: 1-(*tert*-Butoxycarbonyl)-4-formylpiperidine

A solution of 1-(*tert*-butoxycarbonyl)-4-(*N*-methyl-*N*-methoxycarboxamido)piperidine (4.80 g, 17.6 mmol) (from Step A) in methylene chloride (100 mL) at -78 °C was treated with 1.0 M DIBALH solution in methylene chloride (25 mL) and stirred cold for 30 min. The reaction was quenched with 1.0 N HCl (250 mL) and warmed to rt. The quenched mixture was extracted with 300 mL of ether; the extract was washed with 150 mL of 1.0 N NaOH, 150 mL of sat'd sodium chloride, dried over magnesium sulfate and concentrated. Flash chromatography on 125 g of silica gel using 1:1 v/v hexanes/ether as the eluant afforded the title compound:

¹H NMR (500 MHz) δ 1.46 (s, 9H), 1.52-1.59 (m, 2H), 1.85-1.91 (m, 2H), 2.38-2.43 (m, 1H), 2.93 (app t, J= 11.0, 2H), 3.95-4.05 (m, 2H), 9.66 (s, 1H).

Step C: 1-(*tert*-Butoxycarbonyl)-4-(1-(*R/S*)-hydroxy-2-(*R/S*)-methyl-3-oxopent-1-yl)piperidine

A solution of diisopropylamine (0.63 mL, 4.5 mmol) in THF (16 mL) at 0 °C was treated with 1.6 M n-butyllithium in sol'n in hexanes (2.8 mL). The resulting solution was stirred at 0 °C for 10 min, then cooled to -78 °C. 3-Pentanone (0.41 mL, 4.1 mmol) was added and the resulting mixture was stirred cold for 1 h. A solution of 1-(*tert*-butoxycarbonyl)-4-formylpiperidine (435 mg, 2.05 mmol) (from Step B) in THF (3 mL) was then added. After 15 min, the reaction was quenched with sat'd ammonium chloride (25 mL) and extracted with ether (100 mL). The extract was dried over magnesium sulfate and concentrated. MPLC (Biotage) on a 40S silica cartridge using 4:1 v/v, then 3:2 v/v hexanes/ethyl acetate as the eluent afforded the title compound.

Step D: 1-(*tert*-Butoxycarbonyl)-4-(1,3-dioxo-2-(*R/S*)-methylpent-1-yl)piperidine

A solution of oxalyl chloride (0.34 mL, 3.9 mmol) in methylene chloride (12 mL) at -78°C was treated with DMSO (0.43 mL, 6.0 mmol) and the resulting mixture was stirred cold for 10 min. A solution of 1-(*tert*-butoxycarbonyl)-4-(1-(*R/S*)-hydroxy-2-(*R/S*)-methyl-3-oxopent-1-yl)piperidine (514 mg, 1.7 mmol) (from Step C) was added and the resulting solution was stirred cold for 1 h. *N,N*-Diisopropylethylamine (2.4 mL, 13.7 mmol) was added and the resulting mixture was warmed to 0°C . The reaction was quenched with 1.0 N HCl (25 mL) and extracted with ether (100 mL). The extract was dried over magnesium sulfate and concentrated. MPLC (Biotage) on a 40S silica cartridge using 2:1 v/v hexanes/ethyl acetate as the eluent afforded the title compound.

Step E: 1-(*tert*-Butoxycarbonyl)-4-(1,3-diethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine

A solution of 1-(*tert*-butoxycarbonyl)-4-(1,3-dioxo-2-(*R/S*)-methylpent-1-yl)piperidine (435 mg, 1.5 mmol) (from Step D) in 2:1 v/v acetonitrile/water (12 mL) was treated with ethylhydrazine (34% sol'n in water, 0.28 mL, 1.6 mmol) and the resulting mixture was stirred at rt for 20 h. The reaction mixture was partitioned between 75 mL of ether and 25 mL of sat'd sodium chloride and the layers were separated. The organic layer was dried over magnesium sulfate and concentrated. MPLC (Biotage) on a 40S silica cartridge using 4:1 v/v, then 1:1 v/v hexanes/ethyl acetate as the eluent afforded the title compound:

^1H NMR (500 MHz) δ 1.21 (t, $J=7.5$, 3H), 1.36 (t, $J=7.5$, 3H), 1.49 (s, 9H), 1.68-1.72 (m, 2H), 1.86-1.91 (m, 2H), 2.54 (q, $J=1.5$, 2H), 2.72-2.79 (3H), 4.08 (q, $J=7.5$, 2H), 4.20-4.30 (m, 2H).

Step F: 4-(1,3-Diethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine di-HCl salt

A solution of 1-(*tert*-butoxycarbonyl)-4-(1,3-diethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine (348 mg) (from Step E) in 2.5 N HCl in methanol was stirred at rt for 16 h. The solution was concentrated and the resulting solid was suspended in ethyl acetate, filtered and dried to afford the title compound.

PIPERIDINE 9

4-(2-Ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)-piperidine, hydrochloride salt

Step A: 1-Chloro-5,7-nonanedione

5 To a suspension of NaH (60% dispersion in mineral oil: 8.88 g) in THF (250 mL) was added a mixture of 2-butanone (7.98 g) and methyl 5-chlorovalerate (50.0 g) in THF (100 mL) dropwise via cannula at 0°C. The mixture was stirred at 0°C for 10 min and at rt for 24 h. After the reaction was quenched with 2 N HCl (200 mL), aqueous layer was extracted with EtOAc (3X). Concentration of
10 the combined organic phase gave a brown colored oil, which was purified by fractional vacuum distillation. The title compound was collected in the temperature range between 95 °C and 110 °C at 10 mmHg. ¹H NMR (500 MHz, CDCl₃) δ 1.14 (t, 3H, J=7.4 Hz), 1.65-1.90 (m, 4H), 2.30-2.60 (m, 4H), 3.50-3.60 (m, 2H), 5.51 (s, 1H).

15 Step B: 2-Ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridine

To a solution of 1-chloro-5,7-nonanedione (14.74g, from Step A) in a mixture of CH₃CN (100 mL) and H₂O (33 mL) was added 4.87 mL of hydrazine. After refluxing for 18 h, the reaction mixture was partitioned between EtOAc and aqueous NaHCO₃ (saturated). Aqueous layer was extracted with
20 EtOAc (3X). Combined organic phase was washed with brine and dried over anhydrous MgSO₄. After concentration, the residue was purified by flash chromatography with 20% EtOAc in hexanes followed by 50% EtOAc in hexanes to give the title compound as a viscous oil. ¹H NMR (500 MHz, CDCl₃) δ 1.24 (t, 3H, J=7.5 Hz), 1.79-1.85 (m, 2H), 1.95-2.05 (m, 2H), 2.62 (q, 2H, J=7.8Hz), 2.75
25 (t, 2H, J=6.4Hz), 4.08 (t, 2H, J=6.1Hz), 5.78 (s, 1H).

Step C: 3-Bromo-2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridine

To a solution of 2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridine (4.12 g, from Step B) in EtOH (25 mL) was added Br₂ (1.42 mL) dropwise at 0°C.
30 The reaction was stirred at 0°C for 20 min. The reaction mixture was partitioned between EtOAc and aqueous NaHCO₃ (saturated). Aqueous layer was extracted with EtOAc (3X). Combined organic phase was washed with brine and dried over anhydrous MgSO₄. After concentration, the residue was purified by flash chromatography with 10% EtOAc in hexanes followed by 20% EtOAc in hexanes to

give the title compound as a viscous oil. ^1H NMR (500 MHz, CDCl_3) δ 1.25 (t, 3H, $J=7.5$ Hz), 1.80-1.90 (m, 2H), 1.95-2.05 (m, 2H), 2.55-2.70 (m, 4H), 4.07 (t, 2H, $J=6.0$ Hz).

5 Step D: 1-(*tert*-Butoxycarbonyl)-4-hydroxy-4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidine

To a solution of 3-bromo-2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridine (4.01 g, 17.6 mmol, from Step C) in THF (20 mL) was added *tert*-BuLi (1.7 M in pentane, 22.8 mL, 38.7 mmol) dropwise at -78°C . After stirring at -78°C for 30 min., was added *tert*-butyl 4-oxo-1-piperidinecarboxylate (3.51 g, 17.6 mmol) in THF (10 mL) dropwise at -78°C . The mixture was stirred at -78°C for 10 min. and at rt for 4 h. After the reaction was quenched with aqueous NH_4Cl , the mixture was partitioned between EtOAc and water. Aqueous layer was extracted with EtOAc (3X). Combined organic phase was washed with brine and dried over anhydrous MgSO_4 . Concentration was followed by purification by flash chromatography (hexanes : EtOAc = 1 : 1, then 100% EtOAc) to give the title compound as a foamy solid. ^1H NMR (500 MHz, CDCl_3) δ 1.26 (t, 3H, $J=7.4$ Hz), 1.49 (s, 9H), 1.75-1.90 (m, 4H), 1.90-2.10 (m, 4H), 2.76 (q, 2H, $J=7.6$ Hz), 2.89 (t, 2H, $J=6.4$ Hz), 3.10-3.20 (br, 2H), 3.85-4.05 (br, 2H), 4.09 (t, 2H, $J=6.2$ Hz). ESI-MS 276 ($\text{M-tert-Bu-H}_2\text{O+H}$); HPLC A 2.05 min.

Step E: 1-(*tert*-Butoxycarbonyl)-4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)-[1,2,3,6]tetrahydropyridine

To a solution of 1-(*tert*-butoxycarbonyl)-4-hydroxy-4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidine (2.47 g, 7.08 mmol, from Step D) in toluene (20 mL) was added (methoxycarbonylsulfamoyl)-triethylammonium hydroxide inner salt (2.03 g, 8.50 mmol). After stirring at 80°C for 18 h, the mixture was partitioned between EtOAc and aq. NaHCO_3 . Aqueous layer was extracted with EtOAc (3X). Combined organic phase was washed with brine and dried over anhydrous MgSO_4 . Concentration was followed by purification by flash chromatography (hexanes : EtOAc = 4 : 1, then 1 : 1) to give the title compound as a white solid. ^1H NMR (500 MHz, CDCl_3) δ 1.22 (t, 3H, $J=7.5$ Hz), 1.50 (s, 9H), 1.80-1.85 (m, 2H), 1.97-2.05 (m, 2H), 2.32 (br s 2H), 2.61 (q, 2H, $J=7.5$ Hz), 2.69 (t, 2H, $J=6.2$ Hz), 3.55-3.63 (m, 2H), 4.01 (br s), 4.08 (t, 2H, $J=6.2$ Hz), 5.50 (br s, 1H).

Step F: 1-(*tert*-Butoxycarbonyl)-4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)-piperidine

A solution of 1-(*tert*-butoxycarbonyl)-4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)-[1,2,3,6]tetrahydropyridine (1.17 g, from Step E) in MeOH (40 mL) was hydrogenated using Pd(OH)₂ (300 mg) under atmospheric H₂ for 18 h. The mixture was filtered through celite. Concentration was followed by purification by flash chromatography (hexanes : EtOAc = 4 : 1, 1 : 1, then 100% EtOAc) to give the title compound as a viscous oil. ¹H NMR (500 MHz, CD₃OD) δ 1.23 (t, 3H, J=7.5 Hz), 1.49 (s, 9H), 1.55-1.75 (m, 4H), 1.75-1.85 (m, 2H), 1.90-2.02 (m, 2H), 2.50-2.63 (m, 3H), 2.63-2.80 (m, 4H), 4.07 (t, 2H, J=6.1 Hz), 4.10-4.30 (br, 2H).

Step G: 4-(2-Ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)-piperidine, hydrochloride salt

To a solution of 1-(*tert*-Butoxycarbonyl)-4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)-piperidine (1.41g, from Step F) in MeOH (15 mL) was added a saturated HCl solution in MeOH (15 mL) at 0°C. After stirring at rt for 3 h, the reaction mixture was concentrated to give the title compound as a foamy solid, which was used without further purification.

PIPERIDINE 10

4-(1,3-Diethyl-5-methyl-1*H*-pyrazol-4-yl)piperidine, hydrochloride salt

Step A: ($\pm$)-Hex-4-yn-3-ol

Propionaldehyde (18.0 mL, 0.25 mol) was added to 500 mL of 0.5 M 1-propynylmagnesium bromide solution in THF at 0 °C. The resulting mixture was warmed to rt and stirred for 18 h. The reaction was quenched by pouring it into a well stirred mixture of 300 g of sat'd NH₄Cl and 300 g of ice. The resulting mixture was extracted with 2 x 1L of ether. The ether extracts were dried over MgSO₄, combined and concentrated to afford the title compound which was used without further purification.

Step B: Hex-4-yn-3-one

A mixture of 24 g (0.25 mol) of ($\pm$)-hex-4-yn-3-ol (from Step A), 40 g (0.34 mol) of *N*-methyldmorpholine *N*-oxide and 75 g of 4 Å molecular sieves in 250 mL of CH₂Cl₂ at 0 °C was treated with 2 g (5.7 mmol) of tetrapropylammonium perruthenate. The resulting mixture was warmed to rt and stirred for 1 h. The mixture was filtered through a pad of 400 g of silica gel; the flask and pad were rinsed well with CH₂Cl₂ (400 mL). The filtrate was concentrated. Distillation at reduced pressure (45 mmHg) afforded the title compound, bp = 70-75 °C.

10 Step C: 1,3-Diethyl-5-methylpyrazole

A solution of 18.9 g (0.2 mol) of hex-4-yn-3-one (from Step B) in 120 mL of *n*-butanol was treated with 40 mL (0.227 mol) of ethyl hydrazine, 34% solution in water. The resulting mixture was heated at reflux for 1.5 h, then cooled to rt. The mixture was concentrated to ~150 mL volume ; this was partitioned between 1 L of ether and 250 mL of water. The layers were separated and the organic layer was dried and concentrated to afford the title compound, which was used without further purification. ¹H-NMR (400 MHz) δ 1.22 (t, J = 7.6, 3H), 1.37 (t, J = 7.2, 3H), 2.23 (s, 3H), 2.59 (q, J = 7.6, 2H), 4.01 (q, J = 7.2, 2H), 5.81 (s, 1H).

20

Step D: 1,3-Diethyl-4-iodo-5-methylpyrazole

A mixture of 13.2 g (95.7 mmol) of 1,3-diethyl-4-5-methylpyrazole (from Step C) and 1.50 g (3.7 mmol) of sorbitan monopalmitate in 200 mL of 2.5 N NaOH was treated with 44 g (0.17 mol) of iodine. Additional portions of sorbitan monopalmitate and iodine were added after 30 min and 60 min. The mixture was partitioned between 1 L of ether and 500 mL of water and the layers were separated. The organic layer was washed with 500 mL of 5% Na₂S₂O₃, dried over MgSO₄ and concentrated. Chromatography on a Biotage 75L using 9:1 heptane/EtOAc as the eluant afforded the title compound. ¹H-NMR (400 MHz) δ 1.22 (t, J = 7.6, 3H), 1.36 (t, J = 7.2, 3H), 2.27 (s, 3H), 2.58 (q, J = 7.6, 2H), 4.10 (q, J = 7.2, 2H).

30

Step E: 1,3-Diethyl-4-(4-pyridyl)-5-methylpyrazole

A mixture of 17.05 g (64.6 mmol) of 1,3-diethyl-4-iodo-5-methylpyrazole (from Step D) and 11.9 g (105.4 mmol) of pyridine 4-boronic acid in 300 mL of dioxane was treated with a solution of 44 g (392 mmol) of potassium *tert*-butoxide in 100 mL of water. The resulting mixture was treated with 3.75 g (3.2 mmol) of tetrakis(triphenylphosphine)palladium(0), put under an argon atmosphere and heated at 100 °C for 18 h. The mixture was cooled and partitioned between 1 L of ether and 500 mL of water. The organic layer was separated, dried over MgSO₄ and concentrated. Flash chromatography on a Biotage 75S afforded of the title compound. ¹H-NMR (500 MHz) δ 1.19 (t, J = 7.5, 3H), 1.48 (t, J = 7.5, 3H), 2.27 (s, 3H), 2.67 (q, J = 7.5, 2H), 4.09 (q, J = 7.5, 2H), 7.18 (dd, J = 2.0, 4.5, 2H), 8.60 (dd, J = 2.0, 4.5, 2H).

Step F: 1-Benzyl-4-(1,3-diethyl-5-methyl-pyrazol-4-yl)-1,2,3,6-tetrahydropyridine

A solution of 7.55 g (35.0 mmol) of 1,3-diethyl-4-(4-pyridyl)-5-methylpyrazole (from Step E) and 4.20 mL (35.0 mmol) of benzyl bromide in 50 mL of MeOH was heated at reflux for 30 min. The mixture was cooled to 0 °C and treated with 2.65 g (70.0 mmol) of sodium borohydride in portions so as to maintain the internal at ~0 °C. The resulting mixture was stirred cold for 30 min, then concentrated. The residue was partitioned between 300 mL of CH₂Cl₂ and 150 mL of 1.0 N NaOH and the layers were separated. The organic layer was dried over MgSO₄. The organic layer was extracted with 300 mL of ether; the extract was dried over MgSO₄. The organic layers were combined and concentrated. Chromatography on a Biotage 75L using 9:1 v/v heptane/acetone as the eluant afforded the title compound. ¹H-NMR (400 MHz) δ 1.19 (t, J = 7.6, 3H), 1.37 (t, J = 7.6, 3H), 2.17 (s, 3H), 2.31-2.35 (m, 2H), 2.58 (q, J = 7.6, 2H), 2.66 (t, J = 5.6, 2H), 3.13 (app q, J = 2.8, 2H), 3.65 (s, 2H), 4.01 (q, J = 7.6, 2H), 5.46-5.48 (m, 1H), 7.26-7.39.

Step G: 4-(1,3-Diethyl-5-methyl-pyrazol-4-yl)piperidine

A mixture of 5.70 g (18.4 mmol) of 1-benzyl-4-(1,3-diethyl-5-methyl-pyrazol-4-yl)-1,2,3,6-tetrahydropyridine (from Step F), 25 g (0.4 mol) of ammonium formate and 2.0 g of 20% palladium hydroxide on carbon in 100 mL of methanol was heated at reflux for 1 h. The mixture was cooled and filtered

through a pad of Celite. The filtrate was concentrated. The residue was partitioned between 200 mL of CH₂Cl₂ and 100 mL of 10% NH₄OH and the layers were separated. The organic layer was dried over MgSO₄. The aqueous layer was extracted with 2 x 200 mL of CH₂Cl₂; the extracts were dried over
 5 MgSO₄ and all were combined and concentrated. Chromatography on a Biotage 40L using 40:1:0.1, then 20:1:0.1, then 10:1:0.1 v/v/v CH₂Cl₂/MeOH/NH₄OH as the eluant afforded the title compound. ¹H-NMR (500 MHz) δ 1.21 (t, J = 7.5, 3H), 1.35 (t, J = 7.5, 3H), 1.64 (br d, J = 12.5, 2H), 1.78 (dq, J = 4.0, 13.0, 2H), 2.24 (s, 3H), 2.50 (tt, J = 4.0, 12.5, 1H), 2.62 (q, J = 7.5, 2H), 2.69 (dt, J = 2.5,
 10 12.0, 2H), 3.16 (app d, J = 12.0, 2H), 4.02 (q, J = 7.5, 2H); ESI-MS 222 (M+H).

PIPERIDINE 11

4-(2-(2,2,2-Trifluoroethyl)-4,5,6,7-tetrahydro-(2*H*)-indazol-3-yl)piperidine
 15

Step A: (1-*tert*-Butoxycarbonylpiperidin-4-yl)-((2*R*/2*S*)-cyclohexanon-2-yl)ketone

The title compound was prepared using procedures analogous to those described for Piperidine 8, Steps A-D, except cyclohexanone was substituted for 3-pentanone in Step C. R_F: 0.59 (3:2 v/v hexanes/EtOAc); ¹H-NMR (500 MHz) δ 1.47
 20 (s, 9H), 1.59-1.74 (m, 8H), 2.35-2.40 (m, 4H), 2.68-2.78 (m, 4H), 4.11-4.20 (m, 2H).

Step B: 1-*tert*-Butoxycarbonyl-4-(2-(2,2,2-trifluoroethyl)-4,5,6,7-tetrahydro-(2*H*)-indazol-3-yl)piperidine

The title compound was prepared using a procedure analogous to that described for Piperidine 8, Step E, except (2,2,2-trifluoroethyl)hydrazine was substituted for ethylhydrazine. R_F: 0.35 (4:1 v/v hexanes/acetone); ¹H-NMR (500 MHz) δ 1.48 (s, 9H), 1.64-1.87 (m, 8H), 2.52-2.73 (m, 7H), 4.24 (br m, 2H), 4.63 (q, J = 8.2, 2H).
 25

Step C: 4-(2-(2,2,2-Trifluoroethyl)-4,5,6,7-tetrahydro-(2*H*)-indazol-3-yl)piperidine
 30

A solution of 500 mg (1.3 mmol) of 1-*tert*-butoxycarbonyl-4-(2-(2,2,2-trifluoroethyl)-4,5,6,7-tetrahydro-(2*H*)-indazol-3-yl)piperidine (from Step B) in 4.1

mL of CH₂Cl₂ at 0 °C was treated with 2.7 mL of trifluoroacetic acid. After 30 min volatiles were removed under reduced pressure. The residue was partitioned between 25 mL of CH₂Cl₂ and 25 mL of 1 N NaOH. After separating phases, the aqueous layer was extracted with 25 mL of 1 N NaOH. The combined organic layers were
 5 dried over Na₂SO₄ and concentrated to afford the title compound, which was used without further purification. ¹H-NMR (500 MHz) δ 1.68-1.95 (m, 9H), 2.61-2.71 (m, 7H), 3.17-3.20 (m, 2H), 4.61 (q, J = 8.3, 2H).

PIPERIDINE 12

10 4-(2-Methyl-4,5,6,7-tetrahydro-(2*H*)-indazol-3-yl)piperidine

The title compound was prepared using procedures analogous to that described for Piperidine 11, except methylhydrazine was substituted for (2,2,2-trifluoroethyl)hydrazine. ¹H-NMR (500 MHz) δ 1.69-1.89 (m, 8H), 2.33 (br m, 1H), 2.57-2.78 (m, 7H), 3.18-3.21 (m, 2H), 3.77 (s, 3H).

15

PIPERIDINE 13

4-(2-Propyl-4,5,6,7-tetrahydro-(2*H*)-indazol-3-yl)piperidine

The title compound was prepared using procedures analogous to that described for Piperidine 11, except propylhydrazine, oxalate salt was substituted for
 20 (2,2,2-trifluoroethyl)hydrazine. ¹H-NMR (500 MHz) δ 0.94 (t, J = 7.4, 3H), 1.69-1.90 (m, 10H), 2.03 (br s, 1H), 2.58-2.74 (m, 7H), 3.17-3.20 (m, 2H), 3.95 (t, J = 7.4, 3H).

PIPERIDINE 14

4-(1-Ethyl-4-methoxy-3-methyl-(1*H*)-pyrazol-5-yl)piperidine

25

Step A: 4-Acetyl-1-(*tert*-Butoxycarbonyl)piperidine

A solution of 1-(*tert*-butoxycarbonyl)-4-(*N*-methyl-*N*-methoxycarboxamido)piperidine (from Piperidine 8, Step A) in anhydrous ether (400 mL) at 0 °C was treated with 55 mL of 1.4 M methyl magnesium bromide in 3:1
 30 toluene and THF over 30 min. After stirring at 0 °C for 1 h, the reaction was poured into a mixture of ice water (400 mL) and acetic acid (8 mL, 150 mmol). The layers were separated and the aqueous layer was extracted twice with ether. The combined organic layers were washed with 0.1 N HCl (200 mL), 3% sodium bicarbonate (200 mL), water (200 mL) and brine (200 mL), dried over sodium sulfate, and concentrated

to give the crude product (14.322 g). Flash chromatography (20-80% ethyl acetate in hexanes) gave the title compound as a yellowish oil. R_f : 0.27 (25% ethyl acetate in hexanes). Some starting Weinreb amide was also recovered. R_f : 0.10 (25% ethyl acetate in hexanes). ^1H NMR (500 MHz, CDCl_3) δ 4.07-4.14 (m, 2 H), 2.75-2.83 (m, 2 H), 2.46 (tt, $J = 11.3$ and 3.8 Hz, 1 H), 2.17 (s, 3 H), 1.82-1.87 (m, 2 H), 1.48-1.57 (m, 2 H), 1.46 (s, 9 H).

Step B: 1-(*tert*-Butoxycarbonyl)-4-(1,3-dioxo-but-1-yl)piperidine

A solution of 2.27 g (10.0 mmol) of 4-acetyl-1-(*tert*-butoxycarbonyl)piperidine (from Step A), 1.95 mL (20.0 mmol) of ethyl acetate and 2.24 g (20.0 mmol) of potassium *t*-butoxide in 25 mL of MTBE was stirred at rt for 20 h. The reaction was quenched with 50 mL of 0.5 N KHSO_4 and extracted with 150 mL of ether. The extract was dried over MgSO_4 and concentrated. Flash chromatography on 70 g of silica gel using 20:1 v/v hexanes/acetone as the eluant afforded the title compound. The enol form predominated in CDCl_3 solution: ^1H NMR (500 MHz, CDCl_3) δ 1.46 (s, 9H), 1.53 (dq, $J = 4.5, 12.5$, 2H), 1.81 (app d, $J = 13.5, 2\text{h}$), 2.07 (s, 3H), 2.44-2.33 (m, 1H), 2.72-2.79 (m, 2H), 4.18-4.28 (br s, 2H), 5.50 (s, 1H).

Step C: 1-(*tert*-Butoxycarbonyl)-4-(2-diazo-1,3-dioxo-but-1-yl)piperidine

A solution of 0.51 g (1.8 mmol) of 1-(*tert*-butoxycarbonyl)-4-(1,3-dioxo-but-1-yl)piperidine (from Step B) and 0.65 g (1.8 mmol) of *para*-dodecylbenzenesulfonyl azide (Syn. Comm. 1981, 11, 947-956) in CH_3CN at 0°C was treated with 0.26 mL (1.8 mmol) of triethylamine. The reaction was warmed to rt and stirred for 4.5 hours. The reaction was poured into 100 mL of Et_2O and washed with 100 mL of H_2O , 100 mL of 2 N HCl and 100 mL of brine. The organic layer was dried over MgSO_4 and concentrated. The residue was purified with a 40M Biotage column using 9:1 v/v of hexanes/acetone to afford the title compound as a light yellow oil: R_F : 0.33 (4:1 v/v hexanes/acetone); ^1H -NMR (500 MHz) δ 1.46 (s, 9H), 1.57-1.76 (m, 4H), 2.42 (s, 3H), 2.82 (m, 2H), 3.24 (m, 1H), 4.14 (m, 2H).

Step D: 1-(*tert*-Butoxycarbonyl)-4-(1,3-dioxo-2-methoxy-but-1-yl)piperidine

A solution of 532 mg (1.8 mmol) of 1-(*tert*-butoxycarbonyl)-4-(2-diazo-1,3-dioxo-but-1-yl)piperidine in 5 mL of MeOH was treated with 25 mg (0.056

mmol) of rhodium (II) acetate dimer. The reaction was slowly warmed to 65 °C over 2 hours. Upon cooling, volatiles were removed under reduced pressure. The residue was partitioned between 100 mL of EtOAc and 100 mL of H₂O. After separating phases, the organic layer was washed with 100 mL of brine, dried over Na₂SO₄ and concentrated. The residue was purified by flash chromatography using 19:1 v/v hexanes/acetone as the eluant to afford the title compound as a yellow oil: R_F: 0.39 (4:1 v/v hexanes/acetone); ¹H-NMR (500 MHz) δ 1.45, 1.47 (2s, 9H), 1.68-1.71 (m, 3H), 2.19, 2.22 (2s, 3H), 2.78-2.89 (m, 2H), 3.44, 3.58 (2s, 3H), 4.03-4.3 (m, 2H).

10 Step E: 1-*tert*-Butoxycarbonyl-4-(1-ethyl-4-methoxy-3-methyl-(1*H*)-pyrazol-5-yl)piperidine

The title compound was prepared using a procedure analogous to that described for Piperidine 8, Step E, except 1-(*tert*-butoxycarbonyl)-4-(1,3-dioxo-2-methoxy-but-1-yl)piperidine (from Step D) was used. Residue purified by preparative HPLC (Column: Chiralcel OD; Mobile Phase: 4:1 v/v hexanes/isopropanol; Flow: 8 mL/min; 220 nm; Retention Time: 10.8 min.) NOE difference spectroscopy was used to determine regiochemistry. ¹H-NMR (500 MHz) δ 1.37 (t, J= 7.2, 3H), 1.41-1.53 (m, 11H), 1.71-1.74 (m, 2H), 1.86-1.97 (m, 2H), 2.21 (s, 3H), 2.66-2.75 (m, 3H), 3.69 (s, 3H), 3.99 (q, J= 7.2, 2H), 4.15-4.35 (m, 2H).

20

Step F: 4-(1-Ethyl-4-methoxy-3-methyl-(1*H*)-pyrazol-5-yl)piperidine

A solution of 16mg (0.049 mmol) of 1-*tert*-butoxycarbonyl-4-(1-ethyl-4-methoxy-3-methyl-(1*H*)-pyrazol-5-yl)piperidine (from Step E) in 0.1 mL of trifluoroacetic acid and 0.15 mL of CH₂Cl₂ at 0 °C was stirred for 30 min. Volatiles were removed under reduced pressure. The crude product was partitioned between 25 mL of 1 N NaOH and 25 mL of CH₂Cl₂. After separating phases, the aqueous layer was extracted with 3X25 mL of CH₂Cl₂. The combined organic layers were dried over Na₂SO₄ and concentrated to afford the title compound as a yellow film: ¹H-NMR (500 MHz) δ 1.36 (t, J= 7.2, 3H), 1.72-1.74 (m, 2H), 1.91-2.03 (m, 2H), 2.07 (s, 1H), 2.21 (s, 3H), 2.65-2.73 (m, 3H), 3.19-3.21 (m, 2H), 3.71 (s, 3H), 3.99 (q, J= 7.2, 2H).

30

PIPERIDINE 15

4-(1-Ethyl-3-methoxy-4-methyl-(1*H*)-pyrazol-5-yl)piperidine

Step A: 4-Propionyl-1-(*tert*-Butoxycarbonyl)piperidine

The title compound was prepared using a procedure analogous to that described for Piperidine 14, Step A, except ethyl magnesium chloride was substituted for methyl magnesium chloride. ¹H-NMR (500 MHz) δ 1.06 (t, J = 7.3, 3H), 1.46 (s, 9H), 1.49-1.57 (m, 2H), 1.78-1.82 (m, 2H), 2.44-2.50 (m, 3H), 2.75-2.80 (m, 2H), 4.10-4.12 (m, 2H).

Step B: 1-(*tert*-Butoxycarbonyl)-4-(1,3-dioxo-3-methoxy-2-methyl-prop-1-yl)piperidine

A solution of 0.51 g (2.1 mmol) of 4-propionyl-1-(*tert*-butoxycarbonyl)piperidine (from Step A) and 0.35 mL (17.6 mmol) of dimethylcarbonate in 5 mL of *tert*-butyl, methylether at 0 °C was treated with 0.45 g (4.0 mmol) of potassium *tert*-butoxide. After 10 minutes at 0 °C, the reaction was stirred at rt for 17 hours and refluxed for 3 hours. The reaction was quenched with 1 N HCl and partitioned between 100 mL of Et₂O and 100 mL of 1 N HCl. After separating phases, the organic layer was washed with 100 mL of brine, dried over MgSO₄ and concentrated. The residue was purified with a 40M Biotage column using 9:1 v/v of hexanes/acetone as the eluant to afford the title compound as a straw colored oil: R_F: 0.32 (4:1 v/v hexanes/acetone); ¹H-NMR (500 MHz) δ 1.35 (d, J= 7.1, 3H), 1.42-1.66 (m, 11H), 1.79-1.80 (m, 2H), 2.68-2.79 (m, 3H), 3.71 (q, J= 7.1, 1H), 3.73, 3.77 (2s, 3H), 4.12 (m, 2H).

Step C: 1-*tert*-Butoxycarbonyl-4-(4-methyl-(1*H*)-pyrazol-3-one-5-yl)piperidine

A solution of 419 mg (1.4 mmol) of 1-(*tert*-butoxycarbonyl)-4-(1,3-dioxo-3-methoxy-2-methyl-prop-1-yl)piperidine (from Step B) and 0.26 mL (8.4 mmol) of hydrazine in 5 mL of toluene was refluxed for 50 minutes. The reaction was cooled to rt and placed in the freezer overnight. After decanting the solvent, the white solid was triturated with Et₂O to provide the title compound, which was used without further purification. ¹H-NMR (500 MHz) δ 1.49 (s, 9H), 1.55-1.63 (m, 2H), 1.77-1.79 (m, 2H), 1.90 (s, 3H), 2.69-2.77 (m, 3H), 4.22 (m, 2H), 5.15-5.79 (br m, 2H).

Step D: 1-*tert*-Butoxycarbonyl-4-(3-methoxy-4-methyl-(1*H*)-pyrazol-5-yl)piperidine

A suspension of 1-*tert*-butoxycarbonyl-4-(4-methyl-(1*H*)-pyrazol-3-one-5-yl)piperidine (from Step C) in 12.5 mL (9.9 mmol) of 0.8 M diazomethane in Et₂O was allowed to stand (occasional swirling) until all solids were in solution. Excess diazomethane was quenched with HOAc. The reaction was partitioned
5 between 1 N NaHCO₃ and Et₂O. After separating phases, the organic layer was dried over MgSO₄ and concentrated. The residue was purified by flash chromatography using 19:1 v/v hexanes/acetone, 9:1 v/v hexanes/acetone and 4:1 v/v hexanes/acetone as the gradient to afford the title compound as a yellow oil: R_F: 0.18 (4:1 v/v hexanes/acetone); ¹H-NMR (500 MHz) δ 1.48 (s, 9H), 1.57-1.65 (m, 2H), 1.82-1.85
10 (m, 2H), 1.89 (s, 3H), 2.70-2.79 (m, 3H), 3.91 (s, 3H), 4.24 (m, 2H).; ¹³C-NMR (125 MHz) δ 55.7 (O-CH₃).

Step E: 1-*tert*-Butoxycarbonyl-4-(1-ethyl-3-methoxy-4-methyl-(1*H*)-pyrazol-5-yl)piperidine

15 A solution of 30 mg (0.10 mmol) of 1-*tert*-butoxycarbonyl-4-(3-methoxy-4-methyl-(1*H*)-pyrazol-5-yl)piperidine (from Step D) in 1 mL of DMF at 0 °C was treated with 3.5 mg (0.15 mmol) of 95% NaH and 0.012 mL (0.15 mmol) of ethyl iodide. After 50 minutes, the reaction was partitioned between 25 mL of EtOAc and 25 mL of brine. The organic layer was dried over Na₂SO₄ and concentrated. The
20 residue was purified by flash chromatography using 99:1 v/v CH₂Cl₂/acetone, 98:2 v/v CH₂Cl₂/acetone and 97:3 v/v CH₂Cl₂/acetone as the gradient to afford the title compound: R_F: 0.39 (19:1 v/v CH₂Cl₂/acetone); ¹H-NMR (500 MHz) δ 1.33 (t, J= 7.1, 3H), 1.49 (s, 9H), 1.69-1.72 (m, 2H), 1.82-1.90 (m, 2H), 1.91 (s, 3H), 2.68-2.74 (m, 3H), 3.88 (s, 3H), 3.98 (q, J= 7.1, 2H), 4.25 (m, 2H).

25

Step F: 4-(1-Ethyl-3-methoxy-4-methyl-(1*H*)-pyrazol-5-yl)piperidine

 The title compound was prepared from 1-*tert*-butoxycarbonyl-4-(1-ethyl-3-methoxy-4-methyl-(1*H*)-pyrazol-5-yl)piperidine (Step E) using a procedure analogous to that described for Piperidine 14, Step F. ¹H-NMR (500 MHz) δ 1.33 (t, J= 7.1, 3H), 1.70-1.73 (m, 2H), 1.86-1.96 (m, 5H), 2.67-2.72 (m, 3H), 3.19-3.21 (m, 30
2H), 3.89 (s, 3H), 3.99 (q, J= 7.1, 2H).

PIPERIDINE 16

4-(1-Ethyl-3-methoxy-5-methyl-(1*H*)-pyrazol-4-yl)piperidine

Step A: Ethyl 2-(*R/S*)-(1-*tert*-butoxycarbonyl-piperidin-4-yl)-3-(*R/S*)-hydroxy-butanoate

A solution of 0.35 mL (2.5 mmol) of diisopropylamine in 10 mL of THF at 0 °C was treated with 1.6 mL of 1.0 M *n*-butyllithium solution in hexanes. The resulting mixture was stirred at 0 °C for 10 min, then cooled to -78 °C. A solution of 540 mg (2.0 mmol) of ethyl 2-(1-*tert*-butoxycarbonyl-piperidin-4-yl)acetate (from Piperidine 35, Step A) in 2 mL of THF was added and the resulting solution was stirred cold for 30 min. Acetaldehyde (0.17 mL, 3.0 mmol) was added and the resulting mixture was warmed to 0 °C. The reaction was quenched with 10 mL of sat'd NH₄Cl and the resulting mixture was partitioned between 50 mL of ether and 25 mL of water. The organic layer was separated, dried over MgSO₄ and concentrated. Flash chromatography on 20 g of silica gel using 2:1 v/v hexanes/EtOAc as the eluant afforded the title compound.

Step B: Ethyl 2-(*R/S*)-(1-*tert*-butoxycarbonyl-piperidin-4-yl)-3-oxo-butanoate

The title compound was prepared from ethyl 2-(*R/S*)-(1-*tert*-butoxycarbonyl-piperidin-4-yl)-3-(*R/S*)-hydroxy-butanoate (from Step A) using a procedure analogous to that described in Piperidine 8, Step D. ¹H-NMR (500 MHz) δ 1.11-1.22 (m, 2H), 1.27 (t, J = 7.0, 3H), 1.41 (s, 9H), 1.57-1.68 (m, 2H), 2.23 (s, 3H), 2.23-2.30 (m, 1H), 2.72 (br s, 2H), 3.27 (d, J = 9.5, 1H), 4.09 (br s, 2H), 4.21 (q, J = 7.0, 2H).

Step C: 1-*tert*-Butoxycarbonyl-4-(3-oxo-5-methyl-(1*H*)-pyrazol-4-yl)piperidine

A solution of 595 mg (1.9 mmol) of ethyl 2-(*R/S*)-(1-*tert*-butoxycarbonyl-piperidin-4-yl)-3-oxo-butanoate (from Step B) and 0.06 mL (1.9 mmol) of hydrazine in 10 mL of xylenes was heated at reflux for 2 h. The resulting mixture was cooled to rt and the solid that precipitated was filtered and dried to afford the title compound. ¹H-NMR (500 MHz, CD₃OD) δ 1.45 (s, 9H), 1.60 (app d, J = 12.0, 2H), 1.83 (dq, J = 4.0, 13.0, 2H), 2.14 (s, 3H), 2.52-2.58 (m, 1H), 2.65-2.85 (br s, 2H), 4.13 (d, J = 13.5, 2H), 4.81 (s, 2H).

Step D: 1-*tert*-Butoxycarbonyl-4-(3-methoxy-5-methyl-(1*H*)-pyrazol-4-yl)piperidine

The title compound was prepared from 1-*tert*-butoxycarbonyl-4-(5-methyl-3-oxo-(1*H*)-pyrazol-4-yl)piperidine (Step C) using a procedure analogous to that described for Piperidine 15, Step D. R_F : 0.34 (7:3 v/v hexanes/acetone); ^1H -NMR (500 MHz) δ 1.47 (s, 9H), 1.57-1.59 (m, 2H), 1.75-1.83 (m, 2H), 2.16 (s, 3H), 2.44-2.50 (m, 1H), 2.70 (m, 2H), 3.86 (s, 3H), 4.17 (m, 2H); ^{13}C -NMR (125 MHz) δ 55.8 (O-CH₃).

10 Step E: 1-*tert*-Butoxycarbonyl-4-(1-ethyl-3-methoxy-5-methyl-(1*H*)-pyrazol-4-yl)piperidine

The title compound was prepared from 1-*tert*-butoxycarbonyl-4-(3-methoxy-5-methyl-(1*H*)-pyrazol-4-yl)piperidine (Step D) using a procedure analogous to that described for Piperidine 15, Step E. R_F : 0.29 (9:1 v/v hexanes/acetone); ^1H -NMR (500 MHz) δ 1.31 (t, J = 7.3, 3H), 1.47 (s, 9H), 1.54-1.56 (m, 2H), 1.79-1.87 (m, 2H), 2.13 (s, 3H), 2.38-2.45 (m, 1H), 2.70 (m, 2H), 3.84 (s, 3H), 3.91 (q, J = 7.3, 2H), 4.25 (m, 2H).

20 Step F: 4-(1-Ethyl-3-methoxy-5-methyl-(1*H*)-pyrazol-4-yl)piperidine

The title compound was prepared from 1-*tert*-butoxycarbonyl-4-(1-ethyl-3-methoxy-5-methyl-(1*H*)-pyrazol-4-yl)piperidine (Step E) using a procedure analogous to that described for Piperidine 14, Step F. ^1H -NMR (500 MHz) δ 1.33 (t, J = 7.2, 3H), 1.61-1.64 (m, 2H), 1.89-1.98 (m, 2H), 2.17 (s, 3H), 2.42-2.49 (m, 1H), 2.68-2.73 (m, 2H), 2.90 (m, 1H), 3.19-3.22 (m, 2H), 3.87 (s, 3H), 3.92 (q, J = 7.2, 2H).

25

PIPERIDINE 17

4-(2-Ethyl-2,4,5,6-tetrahydrocyclopenta[*c*]- (2*H*)-pyrazol-3-yl)piperidine

30 Step A: (1-Benzoyloxycarbonylpiperidin-4-yl)-((2*R*/2*S*)-cyclopentanone-2-yl)ketone

A solution of 0.59 g (2.2 mmol) of 1-(benzyloxycarbonyl)isonipecotic acid in 4 mL of CH₂Cl₂ at 0 °C was treated with 0.5 mL (5.7 mmol) of oxalyl chloride and 3 drops of DMF. After 1 hour when the bubbling ceased, volatiles were removed

under reduced pressure. The residue was concentrated 3X from CH₂Cl₂ to afford the acyl chloride, which was used without further purification.

A solution of the above acyl chloride in 6 mL of THF at 0 °C was treated with 0.36 (2.2 mmol) of *N*-(1-cyclopenten-1-yl)morpholine and 0.35 mL (2.5 mmol) of triethylamine. The reaction was stirred at rt for 6 hours and at 50 °C for 16 hours. The reaction was cooled to rt and treated with 5 mL of H₂O and 1 mL of HOAc. After stirring at rt for 2 hours and at 50 °C for 2 hours, volatiles were removed under reduced pressure. The residue was partitioned between 100 mL of CH₂Cl₂ and 100 mL of 0.5 N HCl. After separating phases, the organic layer was dried over MgSO₄ and concentrated. The residue was purified with a 40S Biotage column using 7:3 v/v of hexanes/EtOAc as the eluant to afford impure title compound: R_F: 0.36 (3:2 v/v hexanes/EtOAc); ¹H-NMR (500 MHz) (mixture of keto and enol tautomers) δ 1.43-4.26 (m, 16H), 5.13-5.29 (m, 2H), 7.27-7.39 (m, 5H).

15 Step B: 1-Benzyloxycarbonyl-4-(2-ethyl-2,4,5,6-tetrahydrocyclopenta[*c*]-(*2H*)-pyrazol-3-yl)piperidine

The title compound was prepared from (1-benzyloxycarbonylpiperidin-4-yl)-((*2R/2S*)-cyclopentan-2-yl)ketone (Step A) using a procedure analogous to that described for Piperidine 8, Step E. R_F: 0.13 (4:1 v/v hexanes/acetone); ¹H-NMR (500 MHz) δ 1.43 (t, J = 7.3, 3H), 1.65-1.84 (m, 4H), 2.35-2.40 (m, 2H), 2.60-2.87 (m, 7H), 4.06 (q, J = 7.3, 2H), 4.32 (m, 2H), 5.16 (s, 2H), 7.27-7.39 (m, 5H).

Step C: 4-(2-Ethyl-2,4,5,6-tetrahydrocyclopenta[*c*]-(*2H*)-pyrazol-3-yl)piperidine

25 A mixture of 85 mg (0.24 mmol) of 1-benzyloxycarbonyl-4-(2-ethyl-2,4,5,6-tetrahydrocyclopenta[*c*]-(*2H*)-pyrazol-3-yl)piperidine (from Step B) and 26 mg of 10% palladium on carbon in 2 mL of MeOH was hydrogenated at rt under a balloon of hydrogen for 1.25 hours. The reaction was filtered and concentrated to afford the title compound as a colorless film, which was used without further purification. ¹H-NMR (500 MHz) δ 1.38 (t, J = 7.3, 3H), 1.64-1.80 (m, 4H), 2.31-2.36 (m, 2H), 2.60-2.73 (m, 7H), 3.05-3.18 (m, 3H), 4.00 (q, J = 7.3, 2H).

PIPERIDINE 18

4-(4-Ethyl-3-methoxy-4-methyl-(*4H*)-pyrazol-5-yl)piperidine

Step A: 1-tert-Butoxycarbonyl-4-(4-ethyl-3-hydroxy-4-methyl-(4H)-pyrazol-5-yl)piperidine

A solution of 255 mg (0.9 mmol) of 1-tert-butoxycarbonyl-4-(4-methyl-(1H)-pyrazol-3-one-5-yl)piperidine (from Piperidine 15, Step C) and 0.155 mL (1.0 mmol) of freshly distilled tetramethylethylene diamine in 3 mL of THF at –78 °C was treated with 0.8 mL (2.0 mmol) of 2.5 M *n*-butyl lithium in hexanes (J. Med. Chem. 1996, 39, 3920-3928). After stirring for 15 minutes at –78 °C, the reaction was warmed to 0 °C for 15 minutes. Upon recooling to –78 °C, 0.11 mL (1.3 mmol) of ethyl iodide was added. After warming to rt and stirring for 19 hours, the reaction was cooled to 0 °C and quenched with 1 N HCl. The reaction mixture was partitioned between 100 mL of EtOAc and 100 mL of 1 N HCl. After separating phases, the organic layer washed with 100 mL of brine, dried over Na₂SO₄ and concentrated. The residue was purified by flash chromatography using 99:1 v/v CH₂Cl₂/MeOH, 98:2 v/v CH₂Cl₂/ MeOH and 97:3 v/v CH₂Cl₂/ MeOH as the gradient to afford the title compound as a white solid: R_F: 0.40 (19:1 v/v CH₂Cl₂/ MeOH); ¹H-NMR (500 MHz) δ 0.73 (t, J = 7.4, 3H), 1.26 (s, 3H), 1.47 (s, 9H), 1.59-1.85 (m, 6H), 2.38 (m, 1H), 2.76-2.81 (m, 2H), 4.16-4.21 (m, 2H), 8.61 (br s, 1H).

Step B: 1-tert-Butoxycarbonyl-4-(4-ethyl-3-methoxy-4-methyl-(4H)-pyrazol-5-yl)piperidine

A suspension of 49 mg (0.15 mmol) of 1-tert-butoxycarbonyl-4-(4-ethyl-3-hydroxy-4-methyl-(4H)-pyrazol-5-yl)piperidine (from Step A), 50 mg (0.36 mmol) of potassium carbonate and 0.06 mL (0.96 mmol) of methyl iodide in 0.3 mL of acetonitrile was stirred at rt for 17 hours and 85 °C for 7 hours. The reaction was partitioned between 25 mL of EtOAc and 25 mL of brine. After separating phases, the organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by flash chromatography using 4:1 v/v of hexanes/acetone as the eluant to afford the title compound as a colorless film: R_F: 0.21 (4:1 v/v hexanes/acetone); ¹H-NMR (500 MHz) δ 0.65 (t, J = 7.4, 3H), 1.21 (s, 3H), 1.45 (s, 9H), 1.57-1.66 (m, 2H), 1.73-1.81 (m, 4H), 2.37 (m, 1H), 2.73-2.78 (m, 2H), 3.27 (s, 3H), 4.15-4.20 (m, 2H); ¹³C-NMR (125 MHz) δ 54.4 (O-CH₃).

Step C: 4-(4-Ethyl-3-methoxy-4-methyl-(4H)-pyrazol-5-yl)piperidine

A solution of 23.5 mg (0.072 mmol) of 1-*tert*-butoxycarbonyl-4-(4-ethyl-3-methoxy-4-methyl-(4*H*)-pyrazol-5-yl)piperidine (from Step B) in 1 N HCl in methanol was stirred at rt for 4 h. The crude product was partitioned between 10 mL of 1 N NaOH and 25 mL of CH₂Cl₂. After separating phases, the aqueous layer was
 5 extracted with 3X25 mL of CH₂Cl₂. The combined organic layers were dried over Na₂SO₄ and concentrated to afford the title compound, which was used without further purification. ¹H-NMR (500 MHz) δ 0.65 (t, J = 7.4, 3H), 1.21 (s, 3H), 1.57-1.94 (m, 6H), 2.40 (m, 1H), 2.70-2.74 (m, 2H), 3.20-3.28 (m, 2H), 3.28 (s, 3H).

10

PIPERIDINE 19

4-(1-Ethyl-3-hydroxymethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine

Step A: 1-(*tert*-Butoxycarbonyl)-4-(4-benzyloxy-1,3-dioxo-2-(*R/S*)-methylbut-1-yl)piperidine

15

The title compound was prepared using a procedure analogous to that described for Piperidine 15, Step B, except benzyloxyacetic acid, methyl ester was substituted for dimethylcarbonate. R_F: 0.27 (4:1 v/v hexanes/acetone); ¹H-NMR (500 MHz) δ 1.27 (d, J = 6.9, 3H), 1.43-1.86 (m, 15H), 2.54-2.70 (m, 3H), 3.78-4.76 (m, 5H), 7.27-7.40 (m, 5H).

20

Step B: 1-(*tert*-Butoxycarbonyl)-4-(1-ethyl-3-benzyloxymethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine

The title compound was prepared from 1-(*tert*-butoxycarbonyl)-4-(4-benzyloxy-1,3-dioxo-2-(*R/S*)-methylbut-1-yl)piperidine (from Step A) using a
 25 procedure analogous to that described for Piperidine 8, Step E. R_F: 0.13 (9:1 v/v hexanes/acetone); ¹H-NMR (500 MHz) δ 1.39 (t, J = 7.2, 3H), 1.50 (s, 9H), 1.69-1.71 (m, 2H), 1.85-1.94 (m, 2H), 2.08 (s, 3H), 2.75-2.81 (m, 3H), 4.13 (q, J = 7.2, 2H), 4.15-4.27 (m, 2H), 4.49 (s, 2H), 4.57 (s, 2H), 7.26-7.38 (m, 5H).

30

Step C: 1-(*tert*-Butoxycarbonyl)-4-(1-ethyl-3-hydroxymethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine

The title compound was prepared from 1-(*tert*-butoxycarbonyl)-4-(1-ethyl-3-benzyloxymethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine (from Step B) using a procedure analogous to that described for Pyrrolidine 1, Step E. R_F: 0.21 (3:2 v/v

hexanes/acetone); $^1\text{H-NMR}$ (500 MHz) δ 1.36 (t, $J = 7.2$, 3H), 1.48 (s, 9H), 1.67-1.70 (m, 2H), 1.84-1.93 (m, 2H), 2.08 (s, 3H), 2.74-2.80 (m, 3H), 3.14 (br m, 1H), 4.10 (q, $J = 7.2$, 2H), 4.12-4.26 (m, 2H), 4.59 (s, 2H).

5 Step D: 4-(1-Ethyl-3-hydroxymethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine

The title compound was prepared from 1-(*tert*-butoxycarbonyl)-4-(1-ethyl-3-hydroxymethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine (from Step C) using a procedure analogous to that described for Piperidine 8, Step F.

10 PIPERIDINE 20

4-(1-Ethyl-3-methoxymethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine

Step A: 1-(*tert*-Butoxycarbonyl)-4-(1-ethyl-3-methoxymethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine

15 The title compound was prepared from 1-(*tert*-butoxycarbonyl)-4-(1-ethyl-3-hydroxymethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine (from Piperidine 19, Step C) using a procedure analogous to that described for Piperidine 15, Step E, except methyl iodide was substituted for ethyl iodide. R_F : 0.47 (3:2 v/v hexanes/acetone); $^1\text{H-NMR}$ (500 MHz) δ 1.39 (t, $J = 7.2$, 3H), 1.49 (s, 9H), 1.69-1.71 (m, 2H), 1.85-1.94 (m, 2H), 2.08 (s, 3H), 2.75-2.81 (m, 3H), 3.39 (s, 3H), 4.12 (q, $J = 7.2$, 2H), 4.14-4.27 (m, 2H), 4.38 (s, 2H).

Step B: 4-(1-Ethyl-3-methoxymethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine

25 The title compound was prepared from 1-(*tert*-butoxycarbonyl)-4-(1-ethyl-3-methoxymethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine (from Step A) using a procedure analogous to that described for Piperidine 8, Step F. $^1\text{H-NMR}$ (500 MHz) δ 1.36 (t, $J = 7.2$, 3H), 1.71-1.74 (m, 2H), 1.97-2.09 (m, 2H), 2.11 (s, 3H), 2.72-2.80 (m, 3H), 3.25-3.35 (m, 2H), 3.37 (s, 3H), 4.11 (q, $J = 7.2$, 2H), 4.37 (s, 2H).

30 PIPERIDINE 21

4-(2-Methoxy-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)-piperidine

Step A: (2*R/S*, 3*R/S*)-2-(1-*tert*-Butoxycarbonyl-piperidin-4-yl)-7-chloro-3-hydroxy-heptanoic acid, ethyl ester

A solution of 0.32 mL (2.2 mmol) of diisopropylamine in 10 mL of THF at 0 °C was treated with 0.92 mL (2.3 mmol) of 2.5 M *n*-butyllithium in sol'n in hexanes. The resulting solution was stirred at 0 °C for 10 min, then cooled to -78 °C. A solution of 0.51 g (1.8 mmol) of (1-*tert*-butoxycarbonylpiperidin-4-yl)acetic acid, ethyl ester (from Piperidine 35, Step A) in 2 mL of THF was added. After stirring for 30 minutes, a solution of 0.26 g (2.1 mmol) 5-chloropentanal in 2 mL of THF was added (J. Org. Chem. 1981, 46, 2007). The reaction was stirred for 1.75 hours at -78 °C and 3.5 hours at 0 °C. After quenching the reaction with saturated NH₄Cl, volatiles were removed under reduced pressure. The residue was partitioned between 100 mL of Et₂O and 100 mL of H₂O. After separating phases, the organic layer was washed with 100 mL of 0.5 N HCl and 100 mL of 1 N NaHCO₃, dried over MgSO₄ and concentrated. The residue was purified with a 40M Biotage column using 3:1 v/v of hexanes/EtOAc as the eluant to afford impure title compound: R_F: 0.27 (7:3 v/v hexanes/EtOAc); ¹H-NMR (500 MHz) δ 1.24-2.08 (m, 23H), 2.38 (t, J = 6.2, 1H), 2.63-2.71 (m, 2H), 3.53-3.56 (m, 2H), 3.92 (m, 1H), 4.09-4.19 (m, 4H).

Step B: (2*R/S*)-2-(1-*tert*-Butoxycarbonyl-piperidin-4-yl)-7-chloro-3-keto-heptanoic acid, ethyl ester

The title compound was prepared from (2*R/S*, 3*R/S*)-2-(1-*tert*-butoxycarbonyl-piperidin-4-yl)-7-chloro-3-hydroxy-heptanoic acid, ethyl ester (from Step A) using a procedure analogous to that described for Piperidine 8, Step D. R_F: 0.30 (4:1 v/v hexanes/EtOAc); ¹H-NMR (500 MHz) δ 1.09-1.22 (m, 2H), 1.27 (t, J = 7.1, 3H), 1.45 (s, 9H), 1.55 (m, 1H), 1.63-1.79 (m, 5H), 2.29 (m, 1H), 2.46-2.75 (m, 4H), 3.30 (d, J = 9.6, 1H), 3.51-3.54 (m, 2H), 4.06-4.21 (m, 4H).

Step C: 1-(*tert*-Butoxycarbonyl)-4-(4,5,6,7-tetrahydropyrazol-2-one[1,5-*a*]pyridin-3-yl)-piperidine

A solution of 264 mg (0.67 mmol) of (2*R/S*)-2-(1-*tert*-butoxycarbonyl-piperidin-4-yl)-7-chloro-3-keto-heptanoic acid, ethyl ester (from Step B) and 0.064 mL of hydrazine (2.0 mmol) in 2 mL of xylene was refluxed for 24 hours. The reaction was cooled to rt and volatiles removed under reduced pressure. The residue was purified by flash chromatography using 39:1 v/v of CH₂Cl₂/MeOH as the eluant to afford the title compound: R_F: 0.41 (19:1 v/v CH₂Cl₂/MeOH); ¹H-NMR (500 MHz)

δ 1.48 (s, 9H), 1.63-1.65 (m, 2H), 1.79-1.85 (m, 4H), 1.96-2.03 (m, 2H), 2.51 (m, 1H), 2.66-2.72 (m, 4H), 3.93-3.95 (m, 2H), 4.15-4.22 (m, 2H), 6.8 (br m, 1H).

Step D: 1-(*tert*-Butoxycarbonyl)-4-(2-methoxy-4,5,6,7-tetrahydropyrazolo[1,5-
5 *a*]pyridin-3-yl)-piperidine

The title compound was prepared from 1-(*tert*-butoxycarbonyl)-4-(4,5,6,7-tetrahydropyrazol-2-one[1,5-*a*]pyridin-3-yl)-piperidine (from Step C) using a procedure analogous to that described for Piperidine 15, Step D. R_F : 0.72 (19:1 v/v CH₂Cl₂/MeOH); ¹H-NMR (500 MHz) δ 1.45 (s, 9H), 1.57-1.59 (m, 2H), 1.71-1.81
10 (m, 4H), 1.94-1.98 (m, 2H), 2.44 (m, 1H), 2.62-2.68 (m, 4H), 3.84 (s, 3H), 3.91-3.93 (m, 2H), 4.15-4.22 (m, 2H); ¹³C-NMR (125 MHz) δ 55.7 (O-CH₃).

Step E: 4-(2-Methoxy-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)-
15 piperidine

The title compound was prepared from 1-(*tert*-butoxycarbonyl)-4-(2-methoxy-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)-piperidine (from Step D) using a procedure analogous to that described for Piperidine 8, Step F.

Piperidines 22-25 were prepared through analogous procedures for
20 Piperidine 8, except substituting the appropriate ketone in Step C.

PIPERIDINE 22

4-(2-Ethyl-2,4,6,7-tetrahydrothiopyrano[4,3-*c*]pyrazol-3-yl)piperidine

25 PIPERIDINE 23

4-(2-Ethyl-2,4,6,7-tetrahydrothiopyrano5,5-dioxide[4,3-*c*]pyrazol-3-yl)piperidine

PIPERIDINE 23A

4-(2-Ethyl-2,4,6,7-tetrahydropyrano[4,3-*c*]pyrazol-3-yl)piperidine

30

PIPERIDINE 24

4-(3-*tert*-Butyl-1-ethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine

PIPERIDINE 24A

4-(3-*tert*-Butyl-2-ethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine

PIPERIDINE 25

4-(1-Ethyl-4-methyl-3-*iso*-propyl(1*H*)-pyrazol-5-yl)piperidine

5

Piperidines 26-30 were prepared through analogous procedures for Piperidine 15, except substituting the appropriate ester for dimethylcarbonate in Step B.

10

PIPERIDINE 26

4-(1,4-Diethyl-3-methyl-(1*H*)-pyrazol-5-yl)piperidine

PIPERIDINE 27

4-(3-Cyclobutyl-1-ethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine

15

PIPERIDINE 28

4-(1,3,4-Triethyl-(1*H*)-pyrazol-5-yl)piperidine

PIPERIDINE 29

20

4-(3,4-Dimethyl-1-ethyl-(1*H*)-pyrazol-5-yl)piperidine

PIPERIDINE 30

4-(3-Cyclopropyl-1-ethyl-4-methyl-(1*H*)-pyrazol-5-yl)piperidine

25

Piperidines 31-34 were prepared through analogous procedures for Piperidine 9, except substituting the appropriate diketone in Step B.

PIPERIDINE 31

4-(1,3,5-Triethyl-(1*H*)-pyrazol-4-yl)piperidine, hydrochloride salt

30

PIPERIDINE 32

4-(1,3,5-Trimethyl-(1*H*)-pyrazol-4-yl)piperidine, hydrochloride salt

Piperidine 33


4-(1-Ethyl-3,5-dimethyl-(1*H*)-pyrazol-4-yl)piperidine, hydrochloride salt

PIPERIDINE 34

4-(1,5-Diethyl-3-methyl-(1*H*)-pyrazol-4-yl)piperidine, hydrochloride salt

5

PIPERIDINE 35



4-(3-Methoxy-1-methyl-5-(trifluoromethyl)-1*H*-pyrazol-4-yl)piperidine

10 Step A: 1-(*tert*-Butoxycarbonyl)-4-piperidineacetic acid ethyl ester

A suspension of sodium hydride (1.90 g of 60% oil dispersion, 48 mmol) in THF (150 mL) was cooled to 0 °C in a 3-neck flask fitted with a mechanical stirrer. Triethyl phosphonoacetate (9.90 mL, 11.2 g, 50 mmol) was added to the stirred mixture, producing vigorous gas evolution. After 20 min, 1-(*tert*-butoxycarbonyl)-4-piperidone (8.00 g, 40 mmol) was added to the clear solution. After an additional 20 min, the cooling bath was removed and the mixture was stirred for 2 h. The mixture was partitioned between Et₂O (200 mL) and 1 *N* aq. NaOH (200 mL). The organic layer was washed with saturated aq. NaCl and the aqueous layers were extracted in succession with Et₂O (100 mL). The organic layers were dried (Na₂SO₄), decanted, and evaporated to give 11.6 g of colorless crystals. This material was dissolved in hexane (50 mL) at 60 °C and the solution was allowed to cool to RT, yielding 1-(*t*-butoxycarbonyl)-4-(carboethoxymethylidene)piperidine as white crystals. A second crop of crystals was similarly obtained by evaporation of the mother liquor and recrystallization of the residue.

1-(*tert*-Butoxycarbonyl)-4-(carboethoxymethylidene)piperidine (9.97 g, 37 mmol) in 95% ethanol (75 mL) containing 10% palladium on carbon (250 mg) was hydrogenated on a Parr shaker at 36 psi. After 1.5 h, the mixture was filtered through Celite with additional 95% ethanol, and the filtrate was evaporated to give the title compound as a colorless oil. For the title compound: ¹H NMR (500 MHz, CDCl₃) δ 4.15 (q, *J* = 7, 2H), 4.09 (bd, *J* = 12, 2H), 2.73 (bt, *J* = 12, 2H), 2.24 (d, *J* =

30

7, 2H), 2.00-1.90 (m, 1H), 1.70 (bd, J = 12, 2H), 1.47 (s, 9H), 1.27 (t, J = 7, 3H), 1.18 (qd, J = 12, 4, 2H).

Step B: 1-(*tert*-Butoxycarbonyl)- α -(trifluoroacetyl)-4-piperidineacetic acid
ethyl ester

THF (3.0 mL) and ethyl trifluoroacetate (1.32 mL, 1.58 g, 11.1 mmol) were added to sodium hydride (442 mg of 60% oil dispersion, 11.1 mmol) in a flask fitted with a mechanical stirrer and a reflux condenser. 1-(*tert*-butoxycarbonyl)-4-piperidineacetic acid ethyl ester (1.50 g, 5.52 mmol) dissolved in THF (2.0 mL) was added over 30 min, with additional THF (2 x 1 mL) to complete the transfer. The mixture was warmed to 45 °C overnight. An additional portion of ethyl trifluoroacetate (1.0 mL, 1.19 g, 8.4 mmol) was added the temperature was increased to 70 °C for 17 h. After cooling to RT, the mixture was partitioned between EtOAc (50 mL) and a mixture of saturated aq. NaCl (25 mL) and 2 N aq. HCl (10 mL). The aqueous layer was extracted with EtOAc (25 mL). The organic layers were washed in succession with saturated aq. NaCl (2 x 10 mL), dried (Na₂SO₄), decanted, and evaporated. The crude product was purified by flash column chromatography on silica gel, eluting with 90:10 to 85:15 v/v hexanes/EtOAc to give the title compound as a colorless oil. For the title compound: ¹H NMR (500 MHz, CDCl₃) showed an apparent mixture of tautomers; ESI-MS 268.2 (M+H-100); HPLC A: 3.3 min.

Step C: 1-(*tert*-Butoxycarbonyl)-4-(3-hydroxy-5-(trifluoromethyl)-(1*H*)-pyrazol-4-yl)piperidine

Anhydrous hydrazine (0.040 mL, 41 mg, 1.27 mmol) was added to a stirred solution of 1-(*tert*-butoxycarbonyl)- α -(trifluoroacetyl)-4-piperidineacetic acid ethyl ester (275 mg, 0.75 mmol, from Step B) in toluene (2.0 mL) at RT. The mixture was warmed to 60 °C for 4 h, followed by 16 h at 80 °C. The mixture was allowed to cool to RT, transferred to another flask with CH₃OH, and evaporated to give the title compound as a white solid. For the title compound: ¹H NMR (500 MHz, CD₃OD) δ 4.15 (bd, J = 13, 2H), 2.86-2.70 (m, 3H), 1.88 (bq, J = 12, 2H), 1.62 (bd, J = 13, 2H), 1.47 (s, 9H); ESI-MS 280.3 (M+H-56) and 236.3 (M+H-100); HPLC A: 3.0 min.

Step D: 1-(*tert*-Butoxycarbonyl)-4-(3-methoxy-1-methyl-5-(trifluoromethyl)-(1*H*)-pyrazol-4-yl)piperidine


Potassium carbonate (270 mg, 1.95 mmol) and iodomethane (0.12 mL, 0.27 g, 1.9 mmol) were added to a stirred suspension of 1-(*tert*-butoxycarbonyl-4-(3-hydroxy-5-(trifluoromethyl)-(1*H*)-pyrazol-4-yl)piperidine (200 mg, 0.60 mmol, from Step C) in CH₃CN (3.0 mL) at RT. After 5 d, the reaction mixture was diluted into saturated aq. NH₄Cl (15 mL) and extracted with EtOAc (25 mL). The organic layer was washed with saturated aq. NaCl (15 mL), dried (Na₂SO₄), decanted, and evaporated to give 215 mg of colorless oil. Purification by flash column chromatography on silica gel, eluting with 90:10 to 50:50 hexanes/EtOAc gave the title compound as a colorless syrup. For the title compound: ¹H NMR (500 MHz, CD₃OD) δ 4.13 (d, J = 12, 2H), 3.87 (s, 3H), 3.78 (s, 3H), 2.83 (tt, J = 12, 3, 1H), 2.75 (bs, 2H), 1.89 qd, J = 12, 4, 2H), 1.55 (d, J = 12, 2H), 1.48 (s, 9H); ESI-MS 308.2 (M+H-56); HPLC A: 3.5 min.

Later column fractions gave 50 mg of the isomeric product 1-(*tert*-butoxycarbonyl-4-(5-methoxy-1-methyl-3-(trifluoromethyl)-(1*H*)-pyrazol-4-yl)piperidine: ¹H NMR (500 MHz, CD₃OD) δ 4.16 (d, J = 12, 2H), 3.92 (s, 3H), 3.73 (s, 3H), 2.88-2.72 (m, 3H), 1.79-1.68 (m, 4H), 1.47 (s, 9H).

Step E: 4-(3-Methoxy-1-methyl-5-(trifluoromethyl)-(1*H*)-pyrazol-4-yl)piperidine

Trifluoroacetic acid (3.0 mL) was added to a solution of 1-(*tert*-butoxycarbonyl-4-(3-methoxy-1-methyl-5-(trifluoromethyl)-(1*H*)-pyrazol-4-yl)piperidine (150 mg, 0.41 mmol, from Step D) in CH₂Cl₂ (3.0 mL). After 2 h, the reaction was concentrated and the residue was dissolved in EtOAc (15 mL) and washed with saturated aq. NaHCO₃ (6 mL) followed by saturated aq. NaCl (5 mL). The organic layer was dried (Na₂SO₄), decanted, and evaporated to give the title compound as a white solid. For the title compound: ¹H NMR (500 MHz, CD₃OD) δ 3.89 (s, 3H), 3.80 (s, 3H), 3.32 (d, J = 13, 2H), 2.95 (tt, J = 13, 4, 1H), 2.93 (td, J = 13, 3, 2H), 2.18 (qd, J = 13, 4, 2H), 1.76 (d, J = 13, 2H); ESI-MS 264.1 (M+H); HPLC A: 1.3 min.


PIPERIDINE 36



4-(5-Methoxy-1-methyl-3-(trifluoromethyl)-(1H)-pyrazol-4-yl)piperidine

The title compound was prepared using conditions similar to those described in Piperidine 35, Step E, substituting 1-(*tert*-butoxycarbonyl-4-(5-methoxy-1-methyl-3-(trifluoromethyl)-(1H)-pyrazol-4-yl)piperidine (from Piperidine 35, Step D) for 1-(*tert*-butoxycarbonyl-4-(3-methoxy-1-methyl-5-(trifluoromethyl)-(1H)-pyrazol-4-yl)piperidine. For the title compound: ^1H NMR (500 MHz, CD_3OD) δ 3.94 (s, 3H), 3.72 (s, 3H), 3.10 (d, $J = 13$, 2H), 2.70 (tt, $J = 13$, 4, 1H), 2.64 (td, $J = 13$, 3, 2H), 1.84 (qd, $J = 13$, 4, 2H), 1.71 (d, $J = 13$, 2H); ESI-MS 264.1 (M+H); HPLC A: 1.1 min.

BICYCLIC AMINE 1



(1 α ,5 α ,6 α)-6-(3,5-Diethyl-1-methyl-(1H)-pyrazol-4-yl)-3-azabicyclo[3.1.0]hexane

Step A: (1 α ,5 α ,6 α)-3-(*tert*-Butoxycarbonyl)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane

A solution of di-*tert*-butyl dicarbonate (967 mg, 4.42 mmol) in CH_2Cl_2 (3.0 mL) was added to a stirred solution of (1 α ,5 α ,6 α)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane (456 mg, 4.02 mmol, for preparation see K.E. Brighty and M.J. Castaldi, *Synlett*, **1996**, 1097-1099) in CH_2Cl_2 (7.0 mL) at RT. After 15 h, the solution was partitioned between 2 *N* aq. HCl (50 mL) and EtOAc (50 mL). The organic layer was washed with saturated aq. NaHCO_3 (50 mL) followed by saturated aq. NaCl (50 mL). The aqueous layers were extracted in succession with EtOAc (2 x 50 mL). The organic layers were dried (Na_2SO_4), decanted, and evaporated. The crude product was purified by flash column chromatography on silica gel, eluting with 80:20 v/v to 0:100 hexane/EtOAc to give the title compound as a colorless syrup.

For the title compound: ^1H NMR (500 MHz, CDCl_3) δ 3.60 (d, $J = 11$, 2H), 3.53 (d, $J = 6$, 2H), 3.36 (d, $J = 11$, 2H), 1.44 (s, 11H), 0.96 (tt, $J = 6$, 3, 1H); ESI-MS 158.1 (M+H-56); HPLC A: 2.1 min.

5 Step B: (1 α ,5 α ,6 α)-3-(*tert*-Butoxycarbonyl)-3-azabicyclo[3.1.0]hexane-6-carboxaldehyde

A solution of DMSO (1.0 mL, 1.1 g, 7.0 mmol) in CH_2Cl_2 (0.6 mL) was added dropwise to a solution of oxalyl chloride (0.61 mL, 0.89 g, 7.0 mmol) in CH_2Cl_2 (6.4 mL) cooled in a dry ice/*i*-PrOH bath. After 5 min, (1 α ,5 α ,6 α)-3-(*tert*-
10 butoxycarbonyl)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane (600 mg, 2.81 mmol, from Step A) was added slowly in CH_2Cl_2 (6.4 mL). After another 15 min, *N,N*-diisopropylethylamine (4.9 mL, 3.6 g, 28 mmol) was added and the reaction was allowed to warm to -40°C over 1.5 h. The reaction mixture was poured into water (50 mL) and extracted with CH_2Cl_2 (3 x 50 mL). The combined organic layers were
15 washed with saturated aq. NaCl (50 mL), dried (Na_2SO_4), decanted, and evaporated. Purification by flash column chromatography on silica gel, eluting with hexanes followed by 80:20 to 50:50 v/v hexanes/EtOAc gave the title compound as a colorless syrup. For the title compound: ^1H NMR (500 MHz, CDCl_3) δ 9.44 (d, $J = 4$, 1H), 3.72 (d, $J = 11$, 1H), 3.64 (d, $J = 11$, 1H), 3.51-3.44 (m, 2H), 2.24-2.19 (m, 2H), 1.82
20 (q, $J = 4$, 1H), 1.45 (s, 9H).

Step C: (1 α ,5 α ,6 α)-3-(*tert*-Butoxycarbonyl)-6-(2-nitrobut-1-enyl)-3-azabicyclo[3.1.0]hexane

Potassium fluoride (18 mg, 0.31 mmol) and 1-nitropropane (1.1 mL, 1.1 g, 12.5 mmol) were added to a solution of (1 α ,5 α ,6 α)-3-(*tert*-butoxycarbonyl)-3-
25 azabicyclo[3.1.0]hexane-6-carboxaldehyde (1.32 g, 6.25 mmol, from Step B) in *i*-PrOH (6.0 mL) at RT. After 20 h, the mixture was partitioned between CH_2Cl_2 (75 mL) and saturated aq. NaCl (50 mL). The aqueous layer was extracted with CH_2Cl_2 (2 x 75 mL). The organic layers were dried (Na_2SO_4), decanted, and evaporated to
30 give crude (1 α ,5 α ,6 α)-3-(*t*-butoxycarbonyl)-6-(1-hydroxy-2-nitrobutyl)-3-azabicyclo[3.1.0]hexane as 2.11 g of yellow syrup.

All of the crude (1 α ,5 α ,6 α)-3-(*tert*-butoxycarbonyl)-6-(1-hydroxy-2-nitrobutyl)-3-azabicyclo[3.1.0]hexane was dissolved in CH_3CN (30 mL). 1,3-Dicyclohexylcarbodiimide (2.85 g, 13.8 mmol) and copper(I) chloride (620 mg,

6.26 mmol) were added and the mixture was stirred at RT. After 15 h, the mixture was diluted with EtOAc (200 mL) and 5 mL of 35% (w/w) oxalic acid in CH₃OH was added. The precipitate was removed by filtration through Celite and washed with additional EtOAc (50 mL). The filtrate was washed with saturated aq. NaHCO₃ (2 x 5 100 mL) followed by saturated aq. NaCl (100 mL), dried (Na₂SO₄), decanted, and evaporated. The crude product was purified by flash column chromatography on silica gel, eluting with 90:10 to 50:50 v/v hexanes/EtOAc to give the title compound as a 60:40 mixture of *E*- and *Z*- olefin isomers, respectively. For the title compound: ¹H NMR (500 MHz, CDCl₃) major isomer peaks (partial data) at δ 6.59 (d, J = 11, 1H), 2.51 (q, J = 7, 2H), 1.90 (t, J = 3, 2H), 1.41 (dt, J = 11, 3, 1H), 1.48 (s, 9H), 1.18 10 (t, J = 7, 3H); minor isomer peaks (partial data) at δ 5.14 (d, J = 11, 1H), 2.56 (q, J = 7, 2H), 2.22 (dt, J = 11, 3, 1H), 1.74 (t, J = 3, 2H), 1.46 (s, 9H), 1.11 (t, J = 7, 3H).

Step D: (1α,5α,6α)-3-(*tert*-Butoxycarbonyl)-6-(3,5-diethyl-(1*H*)-pyrazol-4-yl)-
15 3-azabicyclo[3.1.0]hexane
[Note: For safety reasons, flasks having smooth (*not* ground glass) joints and pipets with fire-polished tips were used for diazoalkane reactions]. 3-Nitro-1-nitroso-1-propylguanidine (1.31 g, 7.5 mmol) was added in 6-8 portions over 1 h to a stirred mixture of 40% w/w aqueous potassium hydroxide solution (2.3 mL) and 20 Et₂O (10 mL) at 0 °C. The mixture was stirred for 0.5 h after the last addition, and the Et₂O layer was then decanted using a pipet. The aqueous layer was stirred for 15 min with each of two additional 5-mL portions of Et₂O. The dried Et₂O layers, containing diazopropane, were added in succession to a solution of (1α,5α,6α)-3-(*tert*-butoxycarbonyl)-6-(2-nitrobut-1-enyl)-3-azabicyclo[3.1.0]hexane (0.50 g, 1.8 mmol, 25 from Step C) in Et₂O (5 mL) and the solution was stored in the dark at 0 °C. After 40 h, the excess diazopropane was quenched by the careful addition of acetic acid (0.30 mL). The solution was stirred at 0 °C for 15 min before being partitioned between EtOAc (30 mL) and saturated aq. NaHCO₃ (20 mL). The organic layer was washed with saturated aq. NaCl (10 mL), and the aqueous layers were extracted in succession 30 with EtOAc (30 mL). The EtOAc layers were dried (Na₂SO₄), decanted, and evaporated to give 652 mg of crude cycloaddition product.

A portion (596 mg) of the crude cycloaddition product was stirred for 20 min at RT with 20 mL of 2 *N* potassium hydroxide in 95% EtOH. The solution was then partitioned between water (100 mL) and Et₂O (100 mL). The organic layer

was washed with saturated aq. NaCl (50 mL), and the aqueous layers were extracted in succession with Et₂O (50 mL). The organic layers were dried (Na₂SO₄), decanted, and evaporated to give the title compound as colorless syrup. For the title compound: ¹H NMR (500 MHz, CD₃OD) δ 3.76 (d, J = 11, 2H), 3.50-3.42 (m, 2H), 2.69-2.57 (m, 4H), 1.73-1.68 (m, 2H), 1.45 (s, 9H), 1.26 (t, J = 3, 1H), 1.22 (t, J = 7); ESI-MS 306.2 (M+H); HPLC A: 2.2 min.

Step E: (1α,5α,6α)-3-(*tert*-Butoxycarbonyl)-6-(3,5-diethyl-1-methyl-(1*H*)-pyrazol-4-yl)-3-azabicyclo[3.1.0]hexane

10 Potassium carbonate (92 mg, 0.66 mmol) and iodomethane (0.070 mL, 0.16 g, 1.1 mmol) were added to a solution of (1α,5α,6α)-3-(*tert*-butoxycarbonyl)-6-(3,5-diethyl-1*H*-pyrazol-4-yl)-3-azabicyclo[3.1.0]hexane (100 mg, 0.33 mmol, from Step D) in CH₃CN (1.4 mL) and the mixture was stirred at rt. After 5 h, additional iodomethane (0.040 mL, 91 mg, 0.64 mmol) was added. After stirring overnight at
15 RT, the mixture was added to EtOAc (20 mL) and washed with saturated aq. NH₄Cl (20 mL) followed by saturated aq. NaCl (20 mL). The aqueous layers were extracted in succession with EtOAc (2 x 20 mL). The organic layers were dried (Na₂SO₄), decanted, and evaporated. Purification of the crude product by flash column chromatography on silica gel, eluting with 80:20 to 50:50 v/v hexanes/EtOAc gave
20 the title compound as a colorless syrup. For the title compound: ¹H NMR (500 MHz, CDCl₃) δ 3.76 (d, J = 11, 1H), 3.72 (s, 3H), 3.66 (d, J = 11, 1H), 3.51-3.44 (m, 4H), 2.67-2.59 (m, 4H), 1.67-1.60 (m, 2H), 1.47 (s, 9H), 1.34 (t, J = 3, 1H), 1.25 (t, J = 7, 3H), 1.18 (t, J = 7, 3H).

25 Step F: (1α,5α,6α)-6-(3,5-Diethyl-1-methyl-1*H*-pyrazol-4-yl)-3-azabicyclo[3.1.0]hexane

Trifluoroacetic acid (2.0 mL) was added to a solution of (1α,5α,6α)-3-(*t*-butoxycarbonyl)-6-(3,5-diethyl-1-methyl-1*H*-pyrazol-4-yl)-3-azabicyclo[3.1.0]hexane (67 mg, 0.21 mmol, from Step E) in CH₂Cl₂ (2.0 mL). After
30 2 h, the reaction was concentrated and the residue was dissolved in EtOAc (30 mL) and washed with saturated aq. NaHCO₃ (20 mL) followed by saturated aq. NaCl (20 mL). The aqueous layers were extracted with EtOAc (2 x 30 mL). The organic layers were dried (Na₂SO₄), decanted, and evaporated to give the title compound as yellow syrup. For the title compound: ¹H NMR (500 MHz, CD₃OD) δ 3.67 (s, 3H), 3.23 (d,


J = 11, 2H), 3.05 (bd, J = 11, 2H), 2.69 (q, J = 7), 2.58 (q, J = 7, 2H), 1.71-1.67 (m, 2H), 1.44 (t, J = 3, 1H), 1.20 (t, J = 7, 3H), 1.17 (t, J = 7, 3H); ESI-MS 220.2 (M+H).
HPLC A: 0.40 min.

5

BICYCLIC AMINES 2-7

Bicyclic Amine 2 was prepared using reactions similar to those described for Bicyclic Amine 1, substituting iodoethane for iodomethane and using a mixture of potassium carbonate and cesium carbonate as the base in Step E. Bicyclic Amine 3 was prepared using the reactions similar to those described for Bicyclic Amine 1, substituting 1-iodo-2-methylpropane, sodium hydride, and DMF for iodomethane, potassium carbonate, and CH₃CN, respectively, and increasing the temperature to 45 °C in Step E.


Bicyclic Amines 4-7 were prepared using reactions similar to those described for Bicyclic Amine 1, substituting 1-ethyl-3-nitro-1-nitrosoguanidine for 3-nitro-1-nitroso-1-propylguanidine in Step D. In Bicyclic Amines 4 and 5, a mixture of potassium carbonate and cesium carbonate was used as the base in Step E. The isomeric products in Step E were separated by flash column chromatography prior to Step F. Bicyclic Amines 6 and 7 were prepared in a similar manner, with the substitution of iodoethane and cesium carbonate for iodomethane and potassium carbonate, respectively, in Step E.



Bicyclic Amine	R	R'	R''	ESI-MS	HPLC A
2	Et	Et	Et	234.2 (M+H)	0.48 min
3	<i>i</i> -Bu	Et	Et	262.2 (M+H)	0.99 min
4	CH ₃	Et	CH ₃	206.1 (M+H)	0.32 min
5	CH ₃	CH ₃	Et	206.1 (M+H)	0.32 min

6	Et	Et	CH ₃	220.2 (M+H)	0.45 min
7	Et	CH ₃	Et	220.2 (M+H)	0.48 min

PYRROLIDINE 1

5 3-(*R*)-(tert-Butyldimethylsilyloxymethyl)-4-(*S*)-phenyl pyrrolidineStep A: 3-((*E*)-Cinnamoyl)-4-(*S*)-benzyl oxazolidin-2-one

A solution of 222 g (1.5 mol) of *trans*-cinnamic acid and 250 mL (1.77 mol) of TEA in 3 L of THF at -78°C was treated with 200 mL of trimethylacetyl chloride maintaining the internal temperature at less than -65°C . The resulting mixture was warmed to 0°C , then cooled to -78°C .

In a separate flask, a solution of 4-(*S*)-benzyl-oxazolidin-2-one in 2.05 L of THF at -20°C was treated with 660 mL of 2.5 M *n*-butyllithium in hexanes over 45 min. The resulting turbid mixture was cooled to -78°C and then transferred via cannula to the flask containing the mixed anhydride. The resulting mixture was allowed to warm to rt and was stirred for 20 h. The reaction was quenched with 300 mL of sat'd NH_4Cl ; the resulting mixture was partitioned between EtOAc and H_2O and the layers were separated. The organic layer was dried over MgSO_4 . The aqueous layer was extracted with 2 x EtOAc; the extracts were dried and all of the organic extracts were combined. Partial concentration *in vacuo* caused precipitation of a solid; the mixture was diluted with hexanes and allowed to stand at rt for 1.5 h. The precipitate was filtered and dried to afford the title compound: ^1H NMR (500 MHz) δ 2.86 (dd, $J=13.5, 9.5$, 1H), (3.38, $J=13.5, 3.5$, 1H), 4.20-4.27 (m, 2H), 4.78-4.83 (m, 1H), 7.24-7.42 (5H), 7.63-7.65 (m, 1H), 7.92 (app d, $J=2.5$, 1H).

25

Step B: 3-(1-Benzyl-4-(*S*)-phenylpyrrolidine-3-(*R*)-carbonyl)-4-(*S*)-benzyl
oxazolidin-2-one and 3-(1-benzyl-4-(*R*)-phenylpyrrolidine-3-(*S*)-
carbonyl)-4-(*S*)-benzyl oxazolidin-2-one

A solution of 402 g (1.3 mol) of 3-((*E*)-cinnamoyl)-4-(*S*)-benzyl
5 oxazolidin-2-one (from Step A) and 474 g (2.0 mol) of *N*-methoxymethyl-*N*-
trimethylsilylmethyl benzyl amine in 4 L of CH₂Cl₂ at -10 °C was treated with 6 mL
of trifluoroacetic acid. The resulting mixture was stirred cold for 4 h and then was
treated with an additional 4 mL of trifluoroacetic acid. The reaction mixture was
warmed to rt and stirred for 20 h. The reaction was quenched with 2 L of sat'd
10 NaHCO₃ and the layers were separated. The organic layer was washed with 1 L of
sat'd NaCl and concentrated. Chromatography on 10 kg of silica gel using 4:1 v/v
hexanes/EtOAc (24 L), then 7:3 v/v hexanes/EtOAc (36 L), then 3:2 v/v
hexanes/EtOAc (32 L) afforded 3-(1-benzyl-4-(*S*)-phenylpyrrolidine-3-(*R*)-carbonyl)-
4-(*S*)-benzyl oxazolidin-2-one and 3-(1-benzyl-4-(*R*)-phenylpyrrolidine-3-(*S*)-
15 carbonyl)-4-(*S*)-benzyl oxazolidin-2-one. For 3-(1-benzyl-4-(*S*)-phenylpyrrolidine-3-
(*R*)-carbonyl)-4-(*S*)-benzyl oxazolidin-2-one: ¹H NMR (500 MHz) δ 2.66 (t, J= 8.0,
1H), 2.78 (dd, J= 13.0, 9.0, 1H), 2.87 (dd, J= 9.0, 4.5, 1H), 3.21-3.27 (m, 2H), 3.64 (d,
J= 11.5, 1H), 3.77 (d, J= 11.5, 1H), 4.10-4.15 (m, 2H), 4.61-4.65 (m, 1H), 7.16-7.38
(15H). For 3-(1-benzyl-4-(*R*)-phenylpyrrolidine-3-(*S*)-carbonyl)-4-(*S*)-benzyl
20 oxazolidin-2-one: ¹H NMR (500 MHz) δ 2.69-2.76 (m, 2H), 2.82 (dd, J= 9.5, 5.5,
1H), 3.14-3.22 (3H), 3.64 (d, J= 13.0, 1H), 3.74 (d, J= 13.0, 1H), 4.07-4.12 (m, 2H),
4.16 (t, J= 9.0, 1H), 4.26-4.30 (m, 1H), 4.65-4.69 (m, 1H), 7.03-7.40 (15H).

Step C: 1-Benzyl-3-(*R*)-hydroxymethyl-4-(*S*)-phenylpyrrolidine
25 A solution of 3-(1-benzyl-4-(*S*)-phenylpyrrolidine-3-(*R*)-carbonyl)-4-
(*S*)-benzyl oxazolidin-2-one (from Step B) in 2.5 L of THF at 10 °C
was treated with 1.18 L of 1.0 M lithium aluminum hydride solution in THF over a
period of 2 h. The resulting mixture was warmed to rt and stirred for 20 h. The
reaction was quenched by adding 40 mL of H₂O, then 40 mL of 2.0 N NaOH, then
30 115 mL of H₂O and then was stirred at rt for 1.5 h. The mixture was filtered and the
filtrate was concentrated. Chromatography on 4 kg of silica using 4:1
hexanes/acetone (14 L), then 7:3 hexanes/acetone as the eluant to afford the title
compound: ¹H NMR (400 MHz) δ 2.38-2.46 (m, 2H), 2.78-2.88 (3H), 3.20-3.26

(2H), 3.65 (dd, J= 12.0, 4.0, 1H), 3.66 (app s, 2H), 3.74 (dd, J= 12.0, 4.0, 1H), 7.18-7.34 (10H); ESI-MS 268 (M+H); HPLC A: 2.35 min.


Step D: 1-Benzyl-3-(*R*)-(tert-Butyldimethylsilyloxymethyl)-4-(*S*)-phenyl
pyrrolidine

A solution of 82.0 g (0.31 mol) of 1-benzyl-3-(*R*)-hydroxymethyl-4-(*S*)-phenyl pyrrolidine (from Step C) and 46.5 g (0.36 mol) of *N,N*-diisopropylethylamine in 1 L of CH₂Cl₂ was treated with 54.2 g (0.36 mol) of *tert*-butyldimethylsilyl chloride and the resulting mixture was stirred at rt for 20 h. The reaction was quenched with 750 mL of sat'd NaHCO₃ and the layers were separated. The organic layer was combined with 150 g of silica gel and aged for 45 min. The mixture was filtered and the filtrate was concentrated to afford the title compound.

Step E: 3-(*R*)-(tert-Butyldimethylsilyloxymethyl)-4-(*S*)-phenylpyrrolidine

A mixture of 117 g (0.31 mol) of 1-benzyl-3-(*R*)-(tert-butyldimethylsilyloxymethyl)-4-(*S*)-phenyl pyrrolidine (from Step D), 31.5 g (0.50 mol) ammonium formate, 20.0 g of 20% palladium hydroxide on carbon in 1.5 L of MeOH was heated at 55 °C for 2.5 h. The mixture was cooled and filtered through a pad of Celite. The filtrate was concentrated. The residue was dissolved in 1 L of CH₂Cl₂, washed with 300 mL of 10% NH₄OH solution, 200 mL of sat'd NaCl, dried over MgSO₄ and concentrated to afford the title compound: ¹H NMR (400 MHz) δ -0.09 (s, 3H), -0.08 (s, 3H), 0.77 (s, 9H), 2.25-2.30 (m, 1H), 2.84-2.96 (4H), 3.18 (dd, J= 11.2, 3.2, 1H), 3.29-3.36 (m, 1H), 3.44 (dd, J= 10.0, 6.0), 3.56 (dd, J= 10.0, 4.4, 1H); ESI-MS 292 (M+H); HPLC A: 3.44 min.

PYRROLIDINE 2



3-(*R*)-(tert-Butyldimethylsilyloxymethyl)-4-(*S*)-(3-fluoro)phenylpyrrolidine

The title compound was prepared using procedures analogous to those described to prepare Pyrrolidine 1, except that *trans*-(3-fluoro)cinnamic acid was substituted for *trans*-cinnamic acid in Step A. For the title compound: ¹H NMR (400 MHz) δ 0.013 (s, 3H), 0.016 (s, 3H), 0.87 (s, 9H), 2.09 (br s, 1H), 2.30-2.37 (m, 1H), 2.88-2.90 (3H), 2.23 (dd, J= 8.0, 11.2, 1H), 3.39 (dd, J= 6.8, 10.0, 1H), 3.56 (dd, J= 6.0, 10.0, 1H), 3.64 (dd, J= 5.2, 10.0), 6.86-6.91 (m, 1H), 6.95 (dt, J= 12.0, 2.4, 1H), 7.01 (d, J= 7.6, 1H), 7.22-7.27 (m, 1H); ESI-MS 310 (M+H); HPLC A: 3.05 min.

EXAMPLE 1

3-{[(3*S*,4*S*)-3-[(4-{1,3-Diethyl-4-methyl-(1*H*)-pyrazol-5-yl}piperidin-1-yl)methyl]-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}-bicyclo[3.1.0]hexane)-3-*endo*-carboxylic acid

Step A: 1-Benzyl-3-(*R*)-formyl-4-(*S*)-(3-fluorophenyl)pyrrolidine

The title compound was prepared from 1-benzyl-3-(*R*)-hydroxymethyl-4-(*S*)-(3-fluorophenyl)pyrrolidine (from Pyrrolidine 2, Step C) using a procedure analogous to that described in Example 2, Step C.

Step B: 1-Benzyl-3-{[(3*S*,4*S*)-3-[(4-{1,3-diethyl-4-methyl-(1*H*)-pyrazol-5-yl}piperidin-1-yl)methyl]-4-(3-fluorophenyl)pyrrolidine

A solution of 2.83 g (10.0 mmol) of 1-benzyl-3-(*R*)-formyl-4-(*S*)-(3-fluorophenyl)pyrrolidine (from Example 1, Step A), 2.94 g (10.0 mmol) of Piperidine 8, 2.80 mL (20.0 mmol) of triethylamine and 4.24 g (20.0 mmol) of sodium triacetoxyborohydride in 75 mL of acetonitrile was stirred at rt for 2 h. The mixture was concentrated. The residue was partitioned between 300 mL of ether and 100 mL of 1.0 N NaOH and the layers were separated. The organic layer was dried over MgSO₄ and concentrated. Flash chromatography on 150 g of silica gel using 40:1:0.1 v/v/v CH₂Cl₂/MeOH/NH₄OH as the eluant afforded the title compound. ¹H NMR (400 MHz) δ 1.21 (t, J = 7.2, 3H), 1.34 (t, J = 6.8, 3H), 1.47-1.54 (m, 1H), 1.60-1.68 (m, 1H), 1.77-1.85 (3H), 1.96-2.01 (2H), 2.03 (s, 3H), 2.41-2.57 (7H), 2.66-2.74 (2H), 2.93-3.05 (4H), 3.68 (q, J = 13.2, 2H), 4.05 (q, J = 7.2, 2H), 6.85-7.40 (9H); ESI-MS 489 (M+H); LC-1: 1.87 min.

Step C: 3-{[(3*S*,4*S*)-3-[(4-{1,3-Diethyl-4-methyl-(1*H*)-pyrazol-5-yl}piperidin-1-yl)methyl]-4-(3-fluorophenyl)pyrrolidine

A mixture of 4.65 g (9.5 mmol) of 1-benzyl-3-{[(3*S*,4*S*)-3-[(4-{1,3-diethyl-4-methyl-1*H*-pyrazol-5-yl}piperidin-1-yl)methyl]-4-(3-fluorophenyl)pyrrolidine (from Example 1, Step B), 6.30 g (0.1 mol) of ammonium formate and 1.00 g of 20% palladium hydroxide on carbon in 50 mL of MeOH was heated at 65 °C. After 1 h, second portions of ammonium formate and catalyst were added and stirring was continued for 20 min. The mixture was cooled and filtered through a pad of Celite. The filtrate was concentrated. The residue was partitioned between 150 mL of CH₂Cl₂ and 100 mL of 30% aqueous NH₄OH and the layers were separated. The organic layer was dried over MgSO₄. The aqueous layer was extracted with 2 x 150 mL of CH₂Cl₂; the extracts were dried and all of the extracts were combined and concentrated. Flash chromatography on 125 g of silica gel using CH₂Cl₂, then 20:1:0.1 v/v/v CH₂Cl₂/MeOH/NH₄OH as the eluant afforded the title compound.

ESI-MS 399 (M+H); LC-1: 1.41 min.

Step D: 3-{[(3*S*,4*S*)-3-[(4-{1,3-Diethyl-4-methyl-1*H*-pyrazol-5-yl}piperidin-1-yl)methyl]-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}-bicyclo[3.1.0]hexane)-3-endo-carboxylic acid, benzyl ester

A solution of 100 mg (0.25 mmol) of 3-{[(3*S*,4*S*)-3-[(4-{1,3-diethyl-4-methyl-1*H*-pyrazol-5-yl}piperidin-1-yl)methyl]-4-(3-fluorophenyl)pyrrolidine (from Example 1, Step C) and 61 mg (0.24 mmol) of 3-(3-formyl-bicyclo[3.1.0]hexane)-endo-carboxylic acid, benzyl ester (Prepared as Aldehyde 9 above) in 2 mL of CH₂Cl₂ was treated with 80 mg (0.37 mmol) of sodium triacetoxyborohydride. After 45 minutes at rt the reaction was partitioned between 50 mL of CH₂Cl₂ and 50 mL of 1 N NaHCO₃ and the layers were separated. The aqueous layer was extracted with 50 mL of CH₂Cl₂. The combined organic phases were washed with 100 mL of brine, dried over Na₂SO₄ and concentrated. The residue was purified by flash chromatography using 9:1 v/v of hexanes/acetone as the eluant to afford the title compound as a white foam: R_F: 0.33 (4:1 v/v hexanes/acetone); ¹H-NMR (500 MHz) δ -0.02 (m, 1H), 0.37 (m, 1H), 1.21 (t, J = 7.6, 3H), 1.24-1.31 (m, 2H), 1.34 (t, J = 7.2, 3H), 1.52-2.01 (m, 8H), 2.04 (s, 3H), 2.25-2.32 (m, 4H), 2.53-2.92 (m, 13H), 4.06 (q, J = 7.2, 2H), 5.16 (ABq, J = 12.4, 2H), 6.85 (m, 1H), 7.02-7.06 (m, 2H), 7.19 (m, 1H), 7.27-7.39 (m, 5H).

Step E: 3-{[(3*S*,4*S*)-3-[(4-{1,3-Diethyl-4-methyl-1*H*-pyrazol-5-yl}piperidin-1-yl)methyl]-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}-
bicyclo[3.1.0]hexane)-3-*endo*-carboxylic acid

5 A mixture of 139 mg (0.22 mmol) of 3-{[(3*S*,4*S*)-3-[(4-{1,3-diethyl-4-methyl-1*H*-pyrazol-5-yl}piperidin-1-yl)methyl]-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}-bicyclo[3.1.0]hexane)-3-*endo*-carboxylic acid, benzyl ester (from Example 1, Step D) and 36 mg of 10% palladium on carbon in 3 mL of MeOH was hydrogenated at rt under a balloon of hydrogen for 1.25 hours. The reaction was
10 filtered and concentrated. The residue was purified by flash chromatography using a gradient of 98/2 v/v CH₂Cl₂/MeOH and 90:10:1 v/v/v CH₂Cl₂/MeOH/NH₄OH as the gradient to afford the title compound: R_F: 0.42 (90:10:1 v/v/v CH₂Cl₂/MeOH/NH₄OH); ¹H-NMR (500 MHz, CD₃OD) δ 0.37-0.42 (m, 2H), 1.13 (t, J = 7.6, 3H), 1.25 (t, J = 7.2, 3H), 1.29-1.31 (m, 2H), 1.53 (m, 1H), 1.62 (m, 1H),
15 1.76-1.85 (m, 3H), 1.95-2.07 (m, 6H), 2.45-2.84 (m, 9H), 3.01 (m, 1H), 3.16-3.30 (m, 5H), 3.57-3.64 (m, 2H), 4.01 (q, J = 7.2, 2H), 6.97 (m, 1H), 7.17-7.20 (m, 2H), 7.34 (m, 1H); ESI-MS 537.4 (M+H); HPLC LC 2: 1.84 min.

EXAMPLE 2

20 1-{[(3*S*,4*S*)-3-{[4-(2-Ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid

Step A: 1-{[(3*R*,4*S*)-3-(*tert*-Butyldimethylsilyloxymethyl)-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid,
25 benzyl ester

A solution of 8.3 g (26.9 mmol) 3-(*R*)-(tert-butyl)dimethylsilyloxymethyl)-4-(*S*)-(3-fluoro)phenylpyrrolidine (Prepared as Pyrrolidine 2 above) in 100 mL of CH₂Cl₂ and 6.0 g (24.4 mmol) of 1-formyl-cyclohexane carboxylic acid, benzyl ester (Prepared as Aldehyde 4 above) at 0 °C was
30 treated with 7.8 g (36.7 mmol) of sodium triacetoxyborohydride. The resulting mixture was warmed to rt and stirred for 20 h. The reaction was partitioned between 200 mL EtOAc and 100 mL of saturated NaHCO₃ and the layers were separated. The organic layer was dried over MgSO₄. The mixture was filtered and the filtrate was concentrated. Purification by Biotage Flash 40 using a 40 M cartridge and 95:5

hexanes/ethyl acetate (1 L) as the eluant to afford the title compound: ^1H NMR (500 MHz, CDCl_3) δ 0.00-0.01 (6H), 0.86 (s, 9H), 1.24-3.54 (20H), 5.14 (ABq, $J = 12.3$, 2H), 6.83 – 7.38 (9H).

5 Step B: 1-{[(3*R*,4*S*)-3-(Hydroxymethyl)-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid, benzyl ester

 A solution of 8.1 g (15.0 mmol) 1-{[(3*R*,4*S*)-3-(*tert*-butyldimethylsilyloxymethyl)-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid, benzyl ester (from Step A) in 150 mL of THF
10 at 0 ° C was treated with 45 mL of 1.0 M tetrabutylammonium fluoride solution in THF. The resulting mixture was warmed to rt and stirred for 20 h. The reaction mixture was partitioned between 200 mL of ether and 100 mL of 50% sat'd NaHCO_3 and the layers were separated. The organic layer was dried over MgSO_4 and concentrated. Purification by Biotage Flash 40 using a 40 M cartridge and 0.5 L to
15 1.0 L of 9:1 to 2:1 v/v hexane/ethyl acetate as the eluant afforded the title compound: ^1H NMR (500 MHz, CDCl_3) δ 1.23-3.68 (20H), 5.18 (ABq, $J = 12.3$, 2H), 6.88 – 7.01 (3H), 7.21 – 7.40 (6H).

Step C: 1-{[(3*R*,4*S*)-3-Formyl-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid, benzyl ester

20 A solution of 2.1 mL (24.2 mmol) of oxalyl chloride in 110 mL of CH_2Cl_2 at -78 °C was treated with 2.6 mL (36.8 mmol) of DMSO maintaining the temperature at less than -60 ° C. The resulting mixture was stirred cold for 5 min. A solution of 4.5 g (10.5 mmol) of 1-{[(3*R*,4*S*)-3-(hydroxymethyl)-4-(3-
25 fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid, benzyl ester (from Step B) in 10 mL of CH_2Cl_2 was added maintaining the temperature at less than -60 ° C. The resulting mixture was stirred cold for 60 min. The mixture was treated with 15 mL (84.0 mmol) of *N,N*-diisopropylethylamine maintaining the temperature at less than -60 ° C. The reaction was warmed to 0 °C, stirred for 20 min and quenched with
30 20 mL 0.5 N KHSO_4 . The mixture was partitioned between 250 mL of CH_2Cl_2 and 100 mL of H_2O and the layers were separated. The aqueous layer was extracted with 250 mL of CH_2Cl_2 . The combined organic phases were dried over MgSO_4 and concentrated. Purification by Biotage Flash 40 using a 40 M cartridge and 1.0 L each of 95:5 to 90:10 v/v hexane/ethyl acetate as the eluant afforded the title compound:

¹H NMR (500 MHz, CDCl₃) δ 1.24-3.48 (18H), 5.16 (ABq, J = 12.2, 2H), 6.90 – 7.02 (3H), 7.22 – 7.39 (6H), 9.59 (s, 1H).

Step D: 1-{[(3*S*,4*S*)-3-{[4-(2-Ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid, benzyl ester

The title compound was prepared from 1-{[(3*R*,4*S*)-3-formyl-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid, benzyl ester (from Step C) and 4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)-piperidine, hydrochloride salt (Prepared as Piperidine 9 above) using a procedure analogous to that described in Example 1, Step D. ¹H NMR (500 MHz, CDCl₃) δ 1.22 (t, 3H, J=7.6 Hz), 1.23-1.50 (m, 6H), 1.50-1.70 (br m, 5H), 1.70-2.00 (m, 8H), 2.17 (br d, 2H, J=12.3 Hz), 2.20-2.40 (m, 5H), 2.57 (q, 2H, J=7.3), 2.61-2.96 (m, 9H), 4.07 (t, 2H, J=6.0 Hz), 5.16 (m, 2H), 6.85 (dt, 1H, J=1.8, 8.5 Hz), 7.02-7.10 (m, 2H), 7.20 (q, 1H, J=6.5 Hz), 7.25-7.40 (m, 5H).

Step E: 1-{[(3*S*,4*S*)-3-{[4-(2-Ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid

The title compound was prepared from 1-{[(3*S*,4*S*)-3-{[4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid, benzyl ester (from Step D) using a procedure analogous to that described in Example 1, Step E. ¹H NMR (500 MHz, CD₃OD) δ 1.14 (t, 3H, J=7.5 Hz), 1.30-1.90 (m, 15H), 1.90-2.10 (m, 6H), 2.35-2.45 (m, 1H), 2.45-2.60 (4H), 2.65-2.80 (m, 3H), 2.85 (d, 1H, J=11.9 Hz), 3.01 (d, 1H, J=11.1 Hz), 3.10-3.25 (m, 4H), 3.59-3.64 (m, 2H), 3.97 (t, 2H, 6.1 Hz), 6.98-7.02 (m, 1H), 7.16-7.20 (m, 2H), 7.34-7.38 (m, 1H). ESI-MS 551 (M + H); HPLC A 1.68 min.

EXAMPLE 3

1-{[(3*S*,4*S*)-3-{[(1,3-Diethyl-5-methyl-(1*H*)-pyrazol-4-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid

Step A: 1-{[(3*S*,4*S*)-3-{[(1,3-Diethyl-5-methyl-(1*H*)-pyrazol-4-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid, benzyl ester


The title compound was prepared from 1-{[(3*R*,4*S*)-3-formyl-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid, benzyl ester (from Example 2, Step C) and 4-(1,3-Diethyl-5-methyl-(1*H*)-pyrazol-4-yl)piperidine, hydrochloride salt (Prepared as Piperidine 10 above) using a procedure analogous to that described in Example 1, Step D. ¹H NMR (500 MHz, CDCl₃) δ 1.21 (t, 3H, J=7.6 Hz), 1.26-1.35 (m, 3H), 1.36 (t, 3H, J=7.3 Hz), 1.38-1.48 (m, 3H), 1.55-1.90 (m, 7H), 1.93 (dt, 1H, J=1.6, 11.1 Hz), 2.17 (br d, 2H, J=13.7 Hz), 2.22 (s, 3H), 2.28-2.39 (m, 5H), 2.59 (q, 2H, J=7.5 Hz), 2.63-2.70 (m, 4H), 2.83-2.93 (m, 3H), 2.95 (t, 1H, J=7.1 Hz), 4.02 (q, 2H, J=7.3 Hz), 5.17 (m, 2H), 6.85 (dt, 1H, J=2.3, 8.5 Hz), 7.05-7.09 (m, 2H), 7.20 (q, 1H, J=6.2 Hz), 7.28-7.39 (m, 5H).

Step B: 1-{[(3*S*,4*S*)-3-{[(1,3-Diethyl-5-methyl-(1*H*)-pyrazol-4-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid

The title compound was prepared from 1-{[(3*S*,4*S*)-3-{[(1,3-diethyl-5-methyl-(1*H*)-pyrazol-4-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid, benzyl ester (from Step A) using a procedure analogous to that described in Example 1, Step G. ¹H NMR (500 MHz, CD₃OD) δ 1.14 (t, 3H, J=7.5 Hz), 1.28 (t, 3H, J=7.1 Hz), 1.28-2.15 (m, 17H), 2.21 (s, 3H), 2.30-2.61 (m, 5H), 2.68-2.80 (m, 1H), 2.86 (d, 1H, J=10.7 Hz), 3.02 (d, 1H, J=10.3 Hz), 3.10-3.30 (m, 4H), 3.64 (m, 2H), 4.00 (q, 2H, J=7.1 Hz), 7.00 (m, 1H), 7.17-7.21 (m, 2H), 7.36 (m, 1H). ESI-MS 539 (M +H); HPLC A 1.65 min.

EXAMPLES 4-5


Examples 4-5 were prepared using procedures analogous to those described in Examples 1 and 2 using Aldehyde 1 or 2 and the appropriate piperidine.





EXAMPLE #	R	HPLC Method	HPLC RT (min)	ESI-MS (M+H)
4		LC-1	1.36	511.5
	¹ H NMR (500 MHz, CDCl ₃) δ 1.19 –3.35 (36H), 4.04-4.07 (2H), 6.90 –7.34 (4H)			
5				
	¹ H NMR (500 MHz, CD ₃ OD) δ 1.14 (t, J= 7.6, 3H), 1.23-1.29 (m, 9H), 1.48-1.58 (m, 2H), 1.69-1.88 (m, 2H), 1.96-2.08 (m, 2H), 2.21 (s, 3H), 2.36-2.59 (m, 5H), 2.78-2.89 (m, 2H), 3.00-3.02 (m, 1H), 3.16-3.39 (m, 5H), 3.69-3.73 (m, 2H), 3.99 (q, J= 7.2, 2H), 7.00-7.03 (m, 1H), 7.18-7.22 (m, 2H), 7.35-7.40 (m, 1H)			

EXAMPLES 6-9

- 5 Examples 6-9 were prepared using procedures analogous to those described in Examples 1 and 2 using Aldehyde 3 and the appropriate piperidine.




EXAMPLE #	R	HPLC Method	HPLC RT (min)	ESI-MS (M+H)
6		LC-1	1.5	527.5
	¹ H NMR (500 MHz, CD ₃ OD) δ 0.88-0.93 (m, 6H), 1.13 (t, J= 7.7, 3H), 1.22-1.29 (m, 4H), 1.54-1.56 (m, 1H), 1.61-1.75 (m, 4H), 1.79-1.86 (m, 1H), 1.93-2.07 (m, 6H), 2.43-2.56 (m, 4H), 2.63-2.68 (m, 1H), 2.75-2.85 (m, 2H), 3.01-3.02 (m, 1H), 3.19-3.37 (m, 5H), 3.64-3.69 (m, 2H), 4.02 (q, J= 7.2, 2H), 6.99-7.03 (m, 1H), 7.17-7.22 (m, 2H), 7.35-7.39 (m, 1H)			
7		LC-1	1.5	539.5

	¹ H NMR (500 MHz, CD ₃ OD) δ 0.88-0.93 (m, 6H), 1.14 (t, J= 7.6, 3H), 1.49-1.51 (m, 1H), 1.57-1.74 (m, 6H), 1.79-1.85 (m, 3H), 1.95-2.08 (m, 4H), 2.36-2.41 (m, 1H), 2.44-2.58 (m, 4H), 2.71-2.78 (m, 3H), 2.82-2.85 (m, 1H), 2.99-3.01 (m, 1H), 3.19-3.34 (m, 5H), 3.62-3.66 (m, 2H), 3.97 (t, J= 6.2, 2H), 6.98-7.02 (m, 1H), 7.17-7.21 (m, 2H), 7.34-7.39 (m, 1H)			
8		LC-1	1.5	527.5
	¹ H NMR (500 MHz, CD ₃ OD) δ 0.88-0.93 (m, 6H), 1.14 (t, J= 7.6, 3H), 1.28 (t, J= 7.2, 3H), 1.49-1.52 (m, 1H), 1.57-1.75 (m, 6H), 1.83-1.87 (m, 1H), 1.97-2.10 (m, 2H), 2.21 (s, 3H), 2.37-2.59 (m, 5H), 2.74-2.78 (m, 1H), 2.84-2.86 (m, 1H), 3.01-3.03 (m, 1H), 3.19-3.34 (m, 5H), 3.63-3.66 (m, 2H), 4.00 (q, J= 7.2, 2H), 6.99-7.03 (m, 1H), 7.17-7.21 (m, 2H), 7.35-7.39 (m, 1H)			
9		LC-1	1.63	527.6





EXAMPLES 10-14

Examples 10-14 were prepared using procedures analogous to those described in Examples 1 and 2 using Aldehyde 5 and the appropriate piperidine. Racemic analogs were prepared using procedures analogous to those described in Example 1 substituting the appropriate Piperidine and Aldehyde. The intermediates required in Step B were prepared from the appropriate commercially available substituted benzaldehydes in a three step sequence: 1. Wittig reaction with *N*-methoxy-*N*-methyl-2-(triphenylphosphoranylidene) acetamide in toluene; 2. Azomethine ylide

cyclization using a procedure analogous to that described in Pyrroldine 1, Step B; 3.
DIBAL-H reduction (CH_2Cl_2 , -78°C).




Example #	R	X	HPLC Method	HPLC RT (min)	ESI-MS (M+H)
10			LC-1	1.41	511.5
11			LC-1	1.41	511.5
12			LC-1	1.28	523.5
	^1H NMR (500 MHz, CDCl_3) δ 0.87 – 3.31 (36H), 4.04-4.07 (2H), 6.91 – 7.30 (4H)				





13 (+/-)			LC-1	1.41	541.5
14 (+/-)			LC-1	1.47	541.5
¹ H NMR (500 MHz, CDCl ₃) δ 0.86 –3.28 (36H), 4.05-4.07 (2H), 6.98 –7.15 (3H)					






EXAMPLES 15-23

Examples 15-23 were prepared using procedures analogous to those described
 5 in Examples 1 and 2 using Aldehyde 6 and the appropriate piperidine.



EXAMPLE #	R	HPLC Method	HPLC RT (min)	ESI-MS (M+H)
-----------	---	----------------	------------------	-----------------


15		LC-1	1.81	537.4
	¹ H NMR (500 MHz, CDCl ₃) δ 1.26 –3.37 (38H), 4.01 (q, J = 7.4 Hz, 2H), 6.92 –7.31 (4H)			
16		LC-1	1.97	525.3
	¹ H NMR (500 MHz, CDCl ₃) δ 0.87 –3.37 (40H), 4.02 (q, J = 7.4, 2H), 6.91 –7.33 (4H)			
17		LC-1	1.76	525.2
18		LC-1	2.00	551.5

19		LC-1	1.65	539.5
¹ H NMR (500 MHz, CDCl ₃) δ 1.06 –3.38 (40H), 4.03 (q, J = 7.1, 14.4 Hz, 2H), 6.91 -7.31 (4H)				
20		LC-2	2.35	522.71
21		LC-2	2.64	591.3
22		LC-1	1.7	551.5
23		LC-1	1.60	511.3






EXAMPLES 24-47






Examples 24-47 were prepared using procedures analogous to those described in Examples 1 and 2 using Aldehyde 4 and the appropriate piperidine.





5











EXAMPLE #	R	HPLC Method	HPLC RT (min)	ESI-MS (M+H)
24		LC-1	1.81	551.4
	¹ H NMR (500 MHz, CDCl ₃) δ 0.87 –3.37 (40H), 4.01 (q, J = 7.4 Hz, 2H), 6.91 -7.31 (4H)			
25		LC-1	2.32	569.3

26		LC-1	2.16	539.4
¹ H NMR (500 MHz, CDCl ₃) δ 0.87 –3.37 (40H), 4.02 (q, J = 7.4 Hz, 2H), 6.90 -7.30 (4H)				
27		LC-1	1.76	601.3
28		LC-1	1.84	567.5
29		LC-1	2.32	567.5
30		LC-1	1.79	539.4

31		LC-1	2.11	565.5
32		LC-1	1.73	553.6
33		LC-1	1.73	553.6
34		LC-2	2.28	605.4
35		LC-2	2.65	537.5

36		LC-1	1.8	565.5
37		LC-1	1.7	541.4
38		LC-2	2.0	541.5
39		LC-1	1.8	541.5
¹ H NMR (500 MHz, CD ₃ OD) δ 1.25 (t, J= 7.2, 3H), 1.33-1.66 (m, 10H), 1.89-2.06 (m, 5H), 2.12 (s, 3H), 2.12-2.17 (m, 1H), 2.30-2.35 (m, 1H), 2.46-2.50 (m, 1H), 2.60-2.64 (m, 1H), 2.70-2.74 (m, 1H), 2.87-2.90 (m, 1H), 3.03-3.05 (m, 1H), 3.11-3.31 (m, 5H), 3.56-3.60 (m, 2H), 3.80 (s, 3H), 3.91 (q, J= 7.2, 2H), 7.0-7.02 (m, 1H), 7.15-7.19 (m, 2H), 7.34-7.38 (m, 1H)				


40		LC-1	1.81	553.5
41		LC-1	1.73	525.3
42		LC-1	2.05	551.5
43		LC-1	1.65	537.4
44		LC-1	1.55	541.5

45		LC-1	1.49	541.5
46		LC-1	1.71	555.5
47		LC-1	1.79	553.7
	¹ H NMR (500 MHz, CD ₃ OD) δ 1.33-1.65 (m, 10H), 1.76-2.14 (m, 10H), 2.31 (m, 1H), 2.46 (m, 1H), 2.58-2.63 (m, 3H), 2.71 (m, 1H), 2.86 (m, 1H), 3.02 (m, 1H), 3.11-3.31 (m, 5H), 3.55-3.60 (m, 2H), 3.78 (s, 3H), 3.84-3.86 (m, 2H), 6.99 (m, 1H), 7.14-7.19 (m, 2H), 7.35 (m, 1H)			

EXAMPLES 48-51


Examples 48-51 were prepared using procedures analogous to those described in Examples 1 and 2 using Aldehyde 4, Piperidine 8 and the appropriate pyrrolidine. Racemic analogs were prepared using procedures analogous to those described in Example 1 substituting the appropriate Piperidine and Aldehyde. The intermediates required in Step B were prepared from the appropriate commercially available substituted benzaldehydes in a three step sequence: 1. Wittig reaction with

N-methoxy-*N*-methyl-2-(triphenylphosphoranylidene) acetamide in toluene; 2. Azomethine ylide cyclization using a procedure analogous to that described in Pyrroldine 1, Step B; 3. DIBAL-H reduction (CH_2Cl_2 , -78°C).



EXAMPLE #	X	HPLC Method	HPLC RT (min)	ESI-MS (M+H)
48 (+/-)		LC-1	1.92	589.5
49 (+/-)		LC-1	1.55	557.6
50 (+/-)		LC-1	1.55	557.6
51 (+/-)		LC-1	1.76	535.6

Example 52 was prepared using procedures analogous to those described in Examples 1 and 2 using Aldehyde 7, Pyrrolidine 2 and Piperidine 8.



EXAMPLE #	HPLC Method	HPLC RT (min)	ESI-MS (M+H)
52	LC-1	1.28	541.5
	¹ H NMR (500 MHz, CDCl ₃) δ 1.17 –3.83 (36H), 4.02 (q, J = 7.1 Hz, 2H), 6.91 -7.30 (4H)		


5

EXAMPLES 53-54

Examples 53-54 were prepared using procedures analogous to those described in Example 1 using Aldehyde 9 and the appropriate piperidine.

Diastereomerically pure Example 53 was prepared using analogous procedures to those described for Pyrrolidines 1 and 2.


10



EXAMPLE #	R	X	HPLC Method	HPLC RT (min)	ESI-MS (M+H)
53		F	LC-1	1.60	567.6
	¹ H NMR (500 MHz, CDCl ₃) δ 0.36–3.27 (38H), 4.04–4.07 (2H), 6.62–6.89 (3H)				
54		H	LC-1	1.6	537.5
	¹ H NMR (500 MHz, CD ₃ OD) δ 0.36–0.43 (m, 2H), 1.14 (t, J= 7.6, 3H), 1.26–1.30 (m, 5H), 1.49–1.60 (m, 2H), 1.72–1.91 (m, 4H), 2.04–2.14 (m, 2H), 2.21 (s, 3H), 2.38–2.63 (m, 7H), 2.67–2.71 (m, 1H), 2.87–2.89 (m, 1H), 3.03–3.22 (m, 6H), 3.50–3.57 (m, 2H), 3.98 (q, J= 7.2, 2H), 6.96–7.00 (m, 1H), 7.16–7.20 (m, 2H), 7.32–7.36 (m, 1H)				

EXAMPLE 55

Example 55 was prepared using procedures analogous to those described in Example 1 using Aldehyde 8 and Piperidine 8.




EXAMPLE #	HPLC Method	HPLC RT (min)	ESI-MS (M+H)
55	LC-2	1.79	537.4
	¹ H-NMR (500 MHz, CD ₃ OD) δ 0.12 (m, 1H), 0.80 (m, 1H), 1.12 (t, J = 7.5, 3H), 1.25 (t, J = 7.3, 3H), 1.42-1.63 (m, 6H), 1.80 (m, 1H), 1.94-2.05 (m, 6H), 2.42-2.83 (m, 9H), 3.00 (m, 1H), 3.15-3.34 (m, 5H), 3.60-3.66 (m, 2H), 4.01 (q, J = 7.3, 2H), 6.99 (m, 1H), 7.17-7.20 (m, 2H), 7.35 (m, 1H)		

5









EXAMPLES 56-63

Examples 56-63 were prepared using procedures analogous to those described in Examples 2 and 3 using Aldehydes 4 or 6, Pyrrolidine 2 and the appropriate piperidine.

10







EXAMPLE #	Ra	Rb	MS m/Z (M+1) (HPLC A)
56			537 (1.57 min)
57			553 (1.73 min)
58			497 (1.2 min)
59			525 (1.60 min)

60			511 (1.3 min)
61			511 (1.49 min)
62			525 (1.5 min)
63			525 (1.4 min)

EXAMPLES 64-65


5 Examples 64-65 were prepared using procedures analogous to those described in Examples 2 and 3 using Aldehyde 6, Pyrrolidine 2 and the appropriate piperidine.



EXAMPLE #	Ra	Rb	MS m/Z (M+1) (HPLC A)
-----------	----	----	--------------------------











64			537 (1.60 min)
65			533 (2.00 min)

EXAMPLES 66-71

Examples 66-71 were prepared using procedures analogous to those described in Examples 1 and 2 using Aldehyde 4, Pyrrolidine 2 and the appropriate piperidine, which were prepared using procedures analogous to that described for Piperidine 9.




EXAMPLE #	R ₁	R ₂	ESI-MS M/z (M+H)
66			631.4

67			587.5
68	 (mixture of regioisomers)		617.3
69			615.5
70			693.4
71			721.5

EXAMPLE 72

1-(((3*S*,4*S*)-3-((4-(3-Methoxy-1-methyl-5-(trifluoromethyl)-(1*H*)-pyrazol-4-yl)piperidin-1-yl)methyl)-4-(3-fluorophenyl)pyrrolidin-1-yl)methyl)cyclohexanecarboxylic acid




The title compound was prepared using procedures analogous to those described in Example 2 using Piperidine 35 in Step D. ¹H NMR (500 MHz, CD₃OD) δ 7.37 (q, J = 8, 1H), 7.22-7.12 (m, 2H), 7.00 (td, J = 8, 2, 1H), 3.86 (s, 3H), 3.76 (s, 3H), 3.68-3.57 (m, 3H), 3.36-3.15 (m, 5H), 3.00 (d, J = 11, 1H), 2.83 (d, J = 11, 1H), 2.78-2.68 (m, 1H), 2.64-2.56 (m, 1H), 2.55 (dd, J = 13, 10, 1H), 2.43 (dd, J = 13, 5, 1H), 2.10-1.88 (m, 6H), 1.71-1.31 (m, 9H); ESI-MS 581.5 (M+H); HPLC A: 2.0 min.

10

EXAMPLE 73

1-(((3*S*,4*S*)-3-((4-(5-Methoxy-1-methyl-3-(trifluoromethyl)-(1*H*)-pyrazol-4-yl)piperidin-1-yl)methyl)-4-(3-fluorophenyl)pyrrolidin-1-yl)methyl)cyclohexanecarboxylic acid

15



The title compound was prepared using procedures analogous to those described in Example 2 using Piperidine 36 in Step D. ¹H NMR (500 MHz, CD₃OD) δ 7.37 (q, J = 8, 1H), 7.22-7.12 (m, 2H), 7.01 (td, J = 8, 2, 1H), 3.90 (s, 3H), 3.72 (s, 3H), 3.69-3.56 (m, 3H), 3.38-3.16 (m, 5H), 3.01 (d, J = 11, 1H), 2.84 (d, J = 11, 1H),


20

2.79-2.70 m, 1H), 2.57-2.48 (m, 2H), 2.44 (dd, J = 13, 5, 1H), 2.12-1.82 (m, 5H), 1.78 (qd, J = 12, 3, 1H), 1.72-1.31 (m, 9H); ESI-MS 581.5 (M+H); HPLC A: 1.9 min.

5

EXAMPLE 74

1-(((3*S*,4*S*)-3-(((1*α*,5*α*,6*α*)-6-(3,5-Diethyl-1-methyl-(1*H*)-pyrazol-4-yl)-3-azabicyclo[3.1.0]hexan-3-yl)methyl)-4-(3-fluorophenyl)pyrrolidin-1-yl)methyl)cyclohexanecarboxylic acid




10

The title compound was prepared using procedures analogous to those described in Example 2 using Bicyclic Amine 1 in Step D. ¹H NMR (500 MHz, CD₃OD) δ 7.34 (td, J = 8, 7, 1H), 7.18-7.11 (m, 2H), 6.96 (td, J = 8, 3, 1H), 3.67 (dd, J = 11, 8, 1H), 3.65 (s, 3H), 3.62 (dd, J = 11, 8, 1H), 3.36-3.30 (m, 1H), 3.28-3.14 (m, 5H), 2.90 (d, J = 9, 1H), 2.72-2.54 (m, 3H), 2.62 (q, J = 7, 2H), 2.52 (q, J = 7, 2H), 2.37 (dd, J = 9, 4, 1H), 2.33 (dd, J = 9, 4, 1H), 2.06-1.98 (m, 2H), 1.72-1.27 (m, 11H), 1.16 (t, J = 7, 3H), 1.13 (t, J = 7, 3H); ESI-MS 537.5 (M+H); HPLC A: 1.7 min.

20

EXAMPLES 75-80

Examples 75-80 were prepared using procedures analogous to those described in Example 2 using Bicyclic Amines 2-7 in Step D. .



EXAMPLE #	R	R'	R''	ESI-MS	HPLC A
75	Et	Et	Et	551.6 (M+H)	1.8 min
76	<i>i</i> -Bu	Et	Et	579.6 (M+H)	1.9 min
77	CH ₃	Et	CH ₃	523.5 (M+H)	1.7 min
78	CH ₃	CH ₃	Et	523.5 (M+H)	1.9 min
79	Et	Et	CH ₃	537.6 (M+H)	1.7 min
80	Et	CH ₃	Et	537.5 (M+H)	1.7 min

EXAMPLE 81

2-{ [(3*R*,4*S*)-3-[(4-(1,3-Diethyl-5-methylpyrazol-4-yl)piperidin-1-yl)ethyl]]-4-(3-fluorophenyl)pyrrolidin-1-yl)methyl}-2-methylpropionic acid

Step A: 1-*tert*-Butoxycarbonyl-3-(*R*)-(tert-butyltrimethylsilyloxymethyl)-4-(*S*)-(3-fluorophenyl)pyrrolidine

A solution of 7.0 g (22.7 mmol) 3-(*R*)-(tert-butyltrimethylsilyloxymethyl)-4-(*S*)-(3-fluoro)phenylpyrrolidine (Prepared as Pyrrolidine 2 above) in 75 mL of CH₂Cl₂ at 0 °C was treated with 7.5 mL (43.1 mmol) of *N,N*-diisopropylethylamine and 8.9 g (40.8 mmol) of di-*tert*-butyl dicarbonate. The resulting mixture was warmed to rt and stirred for 20 h. The reaction was partitioned between 200 mL Et₂O and 100 mL of H₂O and the layers were separated. The organic layer was dried over MgSO₄. The mixture was filtered and the filtrate was concentrated. Chromatography on 175 g of silica using 9:1 hexanes/diethyl ether (3 L) as the eluant to afford the title compound: ¹H NMR (500 MHz, CDCl₃) δ 0.86-0.87 (6H), 1.53 (s, 9H), 2.40 (1H), 3.16-3.86 (7H), 6.91–7.32 (4H).

Step B: 1-*tert*-Butoxycarbonyl-3-(*R*)-(hydroxymethyl)-4-(*S*)-(3-fluorophenyl)

pyrrolidine

A solution of 9.3 g (22.7 mmol) 1-*tert*-butoxycarbonyl-3-(*R*)-(tert-butyltrimethylsilyloxymethyl)-4-(*S*)-(3-fluoro)phenylpyrrolidine (from Step A) in 50 mL of THF at 0 ° C was treated with 29 mL of 1.0 M tetrabutylammonium fluoride solution in THF. The resulting mixture was warmed to rt and stirred for 20 h. The reaction mixture was partitioned between 200 mL of ether and 100 mL of 50% sat'd NaHCO₃ and the layers were separated. The organic layer was dried over MgSO₄ and concentrated. Purification by Biotage Flash 75 using a 75 L cartridge and 6.0 L of 9:1 v/v heptane/ethyl acetate as the eluant afforded the title compound: ¹H NMR (500 MHz, CDCl₃) δ 1.47 (9H), 2.48 (1H), 3.10-3.89 (7H), 6.92 –7.33 (4H).

Step C: 1-*tert*-Butoxycarbonyl-3-(*R*)-(formyl)-4-(*S*)-(3-fluorophenyl)pyrrolidine

A solution of 4.3 mL (49.8 mmol) of oxalyl chloride in 90 mL of CH₂Cl₂ at -78 °C was treated with 5.4 mL (75.7 mmol) of DMSO maintaining the temperature at less than -60 ° C. The resulting mixture was stirred cold for 5 min. A solution of 6.4 g (21.6 mmol) of 1-*tert*-butoxycarbonyl-3-(*R*)-(hydroxymethyl)-4-(*S*)-(3-fluoro)phenylpyrrolidine (from Step B) in 10 mL of CH₂Cl₂ was added maintaining the temperature at less than -60 ° C. The resulting mixture was stirred cold for 60 min. The mixture was treated with 30 mL (173.1 mmol) of N,N-diisopropylethylamine maintaining the temperature at less than -60 ° C. The reaction was warmed to 0 °C, stirred for 20 min and quenched with 20 mL 0.5 N KHSO₄. The mixture was partitioned between 250 mL of CH₂Cl₂ and 100 mL of H₂O and the layers were separated. The aqueous layer was extracted with 250 mL of CH₂Cl₂. The combined organic phases were dried over MgSO₄ and concentrated. Purification by Biotage Flash 75 using 75 L cartridge and 6.0 L of 9:1 v/v heptane/ethyl acetate as the eluant afforded the title compound: ¹H NMR (500 MHz, CDCl₃) δ 1.48 (s, 9H), 2.48 (1H), 3.17-3.89 (6H), 6.96 –7.35 (4H), 9.67 (s, 1H).

Step D: 1-*tert*-Butoxycarbonyl-3-(*R*)-(1-(*R/S*)-cyano-1-(*R/S*)-(4-(1,3-diethyl-5-methylpyrazol-4-yl)piperidin-1-yl)methyl)-4-(*S*)-(3-fluorophenyl)pyrrolidine

A mixture of 880 mg (3.0 mmol) of 1-*tert*-butoxycarbonyl-3-(*R*)-(formyl)-4-(*S*)-(3-fluorophenyl)pyrrolidine (from Step C), 669 mg (3.0 mmol) of

Piperidine 10, 0.60 mL (4.5 mmol) of trimethylsilylcyanide and 480 mg (4.5 mmol) of lithium perchlorate in 15 mL of THF was heated at reflux for 2.5 h. The mixture was cooled to rt and partitioned between 100 mL of ether and 50 mL of 1.0 N NaOH. The organic layer was separated, dried over MgSO₄ and concentrated.

- 5 Chromatography on a Biotage 40M using 4:1 v/v hexanes/EtOAc as the eluant afforded the title compound.

Step E: 1-*tert*-Butoxycarbonyl-3-(*R*)-(1-(*R*)-(4-(1,3-diethyl-5-methylpyrazol-4-yl)piperidin-1-yl)ethyl)-4-(*S*)-(3-fluorophenyl)pyrrolidine

- 10 A solution of 910 mg (1.7 mmol) of 1-*tert*-butoxycarbonyl-3-(*R*)-(1-(*R*)-(4-(1,3-diethyl-5-methylpyrazol-4-yl)piperidin-1-yl)methyl)-4-(*S*)-(3-fluorophenyl)pyrrolidine (from Step D) at 0 °C was treated with 8.0 mL of 1.4 M methylmagnesium bromide solution in THF/toluene. The resulting mixture was warmed to rt and stirred for 20 h. The reaction was quenched with 50 mL of sat'd
- 15 NH₄Cl/50 g ice and the quenched mixture was extracted with 2 x 100 mL of ether. The extracts were dried over MgSO₄, combined and concentrated. Chromatography on a Biotage 40 M using 2:1 v/v hexanes/EtOAc afforded the title compound contaminated with ~5% of its α-(*S*) diastereomer. Preparative HPLC (Chiralcel OD 2 x 25 cm column, 92:8 v/v hexanes/iPrOH, 9.0 mL/min, 210 nM) afforded the pure
- 20 title compound (Retention time = 13.8 min).

Step F: 3-(*R*)-(1-(*R*)-(4-(1,3-Diethyl-5-methylpyrazol-4-yl)piperidin-1-yl)ethyl)-4-(*S*)-(3-fluorophenyl)pyrrolidine

- 25 The title compound was prepared from 1-*tert*-butoxycarbonyl-3-(*R*)-(1-(*R*)-(4-(1,3-diethyl-5-methylpyrazol-4-yl)piperidin-1-yl)ethyl)-4-(*S*)-(3-fluorophenyl)pyrrolidine (from Step E) using a procedure analogous to that described for Piperidine 8, Step F. ¹H NMR (500MHz) δ 0.94 (d, J = 6.4, 3H), 1.08 (m, 1H), 1.19 (t, J = 7.5, 3H), 1.35 (t, J = 7.2, 3H), 1.56 (m, 1H), 1.79 (m, 1H), 1.92 (m, 1H), 2.10-2.25 (m, 5H), 2.33 (m, 1H), 2.45-2.88 (m, 8H), 3.19-3.39 (m, 3H), 4.01 (q, J =
- 30 7.2, 2H), 6.83 (m, 1H), 7.04 (m, 1H), 7.10 (m, 1H), 7.22 (m, 1H).

Step G: 2-{[(3*R*,4*S*)-3-[(4-(1,3-Diethyl-5-methylpyrazol-4-yl)piperidin-1-yl)ethyl]]-4-(3-fluorophenyl)pyrrolidin-1-yl)methyl}-2-methylpropionic acid, benzyl ester

The title compound was prepared from 3-(*R*)-(1-(*R*)-(4-(1,3-diethyl-5-methylpyrazol-4-yl)piperidin-1-yl)ethyl)-4-(*S*)-(3-fluorophenyl)pyrrolidine (from Step F) and Aldehyde 2 using a procedure analogous to that described in Example 1, Step D. ¹H NMR (500MHz) δ 0.81 (d, J = 6.4, 3H), 1.20-1.39 (m, 16H), 1.60 (m, 1H), 1.87 (m, 1H), 2.15-2.26 (m, 6H), 2.44-2.76 (m, 9H), 2.95 (m, 1H), 3.17 (m, 1H), 4.02 (q, J = 7.2, 2H), 5.13 (ABq, J = 12.4, 2H), 6.81 (m, 1H), 7.12-7.18 (m, 3H), 7.27-7.40 (m, 6H).





Step H: 2-{[(3*R*,4*S*)-3-[(4-(1,3-Diethyl-5-methylpyrazol-4-yl)piperidin-1-yl)ethyl]]-4-(3-fluorophenyl)pyrrolidin-1-yl)methyl}-2-methylpropionic acid

The title compound was prepared from 2-{[(3*R*,4*S*)-3-[(4-(1,3-diethyl-5-methylpyrazol-4-yl)piperidin-1-yl)ethyl]]-4-(3-fluorophenyl)pyrrolidin-1-yl)methyl}-2-methylpropionic acid, benzyl ester (from Step G) using a procedure analogous that described in Example 1, Step E. ¹H NMR (500MHz, CD₃OD) δ 0.96-1.03 (m, 4H), 1.11-1.17 (m, 4H), 1.22-1.28 (m, 9H), 1.51-1.53 (m, 1H), 1.72-1.80 (m, 1H), 2.01-2.06 (m, 1H), 2.16 (s, 3H), 2.21-2.27 (m, 1H), 2.31-2.33 (m, 1H), 2.45-2.54 (m, 3H), 2.68-2.79 (m, 3H), 3.13-3.26 (m, 4H), 3.47-3.52 (m, 1H), 3.58-3.69 (m, 2H), 3.98 (q, J= 7.2, 2H), 6.95-6.99 (m, 1H), 7.19-7.26 (m, 2H), 7.33-7.38 (m, 1H). ESI-MS 513.5 (M+H); HPLC LC 1: 1.6 min.

EXAMPLES 82-86

The compounds in Examples 82-86 were prepared using procedures analogous to those described in Example 81 substituting the appropriate Piperidine in Step D and Aldehyde in Step G. In cases where the diastereomers obtained in Step E were not separable using flash chromatography on silica gel, they were separated by preparative HPLC (Chiralcel[®] OD 2 x 25 cm column, 90:10 v/v hexanes/*i*PrOH eluant).


EXAMPLE #	Piperidine	Aldehyde	HPLC Method	HPLC RT (min)	ESI-MS (M+H)
82	8	6	LC-1	1.55	539.5

					
¹ H NMR (500 MHz, CDCl ₃): δ 0.94 (d, J = 6.4 Hz, 3H), 0.87 –3.45 (40H), 3.99 (q, J = 7.1 Hz, 2H), 6.86 -7.28 (4H)					
83	8	4	LC-1	1.63	553.6
					
¹ H NMR (500 MHz, CDCl ₃): δ 0.94 (d, J = 6.4 Hz, 3H), 0.87 –3.43 (42H), 3.99 (q, J = 7.1 Hz, 2H), 6.85 -7.28 (4H)					
84	8	3	LC-1	1.6	541.6
					
¹ H NMR (500MHz, CD ₃ OD) δ 0.88-0.91 (m, 6H), 1.01 (d, 3H), 1.09-1.15 (m, 4H), 1.20-1.26 (m, 4H), 1.58-1.72 (m, 5H), 1.89-1.95 (m, 4H), 2.01-2.04 (m, 1H), 2.30-2.33 (m, 1H), 2.47-2.58 (m, 4H), 2.67-2.81 (m, 3H), 3.13-3.31 (m, 4H), 3.47-3.63 (m, 3H), 3.97 (q, J= 7.2, 2H), 6.94-6.98 (m, 1H), 7.19-7.26 (m, 2H), 7.33-7.37 (m, 1H)					
85	10	5	LC-1	1.39	525.5
					













88			565.4
89			551.4
90			551.4
91			563.2
92			678.5

EXAMPLES 93-103

Examples 93 - 103 were prepared according to the general procedure given in Example 1 and 2, employing the appropriate aldehydes and piperidines containing substituted pyrazoles.




EXAMPLE #	Ra	Rb	Rc	MS m/Z (M+1)

				(HPLC A)
93		H		537
94		H		537
95		H		523
96		H		535
97		H		549
98		H		549






99		H		563
100		H		537
101		H		523
102		H		497
103		OH		553



EXAMPLES 104 - 114

The compounds in 104 - 114 were prepared using procedures analogous to those described in Example 81 substituting the appropriate Piperidine in Step D and Aldehyde in Step G.




EXAMPLE	R1	R2	R3
104	-H	3,5-di-F	
HPLC Method: LC-1 HPLC RT: 1.60 min ESI-MS (M+H): 567.5			
105	-H	3,4di-F	
HPLC Method: LC-1 HPLC RT: 1.65 min ESI-MS (M+H): 567.5			
106	-CH ₃	3-F	
HPLC Method: LC-1 HPLC RT: 1.70 min ESI-MS (M+H): 563.5			
107	-CH ₃	3-F	
HPLC Method: LC-1 HPLC RT: 1.60 min ESI-MS (M+H): 537.5			


108	-CH ₃	3,5-di-F	
HPLC Method: LC-1 HPLC RT: 1.80 min ESI-MS (M+H): 581.4			
109	-CH ₃	3,5-di-F	
HPLC Method: LC-1 HPLC RT: 1.68 min ESI-MS (M+H): 555.5			
110	-CH ₃	3,5-di-F	
HPLC Method: LC-1 HPLC RT: 1.76 min ESI-MS (M+H): 569.5			
111	-H	3,5-di-F	
HPLC Method: LC-1 HPLC RT: 1.70 min ESI-MS (M+H): 555.5			
112	-H	3,4-di-F	
HPLC Method: LC-1 HPLC RT: 1.80 min ESI-MS (M+H): 567.5			




113	-CH ₃	3,4-di-F	
HPLC Method: LC-1 HPLC RT: 1.70 min ESI-MS (M+H): 569.5			
114	-CH ₃	3,4-di-F	
HPLC Method: LC-1		HPLC RT: 1.70 min	ESI-MS (M+H): 555.5

EXAMPLES 115 - 118

- The compounds in Examples 115 - 118 were prepared using procedures analogous to those described in Example 81 substituting the appropriate Piperidine in Step D and Aldehyde in Step G.




EXAMPLE	R1	R2	R3
115	-H	3,5-di-F	
HPLC Method: LC-1 HPLC RT: 1.90 min ESI-MS (M+H): 553.5			

116	-CH ₃	3-F	
HPLC Method: LC-1 HPLC RT: 1.50 min ESI-MS (M+H): 511			
117	-CH ₃	3-F	
HPLC Method: LC-1 HPLC RT: 1.50 min ESI-MS (M+H): 523			
118	-CH ₃	3-F	
HPLC Method: LC-1 HPLC RT: 1.60 min ESI-MS (M+H): 537			

EXAMPLE 119

Example 119 was prepared using procedures analogous to those described in Example 81 substituting the appropriate Piperidine in Step D and Aldehyde in Step G.




Example #	ESI	HPLC RT (LC1)
-----------	-----	------------------

119	523.4	1.5 min
¹ H-NMR (500 MHz, CD ₃ OD) δ 0.71-0.89 (m, 3H), 1.00 (d, J = 6.5, 3H), 1.11 (t, J = 7.5, 3H), 1.20-1.23 (m, 2H), 1.51 (m, 1H), 1.65-1.98 (m, 6H), 2.16-2.27 (m, 2H), 2.43-2.84 (m, 9H), 3.25-3.34 (m, 4H), 3.53-3.76 (m, 3H), 3.95 (t, J = 6.1, 2H), 6.98 (m, 1H), 7.19-7.25 (m, 2H), 7.36 (m, 1H)		

EXAMPLES 120-123

Examples 120-123 were prepared using procedures analogous to those described in Example 2 using the appropriate piperidines, pyrrolidines and aldehydes.



5

Example #	R ¹	R ²	R ³	ESI	HPLC RT (LC1)
120 (Diastereomer 1)	H	CH ₃	CH ₂ CH ₃	513.5	1.60 min
¹ H NMR (500 MHz, CD ₃ OD): δ 0.91 (t, J = 7.4, 3H), 1.14 (t, J = 7.5, 3H), 1.20 (s, 3H), 1.28 (t, J = 7.2, 3H), 1.48-1.59 (m, 3H), 1.67-1.75 (m, 2H), 1.84 (dq, J = 3.6, 9.2, 1H), 1.99 (dt, J = 2.2, 11.7, 1H), 2.06 (dt, J = 2.3, 11.7, 1H), 2.21 (s, 3H), 2.39 (tt, J = 3.7, 12.6, 1H), 2.44-2.59 (m, 4H), 2.75-2.80 (m, 1H), 2.84 (d, J = 11.5, 1H), 3.01 (d, J = 11.0, 1H), 3.08 (m, 1H), 3.24-3.37 (m, 4H), 3.65-3.69 (m, 2H), 4.00 (q, J = 7.3, 2H), 7.01 (dt, J = 2.3, 8.4, 1H), 7.17-7.21 (m, 2H), 7.37 (m, 1H)					
121 (Diastereomer 2)	H	CH ₂ CH ₃	CH ₃	--	--


¹ H NMR (500 MHz, CD ₃ OD): δ 0.92 (t, J = 7.5, 3H), 1.14 (t, J = 7.6, 3H), 1.24 (s, 3H), 1.28 (t, J = 7.3, 3H), 1.48-1.58 (m, 2H), 1.62 (q, J = 7.4, 2H), 1.72 (dq, J = 3.8, 12.7, 1H), 1.84 (dq, J = 3.8, 12.7, 1H), 1.97 (dt, J = 2.2, 11.7, 1H), 2.04 (dt, J = 3.1, 11.7, 1H), 2.21 (s, 3H), 2.35-2.46 (m, 2H), 2.51-2.57 (m, 3H), 2.78 (m, 1H), 2.83 (d, J = 11.2, 1H), 3.00 (d, J = 11.4, 1H), 3.05 (m, 1H), 3.21-3.38 (m, 4H), 3.67-3.70 (m, 2H), 4.00 (q, J = 7.2, 2H), 7.01 (dt, J = 2.7, 8.6, 1H), 7.17-7.21 (m, 2H), 7.37 (m, 1H)					
122	H	CH ₃	CH ₂ CF ₃	567.5	1.73 min
¹ H NMR (500 MHz, CD ₃ OD): δ 1.15 (dt, J = 1.2, 7.6, 3H), 1.28 (t, J = 7.2, 3H), 1.33 (d, J = 4.8, 3H), 1.62-1.70 (m, 2H), 1.91-2.01 (m, 2H), 2.23 (d, J = 2.1, 3H), 2.33-2.83 (m, 9H), 2.83-3.01 (m, 4H), 3.01-3.21 (m, 3H), 3.21-3.45 (m, 3H), 4.00 (q, J = 7.2, 2H), 6.96 (m, 1H), 7.14-7.19 (m, 2H), 7.33 (m, 1H)					
123	CH ₃	CH ₃	CH ₂ CF ₃	581.5	1.76 min
¹ H NMR (500 MHz, CD ₃ OD): δ 1.14 (dt, J = 2.1, 7.5 Hz, 3H), 1.18 (t, J = 6.1, 3H), 1.27 (t, J = 7.2, 3H), 1.33 (d, J = 8.2, 3H), 1.35-1.58 (m, 2H), 1.64 (m, 1H), 2.20 (d, J = 3.5, 3H), 2.38-2.81 (m, 10H), 2.85-3.11 (m, 5H), 3.17-3.35 (m, 3H), 3.99 (q, J = 7.1, 2H), 6.93 (m, 1H), 7.18-7.24 (m, 2H), 7.30 (m, 1H)					

While the invention has been described and illustrated with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various adaptations, changes, modifications, substitutions, deletions, or additions of procedures and protocols may be made without departing from the spirit and scope of the invention. For example, effective dosages other than the particular dosages as set forth herein above may be applicable as a consequence of variations in the responsiveness of the mammal being treated for any of the indications with the compounds of the invention indicated above. Likewise, the specific pharmacological responses observed may vary according to and depending upon the particular active compounds selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be

defined by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.

WHAT IS CLAIMED IS:

1. A compound of Formula I:



5

wherein:

R¹ is:

10


- (1) -CO₂H,
- (2) -NO₂,
- (3) -tetrazolyl,
- (4) -hydroxyisoxazole,
- (5) -SO₂NHCO-(C₀₋₃ alkyl)-R^a, or
- (6) -P(O)(OH)(OR^a);


15

wherein R^a is independently selected from hydrogen, C₁₋₆ alkyl, C₅₋₆ cycloalkyl, benzyl and phenyl, where any one of which except hydrogen is optionally substituted with 1-3 substituents where the substituents are independently selected from halo, C₁₋₃ alkyl, -O-C₁₋₃ alkyl, and -CF₃,

20

R² is:





wherein “wavy line” denotes the point of attachment;

5 R^9 is selected from:

- (1) hydrogen,
- (2) C_{1-6} alkyl, which is unsubstituted or substituted with 1-4 substituents where the substituents are independently selected from hydroxy, cyano, and halo,
- 10 (3) cyano,
- (4) hydroxy, and
- (5) halo; and

Y is:

- 15 (1) a direct single bond;
- (2) $-C_{1-10}$ alkyl- or $-(C_{0-6}$ alkyl) C_{3-6} cycloalkyl(C_{0-6} alkyl)-, either of which is optionally substituted with 1-7 substituents independently selected from:
 - (a) halo,
 - 20 (b) hydroxy,
 - (c) $-O-C_{1-3}$ alkyl,
 - (d) $-CF_3$,
 - (e) $-(C_{1-3}$ alkyl)hydroxy, and
 - (f) ethylenedioxy;
- 25 (3) $-(C_{0-6}$ alkyl)- Z^1 -(C_{0-6} alkyl)-, wherein each alkyl is optionally substituted with 1-7 substituents independently selected from:
 - (a) halo,
 - (b) hydroxy,
 - (c) $-O-C_{1-3}$ alkyl, and
 - 30 (d) $-CF_3$;

and where Z^1 is selected from $-SO_2-$, $-N(R^u)-$, $-N(R^u)C(=CHR^s)N(R^u)-$, $-N(R^u)C(=NR^s)N(R^u)-$, $-S-$, $-O-$, $-SO-$, $-SO_2N(R^u)-$, $-N(R^u)SO_2-$, and $-PO_2-$;

R^u is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, benzyl, phenyl, $(CO)C_{1-6}$ alkyl, $-SO_2-C_{1-6}$ alkyl, $-SO_2$ -phenyl, $-SO_2$ -heterocycle, or C_{1-6} alkyl- C_{3-6} cycloalkyl; wherein any of which except hydrogen is optionally substituted with 1-3 substituents independently selected from halo, C_{1-3} alkyl, $-O-C_{1-3}$ alkyl, and $-CF_3$;

R^s is hydrogen, C_{1-4} alkyl, $-NO_2$ or $-CN$;
 (4) $-(C_{0-6}$ alkyl)- Z^2 -(C_{0-6} alkyl)-, wherein each alkyl is optionally substituted with 1-7 substituents independently selected from:

- (a) halo,
- (b) hydroxy,
- (c) $-O-C_{1-3}$ alkyl, and
- (d) $-CF_3$;

and where:

Z^2 is selected from $-C(=O)-$, $-C(=O)O-$, $-OC(=O)-$, $-C(=O)NR^v-$, $-NR^vC(=O)-$, $-OC(=O)NR^v-$, $-NR^vC(=O)O-$, and $-NR^wC(=O)NR^v-$;

R^v is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, benzyl, phenyl, or C_{1-6} alkyl- C_{3-6} cycloalkyl; wherein any of which except hydrogen is optionally substituted with 1-3 substituents independently selected from halo, C_{1-3} alkyl, $-O-C_{1-3}$ alkyl, and $-CF_3$; and

R^w is hydrogen or C_{1-6} alkyl;

R^{10} is:

(1) a heterocycle selected from pyrazolyl and imidazolyl, wherein the pyrazolyl or imidazolyl is substituted with three of R^d , wherein each R^d is independently selected from the group consisting of:


- (a) halo,
- (b) cyano,
- (c) hydroxy,
- (d) C_{1-6} alkyl, which is unsubstituted or substituted with 1-5 of R^e where R^e is independently selected from halo, cyano, hydroxy, $-O-C_{1-6}$ alkyl, $-C_{3-6}$ cycloalkyl, $-CO_2H$, $-CO_2-(C_{1-6}$ alkyl), $-CF_3$, $-SO_2R^a$, $-NR^aR^b$

(where R^a is independently as defined above and R^b is independently selected from the definitions of R^a), phenyl, naphthyl, biphenyl, and heterocycle;

- 5 wherein phenyl, naphthyl, biphenyl, or heterocycle is unsubstituted or substituted with 1-7 of R^f where R^f is independently selected from halo, cyano, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, $-O-C_{1-6}$ alkyl, $-O-C_{1-6}$ haloalkyl, $-CO_2H$, $-CO_2(C_{1-6}$ alkyl), $-NR^aR^b$, $-(C_{1-6}$ alkyl)- NR^aR^b , $-SO_2R^a$, $-N(R^a)SO_2R^b$, $-N(R^a)COR^b$, $-(C_{1-6}$ alkyl)hydroxy, $-O-C_{3-6}$ cycloalkyl, benzyloxy, phenoxy, and $-NO_2$,
- 10 (e) $-O-C_{1-6}$ alkyl, which is unsubstituted or substituted with 1-5 of R^e ,
- 15 (f) $-O$ -phenyl, which is unsubstituted or substituted with 1-5 of R^f ,
- (g) $-O$ -heterocycle, which is unsubstituted or substituted with 1-5 of R^f ,
- 20 (h) $-NO_2$,
- (i) phenyl,
- (j) $-CO_2R^a$,
- (k) tetrazolyl,
- (l) $-NR^aR^b$,
- (m) $-NR^a-COR^b$,
- 25 (n) $-NR^a-CO_2R^b$,
- (o) $-CO-NR^aR^b$,
- (p) $-OCO-NR^aR^b$,
- (q) $-NR^aCO-NR^aR^b$,
- (r) $-S(O)_m-R^a$, wherein m is an integer selected from 0, 1, and 2,
- 30 (s) $-S(O)_2-NR^aR^b$,
- (t) $-NR^aS(O)_2-R^b$,
- (u) $-NR^aS(O)_2-NR^aR^b$,
- (v) C_{2-6} alkenyl,

- (w) furanyl, which is unsubstituted or substituted with
benzyl which is unsubstituted or substituted with 1-7 of
 R^f wherein R^f is independently as defined above,
(x) -C₃₋₆ cycloalkyl, and
(y) -O-C₃₋₆ cycloalkyl; or

(2) a heterocycle selected from:



wherein n is an integer equal to zero or 1, and

the heterocycle is mono-substituted in the pyrazolyl or imidazolyl ring with any one of R^d as defined above, and is either unsubstituted in the other ring or is substituted with 1 or more substituents where each substituent is independently selected from (a) to (y) of R^d as defined above;

R^3 is phenyl, naphthyl, or heterocycle, any one of which is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

- 5 (a) halo,
 (b) C₁₋₄ alkyl,
 (c) C₁₋₄ haloalkyl,
 (d) hydroxy,
 (e) -O-C₁₋₄ alkyl,
 (f) -O-C₁₋₄ haloalkyl,
 (g) -CO₂R^a,
 (h) -NR^aR^b, and
 (i) -CONR^aR^b;

10

R⁴ is hydrogen, C₁₋₁₀ alkyl, C₃₋₈ cycloalkyl, -(C₁₋₃ alkyl)-C₃₋₈ cycloalkyl, -(C₀₋₂ alkyl)-(C₃₋₈ cycloalkylidenyl)-(C₁₋₂ alkyl), C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, cyclohexenyl, phenyl, -(C₁₋₆ alkyl)-phenyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, octahydronaphthyl, biphenyl, or heterocycle; wherein any one of
 15 which except for hydrogen is unsubstituted or substituted with 1-7 of R^d where R^d is independently as defined above;

R⁵ is hydrogen or C₁₋₆ alkyl, wherein the alkyl is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

- 20 (a) halo,
 (b) -CF₃,
 (c) hydroxy,
 (d) C₁₋₃ alkyl,
 (e) -O-C₁₋₃ alkyl,
 25 (f) -CO₂R^a,
 (g) -NR^aR^b, and
 (h) -CONR^aR^b;

30 or alternatively R⁴ and R⁵ together with the carbon atom to which they are attached form a C₃₋₈ cycloalkyl ring which may be unsubstituted or substituted with 1-7 of R^d;

R^{6a} and R^{6b} are each independently C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, phenyl, naphthyl, or heterocycle; wherein any one of which is

unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

- (a) halo,
- (b) C₁₋₄ haloalkyl,
- 5 (c) hydroxy,
- (d) C₁₋₄ alkyl,
- (e) -O-C₁₋₄ alkyl,
- (f) -O-C₁₋₄ haloalkyl,
- (g) C₃₋₈ cycloalkyl,
- 10 (h) -CO₂R^a,
- (i) -NR^aR^b, and
- (j) -CONR^aR^b;

or alternatively R^{6a} and R^{6b} together with the carbon atom to which they are attached form:

- (a) a 3- to 8-membered saturated carbocyclic ring, in which one of the ring carbons is optionally a member of a 3- to 8-membered spiro ring containing carbon atoms and optionally 1 or 2 heteroatoms independently selected from nitrogen, oxygen and sulfur;
- 20 (b) a 4- to 8-membered monocyclic heterocycle containing from 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, in which one of the ring carbons is optionally a member of a 3- to 8-membered spiro ring containing carbon atoms and optionally 1 or 2 heteroatoms independently selected from nitrogen, oxygen and sulfur;
- 25 (c) a 5- to 8-membered saturated carbocyclic ring to which is fused a C₃₋₈ cycloalkyl, or
- (d) a 5- to 8-membered heterocyclic ring containing from 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, to which is fused a C₃₋₈ cycloalkyl,
- 30 wherein the ring system of (a), (b), (c) or (d) is optionally substituted with from 1 to 3 substituents selected from halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, -O-C₁₋₄ alkyl, -O-C₁₋₄ haloalkyl, and hydroxy;

R⁷ is hydrogen or C₁₋₆ alkyl; and

R^8 is hydrogen or C_{1-6} alkyl;

or a pharmaceutically acceptable salt thereof.

5

2. The compound according to claim 1 wherein R^1 is:

- (1) $-CO_2H$,
- (2) $-P(O)(OH)_2$, or
- (3) $-tetrazolyl$;

10

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 wherein R^1 is:

- (1) $-CO_2H$, or
- (2) $-tetrazolyl$;

15


or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1 wherein R^1 is $-CO_2H$;

20

or a pharmaceutically acceptable salt thereof.


5. The compound according to claim 1, wherein R^2 is:



or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1, wherein R^2 is:

30



or a pharmaceutically acceptable salt thereof.

5 7. The compound according to claim 1 wherein R³ is phenyl, thienyl, pyrazolyl, thiazolyl, thiadiazolyl, furanyl, oxadiazolyl, pyrazinyl, pyrimidinyl, or pyridyl, any one of which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

- (a) halo,
- (b) -CF₃,
- 10 (c) hydroxy,
- (d) C₁₋₃ alkyl, and
- (e) -O-C₁₋₃ alkyl;

or a pharmaceutically acceptable salt thereof.

15

8. The compound according to claim 1 wherein R³ is phenyl or thienyl, either of which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

- (a) halo,
- 20 (b) -CF₃,
- (c) hydroxy, and
- (d) C₁₋₃ alkyl;

or a pharmaceutically acceptable salt thereof.

25

9. The compound according to claim 1 wherein R³ is phenyl or thienyl, wherein the phenyl is optionally substituted with 1-5 substituents independently selected from fluoro and chloro;

30 or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 1 wherein R⁴ and R⁵ are both hydrogen;

or a pharmaceutically acceptable salt thereof.

11. The compound according to claim 1, wherein R^{6a} and R^{6b} are each independently C₁₋₆ alkyl or C₃₋₆ cycloalkyl, either of which is unsubstituted or substituted with 1-7 substituents independently selected from:

- (a) halo,
- (b) -CF₃,
- (c) hydroxy, and
- (d) -O-C₁₋₃ alkyl;

or R^{6a} and R^{6b} together with the carbon atom to which they are attached form:

- (a) a 3- to 6-membered saturated carbocyclic ring,
- (b) a 4- to 6-membered saturated heterocyclic ring containing one oxygen atom, or
- (c) a 5- or 6-membered saturated carbocyclic ring to which is fused a C₃₋₆ cycloalkyl;

wherein the ring system of (a), (b), or (c) is optionally substituted with from 1 to 3 substituents selected from halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, -O-C₁₋₄ alkyl, -O-C₁₋₄ haloalkyl, or hydroxy;

or a pharmaceutically acceptable salt thereof.

12. The compound according to claim 1, wherein R^{6a} and R^{6b} are each C₁₋₃ alkyl;

or one of R^{6a} and R^{6b} is C₁₋₃ alkyl, and the other of R^{6a} and R^{6b} is C₃₋₆ cycloalkyl;

or R^{6a} and R^{6b} together with the carbon atom to which they are attached form cyclopropylidenyl, cyclobutylidenyl, cyclopentylidenyl, cyclohexylidenyl, bicyclo[3.1.0]cyclohexylidenyl, tetrahydropyranylidenyl, or tetrahydrofuranylidenyl;


or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 1, wherein R⁷ is hydrogen;
or a pharmaceutically acceptable salt thereof.
- 5 14. The compound according to claim 1, wherein R⁸ is hydrogen
or methyl;
or a pharmaceutically acceptable salt thereof.
- 10 15. The compound according to claim 1 wherein R⁹ is hydrogen,
fluoro, hydroxy or C₁₋₆ alkyl;
or a pharmaceutically acceptable salt thereof.
- 15 16. The compound according to claim 1 wherein R⁹ is hydrogen;
or a pharmaceutically acceptable salt thereof.
- 20 17. The compound according to claim 1, wherein Y is a direct
single bond;
or a pharmaceutically acceptable salt thereof.
- 25 18. The compound according to claim 1, wherein R¹⁰ is:
(1) a heterocycle selected from pyrazolyl and imidazolyl, wherein
the pyrazolyl or imidazolyl is substituted with three substituents independently
selected from the group consisting of:
- 30 (a) halo,
(b) cyano,
(c) hydroxy,
(d) C₁₋₆ alkyl, which is unsubstituted or substituted with 1-
5 of R^e where R^e is independently selected from halo,
cyano, hydroxy, -O-C₁₋₆ alkyl, -C₃₋₅ cycloalkyl, -
CO₂H, -CO₂(C₁₋₆ alkyl), -CF₃, -SO₂R^a, -NR^aR^b,

- 5 where R^a and R^b are independently selected from hydrogen, C_{1-6} alkyl, C_{5-6} cycloalkyl, benzyl or phenyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from halo, C_{1-3} alkyl, $-O-C_{1-3}$ alkyl, C_{1-3} fluoroalkyl, and $-O-C_{1-3}$ fluoroalkyl,
- 10 phenyl, naphthyl, biphenyl, and heterocycle, wherein the phenyl, naphthyl, biphenyl or heterocycle is unsubstituted or substituted with 1-7 of R^f where R^f is independently selected from halo, cyano, hydroxy, C_{1-4} alkyl, $-O-C_{1-4}$ alkyl, $-O-C_{3-5}$ cycloalkyl, $-CO_2H$, $-CO_2(C_{1-6}$ alkyl), $-CF_3$, $-OCF_3$, $-SO_2R^a$, $-N(R^a)SO_2R^b$ and $-NR^aR^b$,
- 15 (e) $-O-C_{1-6}$ alkyl, which is unsubstituted or substituted with 1-5 of R^e ,
- (f) $-NO_2$,
- (g) phenyl,
- 20 (h) $-CO_2R^a$,
- (i) tetrazolyl,
- (j) $-NR^aR^b$,
- (k) $-NR^a-COR^b$,
- (l) $-NR^a-CO_2R^b$,
- 25 (m) $-CO-NR^aR^b$,
- (n) $-OCO-NR^aR^b$,
- (o) $-NR^aCO-NR^aR^b$,
- (p) $-S(O)_m-R^a$, wherein m is an integer selected from 0, 1, and 2,
- 30 (q) $-S(O)_2-NR^aR^b$,
- (r) $-NR^aS(O)_2-R^b$,
- (s) $-NR^aS(O)_2-NR^aR^b$,
- (t) $-C_{2-3}$ alkenyl,
- (u) $-C_{3-6}$ cycloalkyl, and

(v) -O-C₃₋₆ cycloalkyl; or

(2) a heterocycle selected from:



wherein the heterocycle is mono-substituted in the pyrazolyl or imidazolyl ring with any one of R^d as defined above, and is either unsubstituted in the other ring or substituted with 1 to 3 substituents independently selected from:

- 10
- (a) halo,
 - (b) C₁₋₄ alkyl,
 - (c) C₁₋₄ haloalkyl,
 - (d) -OH,
 - (e) -O-C₁₋₄ alkyl,
 - 15 (f) -O-C₁₋₄ haloalkyl, and
 - (g) -CN;

or a pharmaceutically acceptable salt thereof.


20 19. The compound according to claim 1, wherein R¹⁰ is:

(1) pyrazolyl substituted with three substituents independently selected from the group consisting of:

- 25
- (a) fluoro,
 - (b) chloro,
 - (c) C₁₋₆ alkyl,
 - (d) -CH₂-phenyl, wherein the phenyl is unsubstituted or substituted with 1 or 2 substituents independently selected from chloro, fluoro, -CN, -C₁₋₃ alkyl, -O-C₁₋₃ alkyl, -O-cyclopropyl, -O-cyclobutyl, -CF₃, -OCF₃, -SO₂-(C₁₋₃ alkyl), and -N(H)SO₂-(C₁₋₃ alkyl),
 - 30 (e) -CH₂CH₂-phenyl, and

(f) phenyl; or

(2) a heterocycle selected from:



wherein the heterocycle is mono-substituted in the pyrazolyl ring with any one of R^d as defined above, and is either unsubstituted in the other ring or substituted with 1 to 3 substituents independently selected from:

- 10
- (a) fluoro,
 - (b) chloro,
 - (b) C_{1-4} alkyl,
 - (c) $-CF_3$,
 - (d) $-OH$,


15

 - (e) $-O-C_{1-4}$ alkyl,
 - (f) $-OCF_3$, and
 - (g) $-CN$;

or a pharmaceutically acceptable salt thereof.


20

20. The compound according to claim 1 which is of the stereochemical configuration:



or a pharmaceutically acceptable salt thereof.

21. The compound of claim 1, which is a compound of formula
5 (II):




wherein


- 10 R^{6a} and R^{6b} are each C_{1-3} alkyl;

or one of R^{6a} and R^{6b} is C_{1-3} alkyl, and the other of R^{6a} and R^{6b} is C_{3-6} cycloalkyl;

- 15 or R^{6a} and R^{6b} together with the carbon atom to which they are attached form:



R^{10} is:



R¹² is C₁₋₃ alkyl, C₁₋₃ fluoroalkyl, or -CH₂-phenyl wherein the phenyl is optionally substituted with 1 or 2 substituents independently selected from chloro, fluoro, -CN, -C₁₋₃ alkyl, -O-C₁₋₃ alkyl, -O-cyclopropyl, -O-cyclobutyl, -CF₃, -OCF₃, -SO₂-(C₁₋₃ alkyl), and -NH-SO₂-(C₁₋₃ alkyl);

each of R¹⁴ and R¹⁶ is independently -C₁₋₃ alkyl, C₁₋₃ fluoroalkyl, -O-C₁₋₃ alkyl, -O-C₁₋₃ fluoroalkyl, cyclopropyl, cyclobutyl, or -CH₂-phenyl wherein the phenyl is optionally substituted with 1 or 2 substituents independently selected from chloro, fluoro, -CN, -C₁₋₃ alkyl, -O-C₁₋₃ alkyl, -O-cyclopropyl, -O-cyclobutyl, -CF₃, -OCF₃, and -SO₂-(C₁₋₃ alkyl);


R¹⁸ is C₁₋₃ alkyl;

R²⁰ is -C₁₋₃ alkyl; and

X is hydrogen or fluoro;

or a pharmaceutically acceptable salt thereof.

22. The compound according to claim 21, wherein R¹⁰ is:



R^{12} is methyl or ethyl;

5 R^{14} is methyl or ethyl;

R^{16} is halo, methyl, or ethyl;


each R^{22} is independently chloro, fluoro, -CN, -C₁₋₃ alkyl, -O-C₁₋₃ alkyl,
 10 -O-cyclopropyl, -O-cyclobutyl, -CF₃, -OCF₃, or -SO₂-(C₁₋₃ alkyl); and

p is an integer from zero to 3;


or a pharmaceutically acceptable salt thereof.

15

23. The compound according to claim 21, wherein R^{10} is:




20




5 or a pharmaceutically acceptable salt thereof.

24. The compound according to claim 23, wherein R¹⁰ is:



10 or a pharmaceutically acceptable salt thereof.

25. The compound according to claim 23, wherein R¹⁰ is:



15 or a pharmaceutically acceptable salt thereof.

26. The compound according to claim 1, which is a compound selected from the group consisting of:

- 5 1-{[(3*S*,4*S*)-3-{[4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclopentanecarboxylic acid;
- 1-{[(3*S*,4*S*)-3-{[4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid;
- 10 1-{[(3*R*,4*S*)-3-((1*R*)-1-[4-(1,3-diethyl-5-methyl-1*H*-pyrazol-4-yl)piperidin-1-yl]ethyl)-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclobutanecarboxylic acid;
- (1*R*,5*R*)-3-[(3*S*,4*S*)-3-(3,5-difluorophenyl)-4-{[4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]methyl}pyrrolidin-1-yl)methyl]bicyclo[3.1.0]hexane-3-carboxylic acid;
- 15 3-[(3*R*,4*S*)-3-((1*R*)-1-[4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]ethyl)-4-(3-fluorophenyl)pyrrolidin-1-yl]-2,2-dimethylpropanoic acid;
- 20 1-{[(3*R*,4*S*)-3-((1*R*)-1-[4-(1,3-diethyl-4-methyl-1*H*-pyrazol-5-yl)piperidin-1-yl]ethyl)-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclopentanecarboxylic acid;
- 1-{[(3*R*,4*S*)-3-((1*R*)-1-[4-(1,3-diethyl-4-methyl-1*H*-pyrazol-5-yl)piperidin-1-yl]ethyl)-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid;
- 25 1-{[(3*S*,4*S*)-3-{[4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclobutanecarboxylic acid;
- 1-{[(3*S*,4*S*)-3-{[4-(1,3-diethyl-4-methyl-1*H*-pyrazol-5-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid;
- 30 1-{[(3*S*,4*S*)-3-{[4-(1,3-diethyl-4-methyl-1*H*-pyrazol-5-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclopentanecarboxylic acid;

1-{[(3*S*,4*S*)-3-{[4-(2-ethyl-4,5,6,7-tetrahydro-2*H*-indazol-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclopentanecarboxylic acid;

5 1-{[(3*S*,4*S*)-3-{[4-(2-ethyl-4,5,6,7-tetrahydro-2*H*-indazol-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}cyclohexanecarboxylic acid;

2-ethyl-2-{[(3*S*,4*S*)-3-{[4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}butanoic acid;

10 2-{[(3*S*,4*S*)-3-{[4-(1,3-diethyl-5-methyl-1*H*-pyrazol-4-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}-2-ethylbutanoic acid;
(1*R*,5*S*)-3-{[(3*S*,4*S*)-3-{[4-(1,3-diethyl-4-methyl-1*H*-pyrazol-5-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}bicyclo[3.1.0]hexane-3-carboxylic acid;

15 (1*R*,5*S*)-3-{[(3*S*,4*S*)-3-{[4-(1,3-diethyl-5-methyl-1*H*-pyrazol-4-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}bicyclo[3.1.0]hexane-3-carboxylic acid;

20 3-[(3*S*,4*S*)-3-{[4-(1,3-diethyl-5-methyl-1*H*-pyrazol-4-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]-2,2-dimethylpropanoic acid;
(1*R*,5*S*)-3-{[(3*R*,4*S*)-3-{(1*R*)-1-[4-(1,3-diethyl-5-methyl-1*H*-pyrazol-4-yl)piperidin-1-yl]ethyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}bicyclo[3.1.0]hexane-3-carboxylic acid;

25 3-[(3*R*,4*S*)-3-{(1*R*)-1-[4-(1,3-diethyl-5-methyl-1*H*-pyrazol-4-yl)piperidin-1-yl]ethyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]-2,2-dimethylpropanoic acid;

30 (1*R*,5*R*)-3-{[(3*S*,4*S*)-3-{[4-(2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)piperidin-1-yl]methyl}-4-(3-fluorophenyl)pyrrolidin-1-yl]methyl}bicyclo[3.1.0]hexane-3-carboxylic acid;

and pharmaceutically acceptable salts thereof.

27. A pharmaceutical composition which comprises an inert carrier and an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

5 28. A method for modulating chemokine CCR5 receptor activity in a subject which comprises administering to the subject an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

10 29. A method for preventing infection by HIV, treating infection by HIV, delaying of the onset of AIDS, or treating AIDS in a subject, which comprises administering to the subject of an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

